Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent

Information

  • Patent Grant
  • 11589981
  • Patent Number
    11,589,981
  • Date Filed
    Wednesday, February 19, 2020
    4 years ago
  • Date Issued
    Tuesday, February 28, 2023
    a year ago
Abstract
The invention relates to a prosthetic heart valve (100) for an endoprosthesis (1) used in the treatment of a stenotic cardiac valve and/or a cardiac valve insufficiency. The prosthetic heart valve (100) comprises of a plurality of leaflets (102), which consist of a natural and/or synthetic material and have a first opened position for opening the heart chamber and a second closed position for closing the heart chamber, the leaflets (102) being able to switch between their first and second position in response to the blood flow through the heart. In addition, the prosthetic heart valve (100) comprises a leaflet support portion (103), consisting of biological and/or synthetic material for mounting of the prosthetic heart valve (100) to a stent (10), and a bendable transition area (104) which forms a junction between the leaflets (102) and the leaflet support portion (103), the transition area (104) progressing essentially in a U-shaped manner similar to a cusp shape of a natural aortic or pulmonary heart valve for reducing tissue stresses during opening and closing motion of the leaflets (102). The invention further relates to an endoprosthesis (1) comprising a prosthetic heart valve (100) and a stent (10).
Description

The present disclosure relates to a prosthetic heart valve. Specifically, the present disclosure relates to a prosthetic heart valve for a transcatheter delivered endoprosthesis used in the treatment of a stenotic cardiac valve and/or a cardiac valve insufficiency.


The present disclosure also relates to a transcatheter delivered endoprosthesis that includes a prosthetic heart valve and a stent for positioning and anchoring of the prosthetic heart valve at the implantation site in the heart of a patient. Specifically, the present disclosure also relates to a collapsible and expandable prosthesis incorporating a prosthetic heart valve and a stent that can be delivered to the implant site using a catheter for treatment of a stenosis (narrowing) of a cardiac valve and/or a cardiac valve insufficiency.


The expression “narrowing (stenosis) of a cardiac valve and/or cardiac valve insufficiency” may include a functional defect of one or more cardiac valves, which is either genetic or has developed. A cardiac defect of this type might affect each of the four heart valves, although the aortic and mitral valves are affected much more often than the right-sided part of the heart (pulmonary and tricuspid valves). The functional defect can result in narrowing (stenosis), inability to close (insufficiency) or a combination of the two (combined vitium). This disclosure relates to a prosthetic heart valve as well as a transcatheter delivered endoprosthesis that includes a prosthetic heart valve and an expandable stent capable of being implanted transluminally in a patient's body and enlarged radially after being introduced by transcatheter delivery for treating such a heart valve defect.


The human heart has four valves which control the blood flow circulating through the human body. On the left side of the heart are the mitral valve, located between the left atrium and the left ventricle, and the aortic valve, located between the left ventricle and the aorta. Both of these valves direct the oxygenated blood, coming from the lungs into the aorta for distribution through the body. The tricuspid valve, located between the right atrium and the right ventricle, and the pulmonary valve, located between the right ventricle and the pulmonary artery, however, are situated on the right side of the heart and direct deoxygenated blood, coming from the body, to the lungs.


The native heart valves are passive structures that open and close in response to differential pressures induced by the pumping motions of the heart. They consist of moveable leaflets designed to open and close in response to the said differential pressure. Normally, the mitral valve has two leaflets and the tricuspid valve has at least two, preferably three leaflets. The aortic and pulmonary valves, however, have normally at least two, preferably three leaflets, also often referred to as “cusps” because of their half-moon like appearance. In the present disclosure, the terms “leaflet” and “cusps” have the same meaning.


Heart valve diseases are classified into two major categories, named stenosis and insufficiency. In the case of a stenosis, the native heart valve does not open properly, whereby insufficiency represents the opposite effect showing deficient closing properties. Medical conditions like high blood pressure, inflammatory and infectious processes can lead to such cardiac valve dysfunctions. Either way in most cases the native valves have to be treated by surgery. In this regard, treatment can either include reparation of the diseased heart valve with preservation of the patient's own valve or the valve could be replaced by a mechanical or biological substitutes also referred to as prosthetic heart valves. Particularly for aortic heart valves, however, it is frequently necessary to introduce a heart valve replacement.


In principle, there are two possibilities of treating the diseased heart valve, when inserting a prosthetic heart valve: The first way includes extracting at least major parts of the diseased heart valve. The second alternative way provides leaving the diseased heart valve in place and pressing the diseased leaflets aside to create space for the prosthetic heart valve.


Biological or mechanical prosthetic heart valves are typically surgically sewn into the cardiac valve bed through an opening in the chest after removal of the diseased cardiac valve. This operation necessitates the use of a heart-lung machine to maintain the patient's circulation during the procedure and cardiac arrest is induced during implantation of the prosthesis. This is a risky surgical procedure with associated dangers for the patient, as well as a long post-operative treatment and recovery phase. Such an operation can often not be considered with justifiable risk in the case of polypathic patients.


Minimally-invasive forms of treatment have been developed recently which are characterized by allowing the procedure to be performed under local anesthesia. One approach provides for the use of a catheter system to implant a self-expandable stent to which is connected a collapsible heart valve. Such a self-expandable endoprosthesis can be guided via a catheter system to the implantation site within the heart through an inguinal artery or vein. After reaching the implantation site, the stent with the prosthetic heart valve affixed thereto can then be unfolded.


An increasing number of patients suffer from stenosis (narrowing) of cardiac valve and/or cardiac valve insufficiency. In this regard, the issue concerning the provision of long term durability is involved with developing prosthetic heart valves. Each of the four major heart valves open and close about 100,000 times a day and stability requirements for replacements valves are particularly high.


Moreover, there is the danger that—due to the dynamic fluid pressure from blood flow through the prosthetic heart valve, the leaflet material, or the threads (e.g. sutures) used in fastening the prosthetic heart valve to the stent may tear or break. These component failures over the course of time may result in loss of overall valve function.


On the basis of the problems outlined above and other issues with current transcatheter technologies, certain embodiments of the present disclosure address the issue of providing a prosthetic heart valve, as well as a self-expandable endoprosthesis for treating a narrowed cardiac valve or a cardiac valve insufficiency which realizes optimum long term durability, excellent hemodynamics (e.g. low pressure gradients and minimal regurgitation), minimization of paravalvular leakage, accurate device alignment and positioning, no coronary obstruction, prevention of device migration and avoidance of heart block. In addition, the disclosure provides an improved attachment of a prosthetic heart valve to a corresponding collapsible stent structure, thereby distributing stress loads over a greater surface area and thus reducing the potential for stress concentration points throughout the prosthetic heart valve, resulting in improved durability.


In this regard and as it will be described later in detail, the disclosure provides a prosthetic heart valve for a transcatheter delivered endoprosthesis used in the treatment of a stenosis (narrowing) of a cardiac valve and/or a cardiac valve insufficiency. The prosthetic heart valve comprises at least two leaflets, a skirt portion, and a transition area representing a junction between the leaflets and the skirt portion. Each of the at least two leaflets of the prosthetic heart valve consists of natural tissue or synthetic material and has a first opened position for opening the patient's heart chamber and a second closed position for closing the patient's heart chamber, the at least two leaflets being able to switch between their first and second position in response to the blood flow through the patient's heart. The skirt portion consists of natural tissue or synthetic material and is used for mounting of the prosthetic heart valve to a stent. The transition area, which represents a junction between the at least two leaflets of the prosthetic heart valve and the skirt portion, progresses approximately in a U-shaped manner, similar to a cusp shape of a natural aortic or pulmonary heart valve, thereby reducing stresses within the heart valve material during opening and closing motion of the at least two leaflets.


The expression “natural tissue” as used herein means naturally occurring tissue, i.e. biological tissue obtained from the patient, from another human donor, or from a nonhuman animal. On the other hand, the herein used expression “natural tissue” shall also cover tissue fabricated by tissue engineering in the laboratory, for example, from combinations of engineered extracellular matrices (“scaffolds”), cells, and biologically active molecules.


As it will be described in detail later on, in some embodiments of the present disclosure, the prosthetic heart valve either comprises xenografts/homografts or synthetic, nonbiological, non-thrombogenic materials. Homografts are either human donor valves, e.g., heart valves, or replacements made of human tissue, e.g., pericardial tissue. In contrast, xenografts describe valves received from animals, e.g., heart valves, or made of animal tissue, e.g., pericardial tissue, typically porcine or bovine respectively. These natural tissues normally contain tissue proteins (i.e., collagen and elastin) acting as a supportive framework and determining the pliability and firmness of the tissue.


It is conceivable to increase the stability of said natural tissues by applying chemical fixation. That is, the natural tissue may be exposed to one or more chemical fixatives (i.e. tanning agents) that form cross-linkages between the polypeptide chains within the protein structures of the natural tissue material. Examples of these chemical fixative agents include: formalaldehyde, glutaraldehyde, dialdehyde starch, hexamethylene diisocyanate and certain polyepoxy compounds.


So far, a major problem with the implantation of conventional biological prosthetic heart valves is that the natural tissue material can become calcified, resulting in undesirable stiffening or degradation of the prosthetic heart valve.


Even without calcification, high valve stresses can lead to mechanical failure of components of the heart valve. In order to overcome problems with mechanical failure and potential stress induced calcification that limit valve durability, some embodiments of the disclosure describe an improved construction of the prosthetic heart valve, the design of the disclosed prosthetic heart valve is suited for reducing stresses, and reducing the potential for calcification to improve durability of the heart valve.


In addition, the disclosure provides an improved attachment of a prosthetic heart valve to a corresponding collapsible stent structure, thereby distributing stress loads over a greater surface area and thus reducing the potential for stress concentration points throughout the prosthetic heart valve, resulting in improved durability.


In some embodiment of the disclosure, the prosthetic heart valve may be made of one piece of flat pericardial tissue. This pericardial tissue can either be extracted from an animal's heart (xenograft) or a human's heart (homograft). Subsequently, the extracted tissue may be cut by a laser cutting system, a die press, a water jet cutting system or by hand with a variety of cutting instruments in order to form a pattern representing each of the at least two leaflets or in another embodiment individual leaflets. This pattern may also include the skirt portion in some embodiments. The skirt portion represents an area of the prosthetic heart valve that is used for connecting the prosthetic heart valve to a stent, for example, by means of sutures. Current prosthetic heart valves consist of separated leaflets and skirt portions, wherein the separated leaflets and skirt portions are sewn together by the time the biological heart valve is connected to the stent. According to the “one piece” embodiment described herein, however, the leaflets are integrally formed with the leaflet support portion, that is the prosthetic heart valve is made of one piece of flat pericardial tissue.


The pattern of the prosthetic heart valve, which represents each of the at least two and preferably three leaflets and the skirt portion, shall substantially be constructed like a native aortic or pulmonary heart valve. To this end, the pattern is preferably designed so as to form leaflets in the aforementioned cusp manner, having three half-moon shaped leaflets like the aortic or pulmonary heart valve. The leaflets can be designed in various shapes such as the geometry of an ellipse, U-shape or substantially oval. In this regard, preferably each of the three different leaflets is formed in such a manner that all of them have the same extent; however, it is also conceivable to design them in different sizes.


The shaping of the leaflets into said pattern, for minimizing stresses in the closed position of the prosthetic heart valve, can be achieved in several ways. Most importantly, the mechanical properties of the leaflets of the prosthetic heart valve are influenced by the free margin and the shape of the supported edges. To this end, in an advantageous embodiment disclosed herein, the leaflets are formed into a predetermined 3D shape, by means of a cross-linking the flat tissue on a mandrel. Subsequently, potentially occurring excess material is trimmed off by means of a laser, knife, or water jet respectively to form the edges of the 3D shape. Between the leaflets and the skirt portion, the valve pattern shows a transition area progressing in a substantial U-shaped manner, similar to the cusp shape of a natural aortic or pulmonary heart valve.


In another embodiment of the present disclosure, the lower end section of the prosthetic heart valve exhibits a tapered or flared shape. Such a tapered or flared shape may be advantageous regarding the attachment of the prosthetic heart valve to a corresponding stent. As will be explained in more detail hereinafter, a corresponding stent may comprise a tapered or flared lower end section in order to improve the anchoring of the stent at the implantation site. As a consequence, it may be useful to construct the lower end section of the prosthetic heart valve in a tapered or flared shape, so as to prevent paravalvular leakage between the stent and the blood vessel.


According to another embodiment of the present disclosure, the leaflets may have a cuspidal geometry, which is formed in an elliptically, u-shaped or oval manner. Such a cuspdial geometry reduces the potential for stress concentrations and therefore minimizes the potential for areas of wear and calcium deposition. In another embodiment of the present disclosure all three leaflets are shaped to the same extent, absorbing loads equally throughout the cardiac cycle. However, it is conceivable to assemble a device with leaflets of varying designs.


With reference to another embodiment of the present disclosure, the leaflet portion of the prosthetic heart valve is designed to provide redundant coaptation for potential annular distortion. In particular, redundant coaptation means that each of the leaflets covers more than one third of the inner diameter of the respective stent, in the closed position of the valve. The redundant coaptation may reduce stress on the leaflets and provides reliable closure of the heart chamber in the second closed position of the leaflets, even in the case of an annular distortion. That is, the prosthetic heart valve of the present disclosure is capable of preventing regurgitation even if the size of the heart valve annulus has been altered (annular distortion).


In another embodiment of the present disclosure, the prosthetic heart valve comprises a plurality of fastening holes provided along the progression of the bendable transition area. These fastening holes are preferably introduced into the tissue of the prosthetic heart valve before the valve is attached to the corresponding stent. This plurality of fastening holes may reduce the time needed for attachment of the prosthetic heart valve to the retaining arches of the corresponding stent.


According to another aspect of the present disclosure, the prosthetic heart valve is designed for collapsing and delivering in a catheter. To this end, the prosthetic heart valve can be designed in such a way as to fit inside the corresponding stent structure. Furthermore, it is conceivable that the design of the prosthetic heart valve comprises certain folds in order to allow for collapsing to very small diameters.


In another embodiment of the invention, the tissue material of the prosthetic heart valve has a thickness of 160 μm to 300 μm, preferably from 220 μm to 260 μm. However, it should be noted that the thickness may be dependent on the tissue material of the prosthetic heart valve. In general, the thickness of bovine tissue is thicker than the thickness of porcine tissue.


The blood vessels and heart valve orifices of the individual patients can have significantly varying diameter, accordingly, the prosthetic heart valve may have a diameter ranging form 19 mm to 28 mm. Thus, the prosthetic heart valve of the present disclosure is adapted to fit to the individual characteristics of individual patient's heart anatomy.


In another embodiment of the present disclosure, the bendable transition area of the prosthetic heart valve is attached to retaining arches of the stent by means of sutures, having a diameter larger than the diameter of the sutures used for attachment of the prosthetic heart valve to an annular collar of the stent. Due to this, the prosthetic heart valve can be reliably attached to the stent without adding too much bulk to the stent, in order to collapse the endoprosthesis to a small diameter.


The disclosure also provides a transcatheter delivered endoprosthesis having a prosthetic heart valve affixed to a stent. The stent provides retaining arches which are configured once in the expanded state to be in a gradually uniform U-shape. The transition area of the tissue is attached to the retaining arches of the stent in a number of possible embodiments. The purpose of the retaining arches is to control the motion of the leaflets during the opening and closing phases of the valve in a manner which minimizes the stresses associated with the cyclic motion.


In general, current transcatheter prosthetic heart valves consist of separated leaflets and skirt portions, wherein the separated leaflets and skirt portions are sewn together by the time the biological heart valve is connected to the stent. Hence, with the conventional prosthetic heart valves, additional suture lines are necessary, causing stress concentration and reduced flexibility of the heart valve, thus leading to earlier calcification of the prosthetic heart valves.


In order to reduce or minimize stress concentration and to enhance flexibility of the heart valve, in some embodiments as disclosed herein the leaflets are integrally formed with the skirt portion. For example, a single piece of pericardium may be used for forming the prosthetic heart valve. As an alternative, the skirt portion may consist of multiple pieces of tissue, e.g. three pieces of tissue, which are sewn together by the time the biological heart valve is connected to the stent, wherein the leaflets are integrally formed with the tissue material of the pieces which together form the skirt portion. For example, three individual tissue panels may be utilized to construct the valve portion of the prosthetic heart valve. Whether a single piece of pericardium or three panels are used, the tissue structure is sutured to the stent structure to create the desired U-shape of the leaflets. This U-shape helps distribute the load on the leaflets throughout the cardiac cycle, but especially when in the closed position.


By avoiding that the leaflets must be sewn to the skirt portion(s), greater strength and durability of the heart valve assembly may be provided, as the strength and integrity of a uniform piece of tissue is improved from separate pieces of tissue sewn together. Additionally, the advantages of not having a seam include reduced assembly time (less suturing), less overall bulk when collapsing the prosthesis for small catheter delivery and more flexible leaflets at the transition area that could improve leaflet motion and hemodynamics.


The natural tissue material used for the manufacture of prosthetic heart valves typically contains connective tissue proteins (i.e., collagen and elastin) that act as supportive framework of the tissue material. In order to strengthen this compound of tissue proteins, a chemical fixation process may be performed, linking the proteins together. This technique usually involves the exposure of the natural tissue material to one or more chemical fixatives that form the cross-linkages between the polypeptide chains of the collagen molecules. In this regard, it is conceivable to apply different cross-linking techniques for different parts of the prosthetic heart valve tissue. For instance, the leaflets of the prosthetic heart valve could be treated by a different chemical fixative agent than the skirt portion in order to obtain diverse rigidity within the prosthetic heart valve.


In addition, it is conceivable to have leaflets and a skirt which are not integral. In this case, different cross-linking techniques may be applied to the leaflets and the skirt.


Examples of chemical fixative agents conceivably used for cross-linking of the prosthetic heart valve, according to the present disclosure include: aldehydes, (e.g. formaldehyde, glutaraldehyde, dialdehyde starch, para formaldehyde, glyceroaldehyde, glyoxal acetaldehyde, acrolein), diisocyanates (e.g., hexamethylene diisocyanate), carbodiimides, photooxidation, and certain polyepoxy compounds (e.g., Denacol-810,-512).


According to some of the disclosed embodiments, the prosthetic heart valve is mounted to the inner surface of a support stent. This arrangement facilitates protection of the prosthetic heart valve material during collapse and deployment. This is because the prosthetic heart valve is not in contact with the inner wall of the implantation catheter, and thus may not get stuck on the inner surface thereof. On this account, damage to the prosthetic heart valve is avoided. Also, such an endoprosthesis can be collapsed to a smaller diameter compared with a prosthetic heart valve mounted to the outer surface of the stent, hence providing the possibility to use smaller catheters.


On the other hand, it is conceivable to mount the prosthetic heart valve to the outer surface of a support stent. That is, the skirt portion could be in direct contact with the diseased native heart valve and could be attached to the stent by means of sutures. Mounting the prosthetic heart valve to the outer surface of the stent supports the load transfer from the leaflet to the stent. This greatly reduces stresses on the leaflets during closing and consequently improves the durability thereof. Also, it is possible to design the valve to obtain improved hemodynamics in the case of mounting the skirt portion and commissures to the outer surface of the stent. Additionally, the heart valve material which is in direct contact with the diseased native heart valve provides a good interface for sealing against leakage (i.e., paravalvular leakage), tissue in-growth and attachment. The stent designs for this endoprosthesis uniquely accommodate this valve embodiment and advantages, whereas for cage-like transcatheter delivered stent designs this is not possible.


The prosthetic heart valve can be made from pericardial tissue, for example, human pericardial tissue, preferably animal pericardial tissue, whereby bovine or porcine pericardial tissue is preferred. However, it is conceivable to employ kangaroo, ostrich, whale or any other suitable xeno- or homograft tissue of any feasible dimension.


Preferably, porcine tissue thicknesses of 220 to 260 μm after fixation shall be used to manufacture the biological prosthetic heart valves. Of course, this example is not a limitation of the possible kinds of tissues and their dimensions. Rather, it is conceivable to employ kangaroo, ostrich, whale or any other suitable xeno- or homograft tissue of any feasible dimension.


Many aspects of the disclosed prosthetic heart valve embodiments may become clear considering the structure of a corresponding stent to which the prosthetic heart valve may be attached in order to form a transcatheter delivered endoprosthesis used in the treatment of a stenosis (narrowing) of a cardiac valve and/or a cardiac valve insufficiency.


According to an aspect of the disclosure, a stent suitable for implantation with the aforementioned prosthetic heart valve may comprise positioning arches configured to be positioned within the pockets of the patient's native heart valve. Furthermore, the stent may comprise retaining arches. In detail, for each positioning arch one retaining arch may be provided. In the implanted state of the stent, the respective head portions of the positioning arches are positioned within the pockets of the patient's native heart valve such that the positioning arches are located on a first side of a plurality of native heart valve leaflets. On the other hand, in the implanted state of the stent, the retaining arches of the stent are located on a second side of the native heart valve leaflets opposite the first side. In this respect, the positioning arches on the one hand and the retaining arches on the other hand clamp the native heart valve leaflets in a paper-clip manner.


Hence, the positioning arches of the stent are designed to engage in the pockets of the native (diseased) cardiac valve which allows accurate positioning of the stent and a prosthetic heart valve affixed to the stent. Furthermore, in the implanted state, each positioning arch co-operates with a corresponding retaining arch resulting in clipping of the native leaflet between the two arches. In this way, the positioning and retaining arches hold the stent in position and substantially eliminate axial rotation of the stent


In a preferred embodiment, the positioning arch may be formed such as to have a substantially convex shape. In this way, the shape of each positioning arch provides an additional clipping force against the native valve leaflet.


The at least one retaining arch of the stent may be connected to a corresponding positioning arch by a connecting web. The retaining arch may extend substantially parallel to the positioning arch, thus having essentially the same shape. The shape of the retaining arch basically represents a U-shape with a small gap at its lower end. This gap is surrounded by a connection portion which originates during the fabrication of the tip of the positioning arches. The connection portion may be similar to a U- or V-shape and links the two sides of a retaining arch.


Along the retaining arches of the stent, a plurality of fastening holes and optionally one or more notches may be provided. Preferably, these fastening holes and notches are longitudinally distributed at given positions along the retaining arches and guide at least one thread or thin wire to fasten the tissue components of the prosthetic heart valve to the stent, thereby enabling a precise positioning of the tissue components on the stent. The means provided for fastening the tissue components of the biological prosthetic heart valve to the retaining arches of the stent (thread or thin wire) is guided by way of the fastening holes and notches to ensure accurate repeatable securement of the bioprosthetic heart valve within the stent structure. This accurate securement of the biological prosthesis substantially reduces the potential for longitudinal displacement of the biological prosthetic heart valve relative to the stent.


According to another embodiment of the present disclosure, the aforementioned plurality of retaining arches are provided with one or more fastening notches which can be used to fix the bendable transition area to the stent. To this end, the retaining arches may be segmented by a plurality of bending edges forming said fastening notches and defining bending points of the retaining arches. The fastening notches simplify the attachment of the bendable transition area of the prosthetic heart valve to the retaining arches.


In another aspect of the stent which is suitable for implantation with a biological prosthetic heart valve as disclosed herein, the retaining arches are cut from the material portion of a small metal tube in an shape that when expanded essentially form the U-shaped structure corresponding to the aforementioned progression of the transition area.


At the lower end of the stent, an annular collar may be provided. The annular collar may serve as a supporting body through which the radial forces, developing due to the self-expansion, are transmitted to the vascular wall. Attached to the annular collar is the skirt portion of the biological prosthetic heart valve. Typically, this attachment is implemented by means of suturing.


The intent of the self expanding annular collar in combination with the attached skirt region of the valve is to provide sufficient radial forces so as to seal and prevent paravalvular leakage. In addition, the collar aids in anchoring the prosthesis in the annulus to prevent migration. This collar may incorporate a flared or tapered structure to further enhance securement.


As mentioned above, a prosthetic heart valve can be attached to a corresponding stent in order to provide a transcatheter delivered endoprosthesis which can be used in the treatment of a stenosis (narrowing) of a cardiac valve and/or a cardiac valve insufficiency.


A prosthetic heart valve made from pericardial tissue material may be attached to the retaining arches and annular collar of the afore-mentioned stent by means of braided multi-filament polyester sutures. These sutures may have any suitable diameter, typically about 0.07 mm.


In order to increase the strength of the connection of biological prosthetic heart valve to the stent, however, it is conceivable to increase the size of the multi-filament sutures, for example, up to 0.2 mm. In this way, it is possible that the fundamental bond between the transition area of the prosthetic heart valve and the retaining arches of the stent exhibits additional stability. On the other hand, the remaining sutures shall be kept as thin as possible to enable collapsing of the endoprosthesis to a small diameter.


A common running stitch pattern may be used to obtain said bonding. According to the disclosure, the stitch pattern is preferably a locking stitch or a blanket stitch respectively. Of course, any other suitable stitch pattern (i.e. overlocking stitch, slipstitch or topstitch) is also possible.


Considering the stress concentration due to direct stitching in the heart valve material, another aspect of the disclosure may provide that the material of the prosthetic heart valve is reinforced to improve its suture retention force. To this end, laser cut suturing holes may be introduced into the prosthetic heart valve tissue with the laser cutting process strengthening the tissue area around the cut hole. Predefined laser cutting holes might also ease the suturing process itself and reduce stresses on the material of the prosthetic heart valve due to the penetration of the needle during stitching.


In another embodiment of the present disclosure, the connection of the prosthetic heart valve material to a stent may be reinforced by means of reinforcement elements. Such reinforcement elements are intended to reduce stress concentrations in the material of the prosthetic heart valve that may occur from direct stitching in the valve material. In particular, the reinforcement elements might reduce stress concentration in the tissue material of the prosthetic heart valve at the connection between the bendable transition area and the retaining arches of the stent. The reinforcement elements may be placed between an inner suture and the prosthetic heart valve material, thus distributing aforementioned stresses, caused by the stitching, over a larger area of the valve material. These reinforcement elements can be used at discrete locations or continuously along the path of the stitching. For example, they can be placed opposite to the retaining arches of the stent on the other side of the prosthetic heart valve material.


Reinforcement elements may be applied in order to avoid direct contact between knots of the sutures and the tissue of the prosthetic heart valve, thereby reducing abrasion of the prosthetic heart valve tissue due to rubbing against said sutures. To reduce direct contact between the heart valve tissue and the stent structure or any other metallic component of the endoprosthesis, reinforcement elements can further be used to prevent the tissue of the prosthetic heart valve from directly contacting the stent structure or any other metallic component respectively.


In this regard, it is also conceivable to locate reinforcement elements along the entire surface of the prosthetic heart valve. Preferably, such reinforcement elements could also be located at or near the upper edge of the leaflets. These upper edges, building the commissures of the endoprosthesis, are exposed to an increased tension, which are more likely to tear during the operation of the prosthetic heart valve.


Moreover, it is also feasible to place said reinforcement elements inside the tissue of the prosthetic heart valve, instead of a mere attachment on the surface of the prosthetic heart valve. In this regard, it may be advantageous to have a layer of tissue or synthetic material of different mechanical properties inside the aforementioned prosthetic heart valve. This alternative embodiment may be especially useful in order to reinforce the leaflets of the prosthetic heart valve in order to increase their ability to yield mechanical stresses occurring during the operation of the endoprosthesis.


Reinforcement elements can be used at discrete locations or continuously along the path of the stitching. For example, they can be placed opposite to the retaining arches of the stent on the other side of the prosthetic heart valve material.


The reinforcement elements may be folded or formed in such a way that round edges are formed. These round edges are designed to reduce or avoid abrasion of the valve material during opening and closing of the prosthetic heart valve.


With regard to a further embodiment of the present disclosure, the reinforcement elements comprise at least one inner cushion, which is mounted to the inner surface of the bendable transition area of the prosthetic heart valve. This inner cushion is arranged essentially opposite the retaining arches and/or to the commissure attachment region of the stent. Opposite in this context means that the inner cushion is mounted on an opposite side of the prosthetic heart valve. The inner cushion is designed to reduce the stress concentrations in the tissue that occur from direct stitching in the tissue. In more detail, the inner cushion prevents the prosthetic heart valve tissue from directly contacting knots of the suture. Due to this, wear of the heart valve tissue is reduced, as said knots do not rub on the surface of the tissue, during opening and closing of the heart valve.


In a further embodiment, the at least one inner cushion may be a pledget made of one or multiple layer materials. The inner cushion may consist of materials, for examples, like polyester velour, PTFE, pericardial tissue or any other material suitable for forming round edges, distributing or buffering stresses in the valve material, due to the sutures. On this account, the material of the inner cushion can be made from flat sheets or fabrics such as knits or woven constructions. It is to be noted that the reinforcement elements can be applied in order to span between stent struts, in particular across a gap, located at the lower end of the retaining arches, to help support the valve material across said gap.


In an alternative implementation, the reinforcement elements may consist of a wire rail placed at the inner surface of the bendable transition area of the prosthetic heart valve, essentially opposite the retaining arch of the stent. The wire rail may be secured in place using a stitch pattern meant to accommodate the wire rail and the valve material to the stent. In comparison to the inner cushion mentioned above, such a wire rail could be easier to attach to the material of the prosthetic heart valve. Furthermore the already rounded shape of the rail does not require the wire rail to be folded in order to obtain rounded edges for prevention of valve material abrasion.


It is preferable that said wire rail is made of Nitinol in order to allow collapsing of the reinforcement element simultaneously with the stent structure.


Moreover, in another realisation, the reinforcement elements may be essentially of the same size and form as the retaining arches of the stent, hence forming an inner attachment rail. The reinforcement elements, however, shall be of thinner material than the retaining arches. This is due to the fact that thick material may limit the ability of the endoprosthesis to be collapsed to a small size.


In particular, the inner attachment rail may have the same fastening holes and notches longitudinally distributed at given locations as the retaining arches of the stent. Again, the attachment rail may be placed on the inner surface of the bendable transition area of the prosthetic heart valve, opposite to the retaining arches of the stent. Thus, the material of the prosthetic heart valve may be clamped in between the stent and the reinforcement element, which are connected through sutures. The reinforcement element thus may act as an inner attachment rail for the leaflets of the prosthetic heart valve to bend over and evenly distribute stress loads affecting the valve material over a large attachment rail rather than individual suture points.


Although most embodiments of the disclosure use sutures to fix the reinforcement element or valve material to the stent, it is conceivable to use different attachment methods like welding, soldering, locking fixture and rivets. For instance, these methods could be used to attach the aforementioned inner attachment rail to the retaining arches of the stent. This would result in clamping the prosthetic heart valve material in between the inner surface of the stent and the outer surface of the reinforcement element without penetrating the valve material with needles of suture.


Another alternative attachment concept includes a reinforcing element attached to the back side of the prosthetic heart valve material. This concept may be suitable for attachment in a high stress area of a commissure attachment region on top of the retaining arches, which is described in more detail below. This concept involves creating a strengthened region by folding the prosthetic heart valve material and wrapping it with the reinforcing element. Thus, the reinforcement element forms an outer wrapping element which is mounted to the outer surface of the bendable transition area of the prosthetic heart valve, at the commissure attachment region of the stent. The reinforced bendable transition area of the prosthetic heart valve can then be securely attached to the retaining arches of the stent or the commissure attachment region of the stent.


The aforementioned outer wrapping element of the reinforcing element is preferably made of a polymer material such as PTFE or a PET fabric or sheet. However, it could also be a more rigid U-shaped clip or bendable material that can pinch the folded valve material. One advantage this concept has over the other reinforcing elements is that the reinforcing material is not placed on the inner surface of the prosthetic heart valve, hence does not disrupt the blood flow or potentially be a site for thrombus formation.


The outer wrapping element of the reinforcing element may also provide an opening buffer to keep the valve leaflet material from opening too wide and hitting the stent, which would cause wear of the valve material. Similar to the rounded edges of the other reinforcement elements, these buffers should be rounded, smooth or soft to avoid wear when the open valve material hits them. The buffer should be small enough to not significantly over restrict leaflet material opening.


An especially beneficial embodiment of the present invention includes an attachment concept with reinforcement elements attached to the inner surface and to the outer surface of the transition area of the prosthetic heart valve. This configuration optimally prevents stress concentration and resulting wear of the prosthetic heart valve.


In particular, a first reinforcement element is connected to the outer surface of the bendable area of the prosthetic heart valve, preferably lining the retaining arches and the commissure attachment region over their entire length. The said reinforcement element, which is connected to the outer surface of the prosthetic heart valve, can be made of animal pericardial tissue, such as the one used for the prosthetic heart valve itself. Of course, it is conceivable to use any other suitable material for the reinforcement element, such as synthetic materials or even homograft (human) tissue. The reinforcement element, connected to the outer surface of the prosthetic heart valve, has several advantages, such as preventing any rubbing and wear between the leaflet and the stent at the retaining arches or commissure attachment region respectively. Even if the attachment is tightly sutured, the tissue will have strain cycles at the surface during opening and closing motion of the leaflets, which can cause wear against the stent from micro movements. Furthermore, the reinforcement element allows for an additional spring-like compression to tighten the attachment of the leaflet to the stent, providing a more durable attachment than the one achieved by suturing the leaflets to a rigid surface. Also, the reinforcement element serves as a bumper during opening to limit full opening and reduce the accompanied shock affecting the prosthetic heart valve at opening.


In another embodiment, the reinforcement element, which is connected to the outer surface of the prosthetic heart valve, extends along the retaining arches and along the commissure attachment region, having a wider surface than the surface of the retaining arches or the surface of the commissure attachment region respectively. For this reason, the reinforcement element provides a surface, sufficient to cover the retaining arches and the commissure attachment region completely. Thus, abrasion or wear of the tissue at the retaining arches or commissure attachment region respectively is avoided reliably.


Concerning the attachment of the aforementioned reinforcement element another advantageous embodiment includes wrapping the reinforcement element around the retaining arches and the commissure attachment region and securing this connection by means of wrapping and stitching. That is to say that the reinforcement element is secured firmly to the retaining arches or commissure attachment region respectively, providing a stable surface for attachment of the prosthetic heart valve.


With regard to the reinforcement element, which is connected to the inner surface of the transition area of the prosthetic heart valve, in another realisation, the reinforcement element consists of a folded strip of porcine pericardium and is attached to the transition area and stent by means of sutures. This folded strip of porcine pericardium allows the sutures to spread out the compressive forces that secure the leaflet tissue. A tight suture attachment is required to avoid any movement or slipping under physiological loads. If attached tightly, the loads from the leaflet will be at least partially transferred to the stent through friction and not directly to the sutures at the needle holes. This minimizes the stress concentration by spreading out the stresses, especially at the commissure attachment region. Also, the strip of porcine pericardium serves as a bumper to absorb the impact of the tissue during closing and reduces the dynamic stresses transferred to the sutures. Of course, it is conceivable to use different materials to implement the reinforcement element, which is connected to the inner surface of the prosthetic heart valve, such as wires, brackets, synthetic materials or even homograft (human) tissue. In order to reduce or prevent leakage during closed state of the prosthetic heart valve, however, the aforementioned reinforcement element has to be constructed with a minimal size, so as to avoid the formation of a gap in between the closed leaflets.


According to another embodiment of the present invention, the reinforcement elements are wrapped in tissue to avoid wear of the prosthetic heart valve tissue during operation. This is especially advantageous in the case of the implementation of rigid reinforcement elements, such as wires or brackets. The tissue, wrapped around the reinforcement elements, provides a soft contact surface for the prosthetic heart valve tissue and hence prevents it from rubbing and reduces wear.


In addition to the reinforcement elements, other stent structures may also be wrapped in tissue or any other suitable synthetic cover. That is, in order to avoid abrasion of the prosthetic heart valve against the stent structure (e.g. retaining arches), the stent may be wrapped in tissue or any other suitable material. In accordance with this particular embodiment of the present disclosure, the heart valve tissue may not be sutured directly to the metallic stent structure but to the tissue or synthetic material covering it. This could provide a closer contact between the prosthetic heart valve and the stent so as to reliably prevent paravalvular leakage.


Yet another modification of the present disclosure includes exposing the prosthetic heart valve material surface and structure to polymeric material in order to reinforce it. Materials according to this embodiment could be cyanoacrylates or polyepoxides which imply excellent bonding of body tissue and could even be used for suture-less surgery.


In a similar realisation the bendable transition portion of the prosthetic heart valve material includes a layering of various materials with differing mechanical properties used to improve the durability of the prosthetic heart valve. To this end, layer materials with very high suture retention strength overlapping the valve material in regions of very high stress load may be applied. As to that, material layers with high suture retention in lower parts of the transition area of the prosthetic heart valve may be provided, whereas the upper parts of the transition area shall be designed to be flexible for improving the durability of the valve. Examples for such layer materials will be explained in more detail, with reference to the “reinforcement elements” below.


With regard to another embodiment of the present disclosure, an attachment for the prosthetic heart valve material that reduces the concentration of stresses at the bendable transition portion is disclosed. In this embodiment, the bendable transition portion of the prosthetic heart valve is attached to the retaining arches of the stent by folding the valve material from the outside of the stent through slotts provided along the retaining arches. As mentioned previously, the edges of the slotted retaining arches may be rounded and smooth to avoid abrading or wearing of the valve material. In this design, there is some material thickness on the outside of the stent, which could impinge on the anchoring of the stent at the position of the diseased natural prosthetic heart valve.


To accommodate this issue, a thinning of the retaining arches relative to the rest of the stent structure could be conducted. This would also allow for a recess when the stent is compressed so that the collapsed prosthesis does not require a larger delivery catheter.


According to an alternative embodiment of the present disclosure, the prosthetic heart valve is assembled with three separate pieces of pericardial tissue. According to this, the three separate pieces of pericardial tissue are advantageous regarding the thickness of the prosthetic heart valve tissue. When using a one piece flat tissue in order to form the prosthetic heart valve, the thickness of the leaflets can vary and result in less desirable valve performance, unsymmetrical valve opening and closure or less desirable hemodynamics, such as a short durability or insufficient leaflet closure. Therefore, three smaller pieces of pericardial tissue provide the possibility to form prosthetic heart valve with more uniform thicknesses and mechanical properties.


To this end, another embodiment of the present disclosure includes that each of the three separate pieces has a flat tissue pattern in an essentially T-shirt like shape, exhibiting sleeves for connection between the adjacent pieces. As mentioned previously, the adjacent pieces can be constructed, as to reinforce the contiguous edges of the adjacent pieces. To accomplish this, the sleeves of adjacent pieces can be folded to the outside and sutured together to reinforce the joining connection. Attaching this reinforced area to the stent commissure attachment region helps to more uniformly distribute leaflet stresses supported by the commissure attachment.


In order to further improve the reinforcement of the contiguous edges of the separate pieces, in another embodiment of the present invention, the reinforcement elements consist of outer wrapping elements, wrapped around the sleeves of the three separate pieces, in order to reinforce the prosthetic heart valve and attach it to the commissure attachment region of the stent. That is, an outer wrapping element can be used in order to further improve the durability of the prosthetic heart valve. In this regard, the outer wrapping element can consist of a piece of pericardial tissue or a synthetic material respectively. Also, the outer wrapping element is used to attach the reinforced prosthetic heart valve to the commissure attachment region of the stent by means of sutures. Therefore, the stresses due to the suturing between the stent and the prosthetic heart valve is mainly introduced into the material of the reinforcement element, avoiding high stress concentrations in the prosthetic heart valve.





The following will make reference to the attached drawings in describing preferred embodiments of the prosthetic heart valve, a corresponding stent and a transcatheter delivered endoprosthesis according to the present disclosure in greater detail.


Shown are:



FIG. 1 a roll-out view of a prosthetic heart valve according to an exemplary embodiment of the disclosure;



FIG. 2a a plan view of the upper end of the prosthetic heart valve in its closed state;



FIG. 2b a plan view of the upper end of the prosthetic heart valve in its opened state;



FIG. 3 a flat pattern of a prosthetic heart valve material piece having an essentially t-shirt like shape for a prosthetic heart valve according to a further exemplary embodiment of the disclosure;



FIG. 4 a top view of the three prosthetic heart valve material pieces sewn together and attached to commissure attachment regions of a stent according to the further exemplary embodiment of the disclosure; and



FIG. 5a a flat roll-out view of an exemplary embodiment of a first cardiac valve stent which may be used in the endoprosthesis according to FIG. 6a, 6b, 7a or 7b for fixing a prosthetic heart valve according to an exemplary embodiment of the disclosure;



FIG. 5b a first perspective side view of a first cardiac valve stent capable of supporting and anchoring a prosthetic heart valve according to an exemplary embodiment of the disclosure, whereby the cardiac valve stent is shown in its expanded state;



FIG. 5c a second perspective side view of a first cardiac valve stent capable of supporting and anchoring a prosthetic heart valve according to an exemplary embodiment of the disclosure, whereby the cardiac valve stent is shown in its expanded state;



FIG. 5d a third perspective side view of a first cardiac valve stent capable of supporting and anchoring a prosthetic heart valve according to an exemplary embodiment of the disclosure, whereby the cardiac valve stent is shown in its expanded state;



FIG. 5e a plan view of the lower end of a first cardiac valve stent capable of supporting and anchoring a prosthetic heart valve according to an exemplary embodiment of the disclosure, whereby the cardiac valve stent is shown in its expanded state;



FIG. 6a a first perspective side view of an endoprosthesis for treating a narrowed cardiac valve or a cardiac valve insufficiency, where the endoprosthesis is shown in an expanded state and where the endoprosthesis comprises a cardiac valve stent and a prosthetic heart valve according to an exemplary embodiment of the disclosure, said cardiac valve stent is used for holding the prosthetic heart valve;



FIG. 6b a second perspective side view of an endoprosthesis for treating a narrowed cardiac valve or a cardiac valve insufficiency, where the endoprosthesis is shown in an expanded state and where the endoprosthesis comprises a cardiac valve stent and a prosthetic heart valve according to an exemplary embodiment of the disclosure, said cardiac valve stent is used for holding the prosthetic heart valve;



FIG. 7a a first perspective side view of an endoprosthesis for treating a narrowed cardiac valve or a cardiac valve insufficiency, where the endoprosthesis is shown in an expanded state and where the endoprosthesis comprises a cardiac valve stent and a prosthetic heart valve according to an exemplary embodiment of the disclosure, said cardiac valve stent is used for holding the prosthetic heart valve;



FIG. 7b a second perspective side view of the endoprosthesis depicted in FIG. 7a, where the endoprosthesis is shown in an expanded state and where the endoprosthesis comprises a cardiac valve stent and a prosthetic heart valve according to an exemplary embodiment of the disclosure, said cardiac valve stent is used for holding the prosthetic heart valve;



FIG. 8a a flat roll-out view of an exemplary embodiment of a second cardiac valve stent, in its compressed state, which may be used in the endoprosthesis according to FIG. 11a or FIG. 11b for fixing a prosthetic heart valve according to an exemplary embodiment of the disclosure;



FIG. 8b a first perspective side view of the second cardiac valve stent capable of supporting and anchoring a prosthetic heart valve according to an exemplary embodiment of the disclosure, whereby the cardiac valve stent is shown in its expanded state;



FIG. 8c a second perspective side view of the second cardiac valve stent capable of supporting and anchoring a prosthetic heart valve according to an exemplary embodiment of the disclosure, whereby the cardiac valve stent is shown in its expanded state;



FIG. 8d a second flat roll-out view of an exemplary embodiment of a second cardiac valve stent, in its expanded state, which may be used in the endoprosthesis according to FIG. 11a or FIG. 11b for fixing a prosthetic heart valve according to an exemplary embodiment of the disclosure;



FIG. 9 a flat roll-out view of an exemplary embodiment of a third cardiac valve stent, in its expanded state, which may be used in an endoprosthesis for fixing a prosthetic heart valve according to an exemplary embodiment of the disclosure;



FIG. 10 a flat roll-out view of an exemplary embodiment of a fourth cardiac valve stent, in its expanded state, which may be used an endoprosthesis for fixing a prosthetic heart valve according to an exemplary embodiment of the disclosure;



FIG. 11a a first perspective side view of an endoprosthesis for treating a narrowed cardiac valve or a cardiac valve insufficiency, where the endoprosthesis is shown in an expanded state and where the endoprosthesis comprises a cardiac valve stent and a prosthetic heart valve according to an exemplary embodiment of the disclosure, said cardiac valve stent is used for holding the prosthetic heart valve;



FIG. 11b a second perspective side view of the endoprosthesis depicted in FIG. 11a, where the endoprosthesis is shown in an expanded state and where the endoprosthesis comprises a cardiac valve stent and a prosthetic heart valve according to an exemplary embodiment of the disclosure, said cardiac valve stent is used for holding the prosthetic heart valve;



FIG. 11c a perspective top view of the endoprosthesis depicted in FIG. 11a, where the endoprosthesis is shown in an expanded state and where the endoprosthesis comprises a cardiac valve stent and a prosthetic heart valve according to an exemplary embodiment of the disclosure, said cardiac valve stent is used for holding the prosthetic heart valve;



FIG. 12 a cross sectional view along the line A-A shown in FIG. 6b or 11b showing a first exemplary embodiment of reinforcement elements which may be utilized in the endoprosthesis according to the present disclosure for fixing a prosthetic heart valve to a cardiac valve stent;



FIG. 13 a cross sectional view along the line A-A shown in FIG. 6b or 11b showing a second exemplary embodiment of reinforcement elements which may be utilized in the endoprosthesis according to the present disclosure for fixing a prosthetic heart valve to a cardiac valve stent;



FIG. 14 a cross sectional view along the line A-A shown in FIG. 6b or 11b showing a third exemplary embodiment of reinforcement elements which may be utilized in the endoprosthesis according to the present disclosure for fixing a prosthetic heart valve to a cardiac valve stent;



FIG. 15 a cross sectional view along the line B-B shown in FIG. 6b or 11b for explaining a fourth exemplary embodiment of reinforcement elements which may be utilized in the endoprosthesis according to the present disclosure for fixing a prosthetic heart valve to a cardiac valve stent;



FIG. 16 a cross sectional view along the line B-B shown in FIG. 6b or 11b showing a fifth exemplary embodiment of reinforcement elements which may be utilized in the endoprosthesis according to the present disclosure for fixing a prosthetic heart valve to a cardiac valve stent;



FIG. 17 a cross sectional view along the line B-B shown in FIG. 6b or 11b showing a sixth exemplary embodiment of reinforcement elements which may be utilized in the endoprosthesis according to the present disclosure for fixing a prosthetic heart valve to a cardiac valve stent;



FIG. 18 a cross sectional view along the line B-B shown in FIG. 6b or 11b showing an alternative attachment solution for fixing a prosthetic heart valve to a cardiac valve stent;



FIG. 19a-c the steps for connecting two separate prosthetic heart valve material pieces along their contiguous edges according to the second exemplary embodiment of the prosthetic heart valve;



FIG. 20 a top view of the attachment of the prosthetic heart valve to the commissure attachment regions of a stent according to the second exemplary embodiment of the prosthetic heart valve;



FIG. 21 a detailed perspective view of an alternative attachment of the prosthetic heart valve to the commissure attachment regions of a stent according to the second exemplary embodiment of the prosthetic heart valve.






FIG. 1 shows a view of a flat tissue pattern for a prosthetic heart valve 100 according to an exemplary disclosed embodiment. The prosthetic heart valve 100 may comprise at least two leaflets, and as shown in the exemplary embodiment of the flat tissue pattern for a prosthetic heart valve 100 depicted in FIG. 1 three leaflets 102. Each of the leaflets 102 comprises a natural tissue and/or synthetic material. The leaflets 102 are attached to a skirt portion 103. As will be discussed later on in detail, the skirt portion 103 is used for mounting the prosthetic heart valve 100 to a stent 10.


The leaflets 102 of the prosthetic heart valve 100 are adapted to be moveable from a first opened position for opening the heart chamber and a second closed position for closing the heart chamber. In particular, in the implanted state of the prosthetic heart valve 100, the leaflets 102 may switch between their first and second position in response to the blood flow through the patient's heart. During ventricular systole, pressure rises in the left ventricle of the patient's heart. When the pressure in the left ventricle of the patient's heart rises above the pressure in the aorta the leaflets 102 of prosthetic heart valve 100 opens, allowing blood to exit the left ventricle into the aorta. When ventricular systole ends, pressure in the left ventricle rapidly drops. When the pressure in the left ventricle decreases, the aortic pressure forces the leaflets 102 of the prosthetic heart valve 100 to close.



FIGS. 2a and 2b respectively show a plan view of the upper end of a prosthetic heart valve 100 in the closed and opened state. In the closed position of the prosthetic heart valve 100 (see FIG. 2a), the three leaflets 102 come together in the centre of the prosthetic heart valve 100 thereby creating a region of sealing.


During the opening phase the leaflets pivot about a bendable transition area 104, as depicted in FIG. 1. The bendable transition area 104 forms a junction between the leaflets 102 and the skirt portion 103 and progresses in a substantial U-shaped manner, similar to the cusp shape of a natural aortic or pulmonary heart valve. Still within the opening phase, the commissure region 105 and the leaflets 102 move radially outwards opening the valve in response to increased differential pressure allowing blood to flow through the prosthesis.


In the exemplary embodiment depicted in FIG. 1, the prosthetic heart valve 100 is made of one piece of flat pericardial tissue. This pericardial tissue can either be extracted from an animal's heart (xenograft) or a human's heart (homograft). The extracted tissue may be cut by a laser or knife or might be pressed in order to form a flat tissue pattern representing each of the leaflets 102 and the skirt portion 103. After said forming of the flat tissue pattern, the so made heart valve tissue may be sewn into a cylindrical or conical shape, ready to be attached to a corresponding stent structure 10. As will be discussed in detail with respect to FIGS. 6a, 6b, the skirt portion 103 represents an area of the prosthetic heart valve 100 that is used for connecting the prosthetic heart valve 100 to a stent 10, for example, by means of sutures 101.


As can be seen from FIGS. 1 and 2, the pattern of the prosthetic heart valve 100 represents each of the leaflets 102, commissure region 105 and the skirt portion 103 of the intended prosthetic heart valve 100. Hence, the flat tissue pattern is designed so as to form the leaflets 102 in a manner, having three half-moon shaped leaflets like the aortic or pulmonary heart valve. The leaflets 102 can be designed in various shapes such as the geometry of an ellipse, U-shape or substantially oval. Preferably the three leaflets 102 are formed in such a manner that all of them have the same general shape.


Another aspect shown by FIG. 1 is a flared lower end section of prosthetic heart valve 100. As will be explained in more detail below, such a flared lower end section may be advantageous in order to fit the prosthetic heart valve 100 to an annular collar 40 of a respective cardiac heart valve 10. Alternatively, it is further conceivable to produce a prosthetic heart valve 100 comprising a tapered lower end section. A flare or taper at the lower end section of the prosthetic heart valve 100 may be adapted to the geometry of the blood vessel at the implantation site of the prosthesis, so as to obtain the most reliable fit of said prosthesis to said blood vessel.


Between the leaflets 102 and the skirt portion 103, the valve pattern shows the bendable transition area 104 progressing in a substantial U-shaped manner, similar to the cusp-shape of a natural aortic or pulmonary heart valve.


As can be derived from FIG. 2a, the leaflet portion of the prosthetic heart valve 100 is designed to provide redundant coaptation for potential annular distortion. Accordingly, the redundant coaptation may reduce stress on the leaflets 102 and assures a reliable closure of the heart chamber in the second closed position of the leaflets 102. This redundant coaptation provides for more surface contact between the leaflets, allowing for the prosthetic heart valve of the present disclosure to be implanted in a distorted valve annulus, still maintaining sufficient coaptation.


Although not depicted in FIG. 1, the prosthetic heart valve 100 can comprise a plurality of fastening holes 106 provided along the progression of the transition area 104. These fastening holes 106 are introduced into the tissue material of the prosthetic heart valve 100 by means of laser cutting for strengthening the tissue area around the fastening holes 106. Alternatively, however, it is conceivable that fastening holes 106 are introduced by the needle during the sewing process.


The bendable transition area 104 shown in FIG. 1 may include a layering of various materials with differing mechanical properties. Accordingly, the lower parts, particularly associated with retaining arches of a cardiac valve stent, may be more rigid to provide high suture retention, whereas the upper parts, particularly associated with a commissure attachment region 11b of the stent, may be designed to be more flexible in order to support the movement of the leaflets 102. On the same note, the leaflets 102 and the leaflet support portion 103 may exhibit different stability characteristics. This might be achieved by the use of different cross-linking processes for the leaflets 102 or the leaflet support portion 103 respectively. Alternatively, the leaflets 102 or the leaflet support portion 103 could be reinforced by attaching small sheets of tissue or synthetic material in order to increase the mechanical stability.


As the size and diameter of different blood vessels of different patients varies to a certain extent, it may be advantageous to provide prosthetic heart valves 100 of different designs. In particular, tissue material with a thickness of 160 μm to 300 μm, more preferably 220 μm to 260 μm may be used, depending on the particular tissue material used to manufacture the prosthetic heart valve. Furthermore, the prosthetic heart valve 100, according to the present disclosure, may have a diameter ranging form 19 mm to 28 mm.


Reference is made in the following to FIGS. 6a, b which respectively show a first and second perspective side view of an endoprosthesis 1 for treating a narrowed cardiac valve or a cardiac valve insufficiency, where the endoprosthesis 1 comprises an exemplary embodiment of a cardiac valve stent 10 for holding a prosthetic heart valve 100. In the illustrations according to FIGS. 6a, b, the endoprosthesis 1 is shown in an expanded state.


As can be seen from the illustrations according to FIGS. 6a, b, in the affixed state of the prosthetic heart valve 100, the transition area 104 of the prosthetic heart valve 100 extends along the retaining arches 16a, 16b, 16c and, in particular, along the lower leaflet attachment region 11c and the commissure attachment region 11b of the retaining arches 16a, 16b, 16c of the stent 10. The bendable transition area 104 of the prosthetic heart valve 100 is attached to retaining arches 16a, 16b, 16c of the stent 10 such as to enable the leaflets 102 of the prosthetic heart valve 100 to bend inwards in a controlled manner to the centre of the stent 10 forming the valvular leaflets 102.


For adapting the prosthetic heart valve 100 to a corresponding stent 10 so that the valvular leaflets 102 are properly formed and prosthetic heart valve is properly fitted to the stent structure, the pattern of the flat-tissue material of the prosthetic heart valve 100 shall be cut so as to incorporate the leaflet structures, the annular skirt portion 103 and the transition area 104 in between them. In other words, after the prosthetic heart valve material is sewn into its cylindrical or conical shape, the valve exhibits a flared portion at the lower end. This flared geometry fits the structure of the stent 10 and is constructed to optimally fit the vascular wall at the implantation site of the diseased heart valve.


In the exemplary embodiment of the transcatheter delivered endoprosthesis 1 depicted in FIGS. 6a, b, the prosthetic heart valve 100, which is affixed to the stent 10, consists of a one piece flat pericardial tissue material extracted from an animal or human pericardial sack and cut into a pattern representing each of the three leaflets 102 and the skirt portion 103, wherein the pattern is sewn into a cylindrical shape before attachment to the stent 10. In addition, the prosthetic heart valve 100 includes a transition area 104 which is connected to the retaining arches 16a, 16b, 16c and commissure attachment regions 11b of the stent. The transition area 104 connects the leaflets 102 with the skirt portion 103. In particular, the transition area 104 is essentially U-shaped, similar to the cusp shape of a natural aortic or pulmonary heart valve. For this reason, the transition area 104 allows for an opening and closing motion of the leaflets 102, causing minimal stresses within the biological prosthetic heart valve tissue.


Upon assembly of this tissue pattern (see FIG. 1) to a stent 10, the regions of tissue between the retaining arches become the valve leaflets 102. These leaflets can be folded inwards so as to form three essentially closed leaflets. In case of a pressure gradient in a downstream direction (in response to a rising blood pressure in the heart chamber), the leaflets 102 are forced apart, in the direction of the stent 10, enabling blood to exit the heart chambers. On the other hand, if there is a pressure gradient in the opposite, upstream direction (retrograde gradient, in response to an intake pressure in the heart chamber), the blood rushes into the leaflets 102, thereby pressing the leaflets 102 together in the centre of stent 10 and closing the transcatheter delivered endoprosthesis 1.


As has been described in more detail with reference to FIGS. 5a-e and FIGS. 8 to 10, a suitable stent 10, to which the prosthetic heart valve 100 may be attached for forming an endoprosthesis 1, may include an annular collar 40 arranged to a lower section of stent 10. The annular collar 40 of the stent 10 serves as an additional anchoring measure to hold the transcatheter delivered endoprosthesis 1 in a desired location at the site of the diseased heart valve. In the exemplary embodiment of the transcatheter delivered endoprosthesis 1 depicted in FIGS. 6a, b, FIGS. 7a, b and FIGS. 11a to 11c, the annular collar 40 of the stent 100 has a flared shape.


Accordingly, the lower part of leaflet support portion 103 of the prosthetic heart valve 100 affixed to the stent 10 also exhibits an extended diameter in order to accommodate the flared shape of the annular collar 40.


The prosthetic heart valve 100 is fixed to the stent 10 by means of sutures, threads or wires 101 which are attached to the skirt portion 103 and/or the transition area 104 of the prosthetic heart valve 100. The skirt portion 103 serves for keeping the prosthetic heart valve 100 in a predefined position relative to the stent 10.


As will be described in more detail below, a suitable stent 10, to which the prosthetic heart valve 100 may be attached for forming an endoprosthesis 1, may include an annular collar 40 arranged to a lower section of stent 10. The annular collar 40 of the stent 10 serves as an additional anchoring measure to hold the transcatheter delivered endoprosthesis 1 in a desired location at the site of the diseased heart valve.


As can be seen from the illustrations in FIGS. 6a, b, the skirt portion 103 of the prosthetic heart valve 100 may also be attached to the annular collar 40 of the stent 10 by means of sutures, threads or wires 101. For this purpose, multi-filament sutures 101 of a diameter up to 0.2 mm, preferably between 0.1 mm and 0.2 mm may be used.


Moreover, a common running stitch pattern may be used to obtain said bonding. According to the disclosure, the stitch pattern is preferably a locking stitch or a blanket stitch respectively. Of course, any other suitable stitch pattern (i.e. overlocking stitch, slipstitch or topstitch) is also possible.


As indicated by FIGS. 6a and 6b, the bendable transition area 104 of the prosthetic heart valve may be attached to retaining arches 16a, 16b, 16c of the stent 10 by means of sutures 101, having a diameter larger than the diameter of the sutures 101 used for attachment of the prosthetic heart valve to an annular collar 40 of the stent 10. Due to this, the prosthetic heart valve 100 can be reliably attached to the stent without adding too much bulk to the stent 10, in order to collapse the endoprosthesis to a small diameter.


In the exemplary embodiment of the transcatheter delivered endoprosthesis 1 depicted in FIGS. 6a, b, the annular collar 40 of the stent 100 has a flared shape. Accordingly, the lower part of skirt portion 103 of the prosthetic heart valve 100 affixed to the stent 10 also exhibits an extended diameter in order to accommodate the flared shape of the annular collar 40.


The scope of the present disclosure will become more clear by considering some of the possible embodiments of a stent 10 with the prosthetic heart valve 100 attached thereto thereby forming an endoprosthesis. Hence, reference is made in the following to FIGS. 5a-e for describing an exemplary embodiment of a stent 10 to which a prosthetic heart valve 100 may be affixed in order to form the transcatheter delivered endoprosthesis 1 depicted in FIGS. 6a, b.


In particular, FIG. 5b is a first perspective side view of a cardiac valve stent 10, whereby the cardiac valve stent 10 is shown in its expanded state. Second and third side views of the cardiac valve stent 10 in its expanded state are shown in FIGS. 5c and 5d.


On the other hand, FIG. 5e shows a plan view of the lower end of the cardiac valve stent 10 according to the exemplary embodiment of the disclosure in its expanded state, whereas a flat roll-out view of a stent 10 according to the exemplary embodiment is shown in FIG. 5a.


The stent 10 depicted in FIGS. 5a-e is also provided with an annular collar 40 which is arranged at the lower end section of the stent body. The at least one collar 40 may serve as an additional anchoring measure for the stent 10.


In addition, the stent 10 according to the exemplary embodiment has a total of three positioning arches 15a, 15b, 15c, which undertake the function of automatic positioning of the stent 10. Each of the positioning arches 15a, 15b, 15c has a radiused head portion 20, which engages in the pockets of the native heart valve being treated during positioning of the stent 10 at the implantation site in the heart.


The exemplary embodiment of the stent 10 also includes radial arches 32a, 32b, 32c. In particular, the stent 10 has three radial arches 32a, 32b, 32c, with each arch 32a, 32b, 32c located between the two arms 15a, 15a′, 15b, 15b′, 15c, 15c′ of each positioning arch 15a, 15b, 15c. Each radial arch 32a, 32b, 32c has a shape that is roughly inverse to each positioning arch 15a, 15b, 15c and extends in the opposite direction to each one of the positioning arches 15a, 15b, 15c.


In addition, the stent 10 according to the exemplary embodiment depicted in FIGS. 5a-e is provided with corresponding retaining arches 16a, 16b, 16c. Each one of the retaining arches 16a, 16b, 16c is allocated to one of the positioning arches 15a, 15b, 15c. Also, according to this exemplary embodiment of the stent 10, a number of commissure attachment regions 11b with a number of additional fastening holes 12c is configured at one end of each arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c.


In addition to the commissure attachment regions 11b, the stent 10 also comprises second lower leaflet attachment regions 11c for additional fastening of the tissue component(s) of a prosthetic heart valve 100 (see FIGS. 6a, b). In this regard, the stent 10 according to the exemplary embodiment depicted in FIGS. 5a-e has a configuration with a number of attachment regions 11b, 11c to attach the material of a prosthetic heart valve 100.


The stent 10 may also be provided with leaflet guard arches, wherein one leaflet guard arch may be provided in between each positioning arch 15a, 15b, 15c. The structure and function of the leaflet guard arches will be described later with reference to FIGS. 7a and 7b. Hence, although for reasons of clarity not explicitly shown, in the stent design according to the exemplary embodiment depicted in FIGS. 5a-e, one leaflet guard arch may be allocated to each positioning arch 15a, 15b, 15c.


The exemplary embodiment of the sent 10 is characterized by a specific structure of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c. In detail, in the expanded state of the stent 10, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c have a shape similar to a prosthetic heart valve 100. Furthermore, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c are provided with a number of lower leaflet attachment regions 11c, each having a number of additional fastening holes 12a or eyelets provided for fastening the tissue component(s) of a prosthetic heart valve 100. These additional fastening holes 12a or eyelets provide attachment points for the bendable transition area 104 of a prosthetic heart valve 100 attached to the stent 10.


As will be described in more detailed below, in an alternative embodiment, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c may be provided with a number of fastening notches which can be used to fix the bendable transition area 104 to stent 10. Thus, in this alternative embodiment, there are no additional fastening holes 12a needed along the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c.


According to the stent designs of the embodiments depicted in FIGS. 5a-e and FIGS. 8 to 10, in the expanded state of the stent 10, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c have a shape that substantially matches the transition area 104 of a prosthetic heart valve 100 attached to the stent 10 (see FIG. 6a, b or 11a, b).


This specific design of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c has valve durability advantages. The so formed arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c serve for supporting the skirt portion 103 and edge of the leaflets 102 of a prosthetic heart valve 100 attached to the stent 10.


As depicted, for example, in FIGS. 6a, b and 11a, b, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c follow the shape of the bendable transition area 104 of a prosthetic heart valve 100 affixed to the stent 10 in its expanded state. Furthermore, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c are designed to have a minimized unsupported gap from one arm to the other arm of a retaining arch 16a, 16b, 16c at the location behind the positioning arches 15a-c.


In detail and as depicted in the cutting pattern shown in FIG. 5a, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c are provided with a plurality of bending edges 33. These bending edges 33 divide each arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ into a plurality of arm segments. The arm segments of a single arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c are interconnected thereby constituting a retaining arch arm which describes an essentially straight line in the not-expanded state of the stent 10. In this regard, reference is also made to the cutting pattern depicted in FIG. 5a which shows the uncurved configuration of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c.


When manufacturing the stent 10, the stent structure and in particular the structure of the retaining arches 16a, 16b, 16c is programmed such that the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c have a curved shape in the expanded state of the stent 10. The shape of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c is such defined that the arms follow the shape of the transition area 104 of a prosthetic heart valve 100 to be affixed to the stent 10 (see FIGS. 6a and 6b).


Hence, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c of the stent 10, onto which the transition area 104 of a prosthetic heart valve 100 is sewn or sewable, will change their shape when the stent 10 expands, wherein the retaining arches 16a, 16b, 16c are curved in the expanded state of the stent 10, but relatively straight when the stent 10 is collapsed.


As can be seen, for example, in FIGS. 5b-d, the curvature of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c is achieved by segmenting the arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″. In detail, the arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ are segmented by providing a plurality of bending edges 33. In the expanded state of the stent 10, two neighboring arm segments are angled relative to each other, wherein the bending point of these two neighboring arm segments is defined by the bending edge 33 which is provided in between the both neighboring arm segments. Hence, the greater the number of bending edges 33 provided in an arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of a retaining arch 16a, 16b, 16c, the greater the number of arm segments which may extend in different directions in the expanded state of the stent 10. In this respect, the shape of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c can be precisely adapted to the shape of transition area 104 of a prosthetic heart valve 100 to be affixed to the stent 10. Also, it should be noted that the embodiments depicted in FIGS. 8 to 10 show an even higher number of bending edges 33 providing a plurality of arm segments. Further to this, the bending edges 33 depicted in FIGS. 8 to 10 are formed so as to provide a plurality of fastening notches along the retaining arches 16a, 16b, 16c, as will be described in more detail below.


The stent 10 depicted in FIGS. 5a-e is also provided with an annular collar 40 which is arranged at the lower end section of the stent body. The at least one annular collar 40 may serve as an additional anchoring measure for the stent.


In the embodiment depicted in FIGS. 6a and 6b, the stent 10 corresponds to a stent pursuant the exemplary embodiment previously described with reference to FIGS. 5a-e. On the other hand, the prosthetic heart valve 100 affixed to the stent 10 corresponds to the exemplary embodiment of the prosthetic heart valve 100 previously described with reference to FIG. 1 and FIGS. 2a, b.


Hence, as shown in the exemplary embodiment of the transcatheter delivered endoprosthesis 1 depicted in FIGS. 6a, b, the prosthetic heart valve 100 affixed to the stent 10 comprises three leaflets 102 made from a biological or synthetic material.


To reduce longitudinal displacement of the prosthetic heart valve 100 relative to the stent 10, the stent 10 comprises a plurality of fastening portions in the form of lower leaflet attachment regions 11c, essentially extending in the longitudinal direction L of stent 10. In addition, the stent 100 is provided with commissure attachment regions 11b. By means of the lower leaflet attachment regions 11c and the commissure attachment regions 11b (both acting as fastening portion), the tissue components of the prosthetic heart valve 100 are affixed to the stent 10.


In detail, the prosthetic heart valve 100 is fastened to the stent 10 by means of sutures 101, threads or a thin wire which is guided through fastening holes 12a, 12c of the lower leaflet attachment regions 11c and the commissure attachment regions 11b respectively. This allows fixing of the tissue components of the prosthetic heart valve 100 to the stent 10 at a predefined position relative to the stent 10.


Alternatively, as will be described with reference to FIGS. 8 to 10, the sutures 101, threads or wires may be guided by fastening notches provided along the retaining arches 16a, 16b, 16c, instead of the aforementioned fastening holes 12a. Hence, in the alternative embodiments according to FIGS. 8 to 10, the fastening holes 12a of the lower leaflet attachment region 11c are replaced by notches (provided by bending edges 33), whereas the commissure attachment region 11b may still be provided with fastening holes 12c.


It can further be seen from the FIG. 6a or FIG. 6b illustration how the prosthetic heart valve 100 can be affixed to the stent 10 by means of sutures 101. In the depicted embodiment, a pericardial prosthetic heart valve 100 is used which is sewn to fastening holes 12a, 12c provided in the fastening portions of the retaining arches 16a, 16b, 16c, i.e. the lower leaflet attachment regions 11c on the one hand and in the commissure attachment regions 11b on the other hand. In order to improve the attachment of the prosthetic heart valve 100 to the stent 10, the skirt portion 103 may be sewn to the annular collar 40 as well as other parts of the stent structure. The prosthetic heart valve 100 may be tubular with a substantially circular cross-section.


On the other hand, it is conceivable to mount the prosthetic heart valve 100 to the outer surface of a support stent 1. That is, the skirt portion 102 could be in direct contact with the diseased native heart valve and could be attached to the stent 10 by means of sutures. Mounting the prosthetic heart valve 100 to the outer surface of the stent 10 supports the load transfer from the leaflet 102 to the stent 1. This greatly reduces stresses on the leaflets 102 during closing and consequently improves the durability thereof. Also, it is possible to design the valve to obtain improved hemodynamics in the case of mounting the skirt portion and commissures to the outer surface of the stent. Additionally, the heart valve material which is in direct contact with the diseased native heart valve provides a good interface for sealing against leakage (i.e., paravalvular leakage), tissue in-growth and attachment.


The material for the prosthetic heart valve 100 and, in particular the material for the leaflets 102 of the prosthetic heart valve 100 can be made from synthetics, animal valves or other animal tissues such as pericardium. The animal tissues can be from a number of types of animals. Preferably, the leaflet material of the prosthetic heart valve 100 is from either bovine or porcine pericardium, but other animals can also be considered, for example equine, kangaroo, etc.


Reference is made in the following to FIGS. 12 to 17 for describing exemplary embodiments of reinforcement elements 107.1 to 107.8 which may be utilized in the endoprosthesis 1 according to the present disclosure. The reinforcement elements 107.1 to 107.8 may reduce the stress concentration in the tissue material of the prosthetic heart valve 100 at the connection between the bendable transition area 104 and the lower leaflet attachment region 11c (FIGS. 12 to 14) and/or the commissure attachment regions 11b (FIGS. 15 to 17) of the stent 10.


The reinforcement elements 107.1 to 107.8 can be at discrete locations or continuously along the path of the stitching. For example, they can be placed opposite to the retaining arches of the stent on the other side of the prosthetic heart valve material. The depicted reinforcement elements 107.1 to 107.8 are applied in order to strengthen the attachment to the stent and reduce stress concentrations in the leaflet material that would occur by suturing directly to the bendable transition portion 104 or leaflet support portion 103 respectively. Further to this, the reinforcement elements 107.1 to 107.8 may avoid direct contact between knots of the sutures and the tissue of the prosthetic heart valve. Also, direct contact between the heart valve tissue and the stent structure or any other metallic component of the endoprosthesis can be avoided by the reinforcement elements.


The reinforcement elements 107.1 to 107.8 are preferably designed with rounded edges to avoid abrasion of the valve tissue during opening and closing of the prosthetic heart valve 100.


In more detail, FIG. 12 shows a cross sectional view along the line A-A in FIG. 6b or FIG. 11b respectively, i.e. a cross sectional view of one retaining arch 16a, 16b, 16c of the stent 10 utilized in an endoprosthesis 1 of the present disclosure. As depicted in FIG. 12, a first exemplary embodiment of reinforcement elements 107.1 may be utilized for fixing the prosthetic heart valve 100 to the stent 10.


According to this exemplary embodiment, the connection of the prosthetic heart valve tissue to the stent 10 is reinforced by means of at least one reinforcement element in the form of a inner cushion 107.1 which is intended to reduce stress concentrations in the tissue material of the prosthetic heart valve 100, said that stress concentrations may occur from direct stitching in the tissue material of the prosthetic heart valve 100. The at least one reinforcement element in the form of the inner cushion 107.1 is placed between a suture 101.1 and the tissue material of the prosthetic heart valve 100. In this respect, any stress caused by the suture 101.1 is distributed over a larger area of the tissue material of the prosthetic heart valve 100. The at least one reinforcement element in the form of the inner cushion 107.1 is placed opposite to the corresponding retaining arch 16a, 16b, 16c of the stent 10 on the other side of the tissue material of the prosthetic heart valve 100. That is, the at least one reinforcement element in the form of the inner cushion 107.1 is mounted to the inner surface of the bendable transition area 104 of the prosthetic heart valve 100. The at least one inner cushion 107.1 representing a first embodiment of the reinforcement elements may be folded in such a way that at least one round edge 108 is formed. This at least one round edge 108 is designed to avoid abrasion of tissue material of the leaflets 102 during opening and closing of the prosthetic heart valve 100.


The reinforcement element in the form of the inner cushion 107.1 may be made of one or multiple layer materials, consisting of materials like polyester velour, PTFE, pericardial tissue, or any other material suitable for forming round edges, distributing or buffering stresses in the tissue material of the prosthetic heart valve 100. The reinforcement element in the form of the inner cushion 107.1 can be applied to span across the gap formed between the lower end of two neighbouring arms 16a′, 16a″; 16b′, 16b″; 16c′, 16c″ of one retaining arches 16a, 16b, 16c (see FIG. 6a) for supporting the tissue material of the prosthetic heart valve 100 across the gap.


Reference is further made to FIG. 15, which is a cross sectional view along the line B-B (commissure attachment region 11b) shown in FIG. 6b or 11b for explaining a second exemplary embodiment of the reinforcement elements which may be utilized in the transcatheter delivered endoprosthesis 1 of the present disclosure, for fixing a prosthetic heart valve 100 to a cardiac valve stent 10.


Again, the reinforcement element may be made of one or multiple layer materials and consisting of materials like polyester velour, PTFE, pericardial tissue or any other material suitable for forming round edges. As shown in FIG. 15, at the upper end section of the prosthetic heart valve 100, the tissue material of the prosthetic heart valve 100 may be attached to the commissure attachment region 11b in such a manner that when the leaflets 102 are folded together, during closure of the heart valve, a small cavity 109 is created. Inside this cavity 109, a reinforcement element in the form of an inner cushion 107.2 is inserted. It has to be noted that the cavity 109 is formed, so as to be as small as possible in order to avoid leakage during the closing phase of the heart valve prosthesis 1.



FIG. 13 is a cross sectional view along the line A-A shown in FIG. 6b or 11b for explaining a third exemplary embodiment of reinforcement elements which may be utilized in the endoprosthesis 1 according the present disclosure. According to this exemplary embodiment, the reinforcement element may consist of a wire rail 107.3 which is substantially at the same place as the reinforcement elements consisting of an inner cushion 107.1 illustrated in FIG. 12. In this case, the sutures 101.1 are coiled around the wire rail 107.3 on the inner surface of the prosthetic heart valve 100, whilst on the outer surface of the biological prosthetic heart valve, the sutures 101.1 are attached to a retaining arch 16a, 16b, 16c by means of a suitable stitch pattern. That is, the wire rail 107.3 is mounted to the inner surface of the bendable transition area 104 of the prosthetic heart valve. The wire rail 107.3 is preferably made of Nitinol, thus allowing for the wire rail 107.3 to collapse together with the stent 10. Again, the reinforcement element of the third embodiment is designed with rounded edges to avoid abrasion of the leaflet tissue during opening and closing of the prosthetic heart valve 100.



FIG. 14 is a cross sectional view along the line A-A shown in FIG. 6b or 11b for explaining a fourth exemplary embodiment of reinforcement elements which may be utilized in the endoprosthesis 1 according to the present disclosure. Hence, instead of using inner cushions 107.1, 107.2 which consist of materials like polyester velour or PTFE, the reinforcement element, according to the fourth exemplary embodiment, can be arranged as essential copies of the retaining arches 16a, 16b, 16c. In this embodiment, however, the reinforcement element is an inner attachment rail 107.4 which is thinner than a corresponding retaining arch 16a, 16b, 16c since a thick material would inhibit the endoprosthesis 1 from being collapsed to a small size. In particular, the inner attachment rail 107.4 has the same fastening holes 12a and notches longitudinally distributed at given locations as the corresponding retaining arch 16a, 16b, 16c.


Moreover, the inner attachment rail 107.4 is placed on the inner surface of the tissue material of the prosthetic heart valve 100, opposite to the retaining arches 16a, 16b, 16c. Thus the prosthetic heart valve 100 is clamped in between the retaining arches 16a, 16b, 16c and the inner attachment rail 107.4, wherein the retaining arches 16a, 16b, 16c and the inner attachment rail 107.4 are connected by means of sutures 101.1.


In an alternative embodiment, however, the connection between retaining arches 16 and the inner attachment rail 107.4 may utilize rivets, welding or soldering, so as to clamp the biological prosthetic heart valve tissue without penetrating it with needles or suture. In turn, it is preferable, that the inner attachment rail 107.4 may be made of Nitinol, in order to allow simultaneously collapsing with the stent 10.


Of course, the edges of the inner attachment rail 107.4 may be rounded in order to prevent abrasion of the leaflets 102. In addition, the inner attachment rail 107.4 could be wrapped in tissue or synthetic material to further reduce the potential wear during the contact with the leaflet material upon the heart valve operation.



FIG. 16 shows a cross sectional view along the line B-B shown in FIG. 6b or 11b for explaining a fifth exemplary embodiment of reinforcement elements which may be utilized in the endoprosthesis 1 of the present disclosure.


As depicted in FIG. 16, the reinforcement element according to this exemplary embodiment is an outer wrapping element 107.5 attached to the back side of the prosthetic heart valve tissue, at the commissure attachment region 11b of the stent 10. The leaflets 102 are folded without forming a cavity. Rather, the outer wrapping element 107.5 is clamped on the outer surface of the biological prosthetic heart valve 100, more particularly to the outer surface of the bendable transition area 104, pressing the leaflets 102 together. Thereby, a strengthened region is created by folding the prosthetic heart valve tissue and wrapping it with the outer wrapping element 107.5.


The outer wrapping element 107.5 is attached the commissure attachment region 11b by means of sutures 101.1. Additional lateral sutures 101.2 are provided to press the outer wrapping element 107.5 onto the outer surface of the bendable transition area 104 of the prosthetic heart valve 100.


The outer wrapping element 107.5 is preferably made of a polymer material such as PTFE, PET fabric or sheet or a piece of pericardial tissue. However, it could also be a more rigid u-shaped clip or bendable material that can pinch the folded tissue material of the prosthetic heart valve 100 without the use of additional lateral sutures 101.2. In addition, this outer wrapping element 107.5 acts as a bumper to limit the opening of the leaflets 102 in order to prevent them from hitting stent 10.


The dashed lines in FIG. 16 represent the closed position of the leaflets 102.



FIG. 18 shows an alternative attachment solution where the prosthetic heart valve 100 is mounted to the stent 10 from the outside. For this purpose, the tissue material of the prosthetic heart valve 100 is folded and passes through slots 110 provided in the retaining arches 16a, 16b, 16c. The edges of the slots 110 are preferably rounded and smooth to avoid abrading or wearing the tissue material of the prosthetic heart valve 100. Furthermore, to further reduce wear of the tissue, the slots 110 could be wrapped in thin pericardial tissue. In this design, there is some material thickness on the outside of the stent 10, which could impinge on the anchoring of the stent 10 at the position of the diseased natural prosthetic heart valve.


One embodiment might include thinning the retaining arches 16a, 16b, 16c on the outer surface relative to the rest of the stent structure, to accommodate the tissue material on the outside surface. This would also allow for a recess when the stent 10 is compressed so that the collapsed prosthesis does not require a larger delivery catheter.



FIG. 17 is a cross sectional view along the line B-B depicted in FIG. 6b or 11b showing a sixth exemplary embodiment of reinforcement elements 107.6, 107.7 which may be utilized in the endoprosthesis according present disclosure.


In detail, FIG. 17 shows an embodiment where reinforcement elements 107.6 and 107.7 are attached to the inner surface and the outer surface of the transition area 104 of the prosthetic heart valve 100. Although FIG. 17 only shows a cross sectional view along the line B-B, it should be noted that the depicted sixth embodiment of the reinforcement elements may also be applied along the retaining arches 16a, 16b, 16c (line A-A) of the stent. In this regard, the outer reinforcement element 107.6 may consist of a wide strip of 200 μm thick porcine pericardium that is long enough to cover the entire length of the retaining arches 16a, 16b, 16c (lower leaflet attachment region 11c) and the commissure attachment region 11b. This strip of pericardium which forms the outer reinforcement element 107.6 can be cut into three short segments of about 5 mm each to match the length of the commissure attachment region 11b and three long segments of about 45 mm each to match the length along the retaining arches 16a, 16b, 16c (lower leaflet attachment region 11c) from one commissure attachment region 11b to the adjacent.


The 4 mm wide porcine pericardium outer reinforcement element 107.6 may be folded in half and sutured using a fine clinging suture 101.4 (e.g. a 8-0 suture) with a running stitch very close to the free edges. The sutured outer reinforcement element 107.6 is then placed along the inner surface of the retaining arches 16a, 16b, 16c and/or the commissure attachment region lib with a 8-0 running stitch placed along the stent surface. The outer reinforcement element 107.6 is sutured to the stent to line the inner surface using 6-0 surrounding sutures 101.3 and zig-zag crossing stitches that wrap around the commissure attachment region 11b and/or the retaining arches 16a, 16b, 16c (not through the eyelets).


With regards to the inner reinforcement element 107.7, the material is preferably a strip of 200 μm porcine pericardium, which is about 3.5 mm wide and cut and overlapped or rolled to three layers. The length of the piece of tissue depends on whether only the commissure attachment region 11b or the retaining arches 16a, 16b, 16c are reinforced. For only the commissure attachment region 11b, three short segments of about 5 mm are needed. The strip is held in the overlapped or rolled shape by clinging sutures 101.4 with an 8-0 running stitch. The inner reinforcement element 107.7 may be constructed such as to exhibit minimal size to avoid causing too big of a cavity 109 in between the leaflets 102 during closure of the prosthetic heart valve 100. The inner reinforcement element 107.7 is secured on the inner surface of the bendable transition area 104 of the prosthetic heart valve 100 and to the stent 10 through the eyelets 12a. Preferably, 4-0 sutures 101.1 with a locking stitch on the outer diameter are used for this purpose. These sutures 101.1 are the most critical in the assembly and need to be very tight with no slack and locking. Instead of a single 4-0 suture 101.1, it is contemplated that two 6-0 sutures for redundancy and similar overall total strength are used. Furthermore, the 4-0 sutures 101.1 hold the outer reinforcement element 107.6 in place.


When opening and closing the leaflets 102 of the prosthetic heart valve 100, the outer reinforcement element 107.6 acts as a bumper to absorb shocks which affect the leaflets 102 during opening. In turn, the inner reinforcement element 107.7 spreads out the compressive forces induced by the sutures 101.1, thus avoiding stress concentration at the transition area 104 of the prosthetic heart valve 100.


In the following, reference is made to FIGS. 7a, b for describing a further exemplary embodiment of a cardiac valve stent capable of supporting and anchoring a prosthetic heart valve. In detail, FIG. 7a shows a first perspective side view of a transcatheter delivered endoprosthesis 1 for treating a narrowed cardiac valve or a cardiac valve insufficiency, where the endoprosthesis 1 comprises a cardiac valve stent 10 according to the first exemplary embodiment of the stent (FIGS. 5a-e) for holding a prosthetic heart valve. FIG. 7b shows a second perspective side view of the endoprosthesis 1 depicted in FIG. 7a.


In contrast to the exemplary embodiment shown in FIGS. 6a and 6b, the endoprosthesis depicted in FIGS. 7a, b shows the prosthetic heart valve 100 according to the second valve embodiment. That is, the prosthetic heart valve 100 attached to the stent 10 of FIGS. 7a, b consists of three separate pieces 120 being sewn together along their contiguous edges 112. These three separate pieces 120 may either be cut from a single pericardial sack (xenograft or homograft) or from a plurality of pericardial sacks.


The endoprosthesis 1 according to the exemplary embodiment illustrated by FIGS. 7a and 7b comprises a stent 10 according to the first stent embodiment depicted by FIGS. 5a to 5e. This stent 10 comprises a plurality of positioning arches 15a, 15b, 15c configured to be positioned within a plurality of pockets of the patient's native heart valve and positioned on a first side of a plurality of native heart valve leaflets, and a plurality of retaining arches 16a, 16b, 16c configured to be positioned on a second side of the plurality of native heart valve leaflets opposite the first side, wherein furthermore a plurality of leaflet guard arches 50a, 50b, 50c are provided, each interspaced between the two arms 15a′, 15a″, 15b′, 15b″, 15c′, 15c″ of one of the plurality of positioning arches 15a, 15b, 15c. In addition, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c are preferably provided with a plurality of bending edges 33 in order to divide each arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ into a plurality of arm segments, wherein the structure of the stent 10 is programmed such that the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c have a curved shape at least in the expanded state of the stent 10. In particular, the shape of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c shall be such defined that the arms follow the shape of the leaflets 102 of a prosthetic heart valve 100 to be affixed to the stent 10.


In the structure of the stent 10 according to the embodiment depicted in FIGS. 7a and 7b, one leaflet guard arch 50a, 50b, 50c is provided in between each positioning arch 15a, 15b, 15c. Hence, one leaflet guard arch 50a, 50b, 50c is allocated to each positioning arch 15a, 15b, 15c.


Each leaflet guard arch 50a, 50b, 50c has a substantially U-shaped or V-shaped structure which is closed to the lower end 2 of the stent 10. In particular, each leaflet guard arch 50a, 50b, 50c has a shape that is roughly similar to the shape of the positioning arch 15a, 15b, 15c and each leaflet guard arch 50a, 50b, 50c is arranged within the arms of the corresponding positioning arch 15a, 15b, 15c. Furthermore, each of the leaflet guard arches 50a, 50b, 50c extends in the same direction as the positioning arch 15a, 15b, 15c.


The leaflet guard arches 50a, 50b, 50c are preferably programmed so that they extend in a radial direction outside the circumference of the stent 10 when the stent 10 is in its expanded state. In this way, an increased contact force can be applied to the leaflets of the native (diseased) cardiac valve when the stent 10 is in its expanded and implanted state. This, in turn, allows an increased security in the fixing of the stent 10 in situ.


When the stent 10 is in its expanded and implanted state, the leaflet guard arches 50a, 50b, 50c actively keep the diseased leaflets, i.e. the leaflets of the native cardiac valve, from impinging the leaflets 102 of a prosthetic heart valve 100 attached to the stent 10, when the positioning arches 15a, 15b, 15c are placed outside the native leaflets. In addition, the leaflet guard arches 50a, 50b, 50c may also provide additional anchoring and securing against migration.


An alternative embodiment of a stent 10 is shown in FIGS. 8a-d (hereinafter also named “second stent embodiment”). The stent 10 according to the embodiment depicted in FIGS. 8a-d essentially comprises the same features as the stent described with reference to FIGS. 5a-e. In particular, the stent 10 also comprises positioning arches 15a, 15b, 15c as well as retaining arches 16a, 16b, 16c and an annular collar 40.


In contrast to the first embodiment of a stent 10 depicted in FIGS. 5a-e, the stent 10 of the second stent embodiment comprises retaining arches 16a, 16b, 16c which are not provided with a number of lower leaflet attachment regions 11c, each having a number of additional fastening holes 12a or eyelets provided for fastening the tissue components of a prosthetic heart valve 100. Rather, the stent of the second stent embodiment is provided with retaining arches 16a, 16b, 16c whose arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ are segmented by a plurality of bending edges 33 which are not only used for defining a bending point of two neighboring arm segments, but also as fastening notches which can be used for fixing the prosthetic heart valve prosthesis 100 to the stent 10. It is conceivable, of course, that the fastening notches are adapted to the thickness of the suture, thread or wire. In particular, the additional notches may be radiused to minimize damage to the suture, thread or wire. Due to the increased number of bending edges 33 providing fastening notches along the retaining arches 16a, 16b, 16c, the retaining arches 16a, 16b, 16c allow for more continuous bending along the entire length of their respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″, simplifying the attachment of said retaining arches 16a, 16b, 16c to the bendable transition area 104 of the prosthetic heart valve 100.


In more detail, FIG. 8a shows a flat roll-out view of a cardiac valve stent 10 pursuant the second embodiment of the stent 10, whereby the stent 10 is in its non-expanded state. This flat roll-out view corresponds to a two-dimensional projection of a cutting pattern which can be used in the manufacture of the stent 10 pursuant the second embodiment. This enables a one-piece stent 10 to be cut from a portion of tube, in particular a metal tube.



FIG. 8b shows a first perspective side view of a cardiac valve stent 10 according to the second stent embodiment, whereby the cardiac valve stent 10 is shown in its expanded state, and FIG. 8c shows a second perspective side view the stent 10 according to the second stent embodiment, whereby the cardiac valve stent is also shown in its expanded state.



FIG. 8d shows a flat roll-out view of a cardiac valve stent 10 according to the second embodiment of the stent. Contrary to the flat roll-out view depicted in FIG. 8a, however, the flat roll-out view according to FIG. 8d shows the cardiac valve stent 10 is in its expanded state.


Thus, the stent 10 according to the second stent embodiment comprises a plurality of positioning arches 15a, 15b, 15c and a plurality of retaining arches 16a, 16b, 16c. Each of the plurality of positioning arches 15a, 15b, 15c is configured to be positioned within a plurality of pockets of the patient's native heart valve and positioned on a first side of a plurality of native heart valve leaflets. On the other hand, each of the plurality of retaining arches 16a, 16b, 16c is configured to be positioned on a second side of the plurality of native heart valve leaflets opposite the first side.


Furthermore, a plurality of leaflet guard arches 50a, 50b, 50c are provided, each interspaced between the two arms 15a′, 15a″, 15b′, 15b″, 15c′, 15c″ of one of the plurality of positioning arches 15a, 15b, 15c. In addition, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c are preferably provided with a plurality of bending edges 33 in order to divide each arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ into a plurality of arm segments, wherein the structure of the stent 10 is programmed such that the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c have a curved shape at least in the expanded state of the stent 10. In particular, the shape of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c shall be such defined that the arms follow the shape of the bendable transition area 104 of the prosthetic heart valve 100 to be affixed to the stent 10.


In detail and as depicted in the flat roll-out view shown in FIG. 8a, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c are provided with a plurality of bending edges 33. These bending edges 33 may be uniformly distributed along the length of each retaining arch arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ thereby dividing each arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ into a plurality of arm segments. The arm segments of a corresponding retaining arch arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ are interconnected thereby constituting a retaining arch arm which describes an essentially straight line in the not-expanded state of the stent 10. In this regard, reference is made to the flat roll-out view depicted in FIG. 8a which shows the uncurved configuration of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c.


When manufacturing the stent 10, the stent structure and in particular the structure of the retaining arches 16a, 16b, 16c is programmed such that the respective retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ have a curved shape in the expanded state of the stent 10. The shape of the respective retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ is such defined that the arms follow the shape of the leaflets of a prosthetic heart valve 100 to be affixed to the stent 10 (cf. FIG. 8d).


Hence, the respective retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″, onto which the prosthetic heart valve 100 is sewn or sewable, will change their shape when the stent 10 expands, wherein the retaining arches 16a, 16b, 16c are curved in the expanded state of the stent 10, but relatively straight when the stent 10 is collapsed. Thus, when in the expanded state, the retaining arches 16a, 16b, 16c of the stent 10 are adapted to fit to the shape of the bendable transition area 104 of the prosthetic heart valve 100. In detail, in their expanded state, the retaining arches 16a, 16b, 16c are adapted to progress in an essentially u-shaped manner, similar to the shape of a natural aortic or pulmonary heart valve, for reducing tissue stresses during the opening and closing motion of the leaflets 102.


As can be seen, for example, in FIG. 8d, the essentially u-shaped curvature of the respective retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ is achieved by segmenting the arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″. In detail, the arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ are segmented by providing a plurality of bending edges 33. In the expanded state of the stent 10, two neighboring arm segments are angled relative to each other, wherein the bending point of these two neighboring arm segments is defined by the bending edge 33 which is provided in between neighboring arm segments. Hence, the greater the number of bending edges 33 provided in an arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of a retaining arch 16a, 16b, 16c, the greater the number of arm segments which may extend in different directions in the expanded state of the stent 10. In this respect, the shape of the respective retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ can be adapted to the shape of the leaflets 102 of the prosthetic heart valve 100 to be affixed to the stent 10.


According to the design of the second stent embodiment, the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c are not provided with fastening holes 12a, as it is the case, for example, in the first embodiment of the stent (FIGS. 5a to 5e). Rather, in the second stent embodiment, the bending edges 33 provided in the retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ are not only used for defining a bending point of two neighboring arm segments, but also as fastening notches which can be used for fixing a prosthetic heart valve 100 to the stent 10.


A comparison with, for example, the flat roll-out view pursuant to FIG. 5a (first stent embodiment) illustrates directly that the respective retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the stent design according to the second stent embodiment is at least partly much more thinner compared with the respective retaining arch arms of the first stent embodiment which are provided with lower leaflet attachment regions having fastening holes 12a. By reducing the width of the retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″, the bendability of the arms is increased which allows a more precise adaptation of the shape of the respective retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ to the shape of the bendable transition area 104 of the prosthetic heart valve 100 to be affixed to the stent 10.


Moreover, by using the bending edges 33 provided in the retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ as fastening notches for fixing a heart valve prosthesis to the stent 10, a greater number of attachment points compared with the number of fastening holes 12a can be generated. In this regard, high stress concentrations at each single attachment point can be effectively avoided. Furthermore, the fastening notches provide space and allow for the sutures 101 to be protected during collapsing of the valve 100 into the catheter. Therefore, adjacent members of the stent 10 do not impinge on and damage the sutures 101 used to attach the prosthetic heart valve 100 to the retaining arches 16a, 16b, 16c, during collapsing and deployment of the prosthetic heart valve 100.


In addition, in the second embodiment of the stent, the attachment points (bending edges 33) to be used for fixing a heart valve prosthesis to the retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the stent 10 are more uniformly distributed along the respective retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″, thereby providing a more uniform fixation of a heart valve prosthesis to the stent. Hence, the risk of an axial displacement of the heart valve prosthesis relative to the stent may be further reduced. Each individual bending edge 30 provided in the respective retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ thereby serves to guide a thread or thin wire with which the tissue component(s) of the prosthetic heart valve is affixed or sewn to the corresponding retaining arch arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the stent 10. In detail, the means (thread or thin wire) provided for fastening the tissue component(s) of the prosthetic heart valve to the respective retaining arch arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ is guided by way of the bending edge 33 acting as fastening notch so that a longitudinal displacement of the prosthetic heart valve relative to the stent 10 is substantially minimized. This also allows exact positioning of the prosthetic heart valve relative the stent 10.


In addition, the stent 10 according to the second stent embodiment may further include at least one auxiliary arch 18a, 18b, 18c interspaced between two adjacent retaining arches 16a, 16b, 16c, wherein the at least one auxiliary arch 18a, 18b, 18c includes a first arm 18a′, 18b′, 18c′ connected at a first end thereof to a first retaining arch 16a, 16b, 16c and a second arm 18a″, 18b″, 18c″ connected at a first end thereof to a second retaining arch 16a, 16b, 16c, and wherein the first and second arms 18a′, 18a″, 18b′, 18b″, 18c′, 18c″ of the at least one auxiliary arch 18a, 18b, 18c each include respective second ends connected to an annular collar 40 which is arranged at the lower end section of the stent body. As in the previously described stent design (first stent embodiment), this at least one collar 40 serves as an additional anchoring measure for a stent cut from a portion of a tube by using the cutting pattern depicted in FIG. 8a.


In detail, the respective first and second arms 18a′, 18a″, 18b′, 18b″, 18c′, 18c″ of the at least one auxiliary arch 18a, 18b, 18c are part of a strut or web structure which is provided between the first and second arms 18a′, 18a″, 18b′, 18b″, 18c′, 18c″ of two adjacent auxiliary arches 18a, 18b, 18c in order to support the prosthetic heart valve 100 to be affixed to the stent 10 (see, for example, FIGS. 11a and 11b). As can be seen, for example, from FIG. 8d the strut or web structure may be composed by a plurality of struts or strut-like members which are interconnected such as to form a reinforcement structure. Each strut or strut-like element of the reinforcement structure serves as reinforcement member in order to increase the strength or resistance to deformation of the area between the first and second arms 18a′, 18a″, 18b′, 18b″, 18c′, 18c″ of two adjacent auxiliary arches 18a, 18b, 18c. The reinforcement structure thereby provides mechanical reinforcement to the stent 10. Moreover, the reinforcement members of the reinforcement structure between the first and second arms 18a′, 18a″, 18b′, 18b″, 18c′, 18c″ of two adjacent auxiliary arches 18a, 18b, 18c provides for an additional support for the skirt portion 103 of a prosthetic heart valve 100 to be attached to the stent 10. In fact, it is conceivable to attach the skirt portion 103 of a prosthetic heart valve 100 directly to the auxiliary arches 18a, 18b, 18c by means of sutures, threads or thin wires, as will be explained in more detail with reference to FIGS. 11a and 11b below.


The terms “strength” or “resistance to deformation” as used herein may be used to denote any of a number of different properties associated with the reinforcement members. For example, the terms may be used to refer to properties of the material from which the reinforcement members are made, such as the yield strength, the modulus of elasticity, the modulus of rigidity, or the elongation percentage. Similarly, the terms may be used to refer to the hardness of the reinforcement members. Hardness may be characterized as the “durometer” of the material, in reference to the apparatus used to measure the hardness of the material. The terms may also be used to denote geometric characteristics of the reinforcement members, such as the thickness of the reinforcement members. The terms “strength” or “resistance to deformation” may also be used to characterize any combination of the above properties as well as additional properties and/or characteristics.


The strength or resistance to deformation of the area between the first and second arms 18a′, 18a″, 18b′, 18b″, 18c′, 18c″ of two adjacent auxiliary arches 18a, 18b, 18c can be increased in any number of ways. As can be seen from FIG. 8d, the strength or resistance to deformation of the area between the first and second arms 18a′, 18a″, 18b′, 18b″, 18c′, 18c″ of two adjacent auxiliary arches 18a, 18b, 18c can be increased, for example, by providing a reinforcement structure formed by at least one, and preferably by a plurality of reinforcement elements (e.g. struts or strut-like members) which are interconnected to each other.


It is also conceivable that a reinforcement web is provided in order to increase the strength or resistance to deformation of the area between the first and second arms 18a′, 18a″, 18b′, 18b″, 18c′, 18c″ of two adjacent auxiliary arches 18a, 18b, 18c. This reinforcement web may also be composed by a plurality of reinforcement elements (e.g. struts or strut-like members) which are interconnected to each other thereby forming a rhomboidal pattern.


The strength or resistance to deformation of the area between the first and second arms 18a′, 18a″, 18b°, 18b′, 18c′, 18c″ of two adjacent auxiliary arches 18a, 18b, 18c can be increased, for example, by increasing the thickness of the reinforcement members, by eliminating stress concentration risers in the design of the stent 10, or by changing other aspects of the geometry of the reinforcement members. The strength can also be increased by changing the material properties of the stent 10 and/or the reinforcement members. For example, the reinforcement members can be made from a number of different materials, preferably shape memory materials, each having a different level of hardness. In this regard, it is conceivable to vary the stoichiometric composition of the material used for forming the stent and the reinforcement members such as to adapt the material properties of the stent 10 and/or the reinforcement members to the specific needs of each stent application. It is also conceivable to use different materials, for example nitinol and a shape-memory polymer, for forming the stent and the reinforcement members. In this manner, the selection of the reinforcement members can be tailored to the specific needs of each stent application. For example, in regions where a high external force is expected, reinforcement members having a high hardness may be preferred. The strength may also be increased by combining material properties with geometric changes.


As can be seen from FIG. 8d, the stent 10 according to the second stent embodiment is provided with a reinforcement structure which is constituted by a plurality of lattice cells 70 formed by a plurality of struts in the area between the arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of two neighbouring (adjacent) retaining arches 16a, 16b, 16c, thereby providing for an additional support for the bendable transition area 104 of a prosthetic heart valve 100 to be attached to the stent 10.


In addition, this structure of the lattice cells 70 formed by a plurality of struts in the area between the adjacent arms of two neighbouring retaining arches 16a, 16b, 16c may provide uniform stent structure which may minimize blood leakage in the implanted stage of the stent 10 having a heart valve prosthesis attached thereto.


The upper end sections of the respective struts which are forming the structure of the lattice cells 70 are connected to the respective arms of the retaining arches 16a, 16b, 16c. Preferably, the upper end sections of the struts comprise a widened diameter in order to strengthen the connection between the upper end sections of the struts and the arms of the retaining arches 16a, 16b, 16c.


The already mentioned annular collar 40, which is provided at the lower end section of the stent body, is connected with the stent body via the retaining arches 16a, 16b, 16c on the one hand and the second ends of the respective arms 18a′, 18a″, 18b′, 18b″, 18c′, 18c″ of the at least one auxiliary arch 18a, 18b, 18c on the other hand, wherein these arms 18a′, 18a″, 18b′, 18b″, 18c′, 18c″ of the at least one auxiliary arch 18a, 18b, 18c are part of the structure of the lattice cells 70. In particular, the stent 10 according to the second embodiment is provided with an annular collar 40 which is shortened in its length by having only a single row of cells.


As can be seen from the flat roll-out view pursuant to FIG. 8a, the annular collar 40 at the lower end section of the stent body exhibits a plurality of supporting webs 41 which run parallel to the longitudinal axis L of the stent 10 in the non-expanded state of the stent 10 and are inter-connected by transversal webs 42. As can be seen from the two-dimensional roll-out view pursuant to FIG. 8c, however, in the expanded state of the stent 10, the supporting webs 41 and the transversal webs 42 forms a rhomboidal or serpentine-like annular collar 40 which abuts against the vascular wall in the implanted state of the stent 10.


In order to further improve securing of the position of an implanted and expanded endoprosthesis 1 and preventing antegrade migration, the stent 10 according to the second stent embodiment is provided with a flared or tapered section with a radius shape at its lower end section 2. In detail and as depicted in FIGS. 8b and 8c, in the expanded state of the stent 10, the lower end section of the annular collar 40 constitutes the flared or tapered section of the stent 10. As has been described before, the prosthetic heart valve 100 according to the present disclosure, may comprise a flared or tapered lower end section so as to fit to the described stent shapes.


The stent 10 depicted in FIGS. 8b and 8c has at its lower end section 2 a flared or tapered section with a radius shape; however, it is also conceivable that the flared or tapered section is not uniformly around the circumference of the stent 10. For example, the stent 10 may have a flare only near the locations of the positioning arches 15a, 15b, 15c, wherein no flare is provided near the commissure regions, i.e. the regions in between the two arms 15a′, 15a″, 15b′, 15b″, 15c′, 15c″ of two neighboring positioning arches 15a, 15b, 15c.


As depicted in FIGS. 8b and 8c, the stent 10 according to the second stent embodiment comprises a continuous design of its lower end section 2. Due to this continuous design, in the implanted and expanded state of the stent 10, via the lower end section 2 of the stent 10 an uniform radial force is applied to the wall of the blood vessel into which the stent 10 is deployed.


If the implanted and expanded stent together with a prosthetic heart valve affixed thereto extend too far below the annulus of the heart, there may be the risk that the implanted endoprosthesis consisting of the stent 10 on the one hand and the prosthetic heart valve 100 on the other hand contacts the nerve bundles and heart block. The nerve bundles may enter at a location approximately 6 to 10 mm below the annulus of the heart.


In order to avoid the lower end section 2 of the implanted stent 10 touching the atrioventricular node, the stent 10 pursuant to the second stent embodiment is provided with an annular collar 40 which is shortened in its length by having only a single row of cells. In this regard, the total height of the stent 10 and thus the total height of the endoprosthesis 1 to be implanted into the body of the patient are reduced.


Moreover, in the programming process during which the shape of the desired (expanded) stent structure is fixed, the supporting webs 41 of the annular collar 40 may be programmed so that—when the stent 10 of the second embodiment is in its expanded state—only the upper section of the annular collar 40 extends in a radial direction outside the circumference of the stent 10, whereas the lower end section of the annular collar 40 bended relative to the upper section of the annular collar 40 in the radial direction inside the circumference of the stent 10. The lower end section of the annular collar 40 may be bent such that it extends, for example, approximately parallel to the longitudinal direction L of the stent 10. In this way, an increased contact force (radial force) is applied by the upper section of the annular collar 40 to the wall of the blood vessel into which the stent 10 is deployed, whereas the risk is reduced that the lower end section of the annular collar 40 can touch the atrioventricular node.


It is important to note, that the stent 10 according to the second stent embodiment comprises a number of notches 12e uniformly distributed around the lower end section of the annular collar 40. These notches 12e can be used for fixing a heart valve prosthesis (not shown in FIGS. 8b and 8c) to the stent 10, which may reduce the risk of an axial displacement of the heart valve prosthesis 100 relative to the stent 10. Since a plurality of notches 12e are used as additional fastening means it is possible to utilize the lower end sections of every supporting web 41 of the annular collar 40 for additionally fastening a heart valve prosthesis to the stent 10. This appears directly from the flat roll-out view pursuant to FIG. 8a.


A comparison with, for example, the flat roll-out view pursuant to FIG. 5a (first stent embodiment) illustrates directly that the provision of eyelets 12f at the lower end sections of every supporting web 41 of the annular collar 40 requires much more material for each eyelet 12f compared with the amount of material which is necessary for forming respective notches 12e. Since it is conceivable for the stent 10 to exhibit a structure integrally cut from a portion of tube, in particular from a metal tube, which incorporates all structural components of the stent 10, in particular the positioning arches 15a, 15b, 15c, the retaining arches 16a, 16b, 16c and the annular collar 40 with defined additional fastening means at the lower end thereof, an elaborate cutting pattern for forming the design of the stent 10 from the original tube portion is important. In particular, it must be taken into account that the structure of the stent 10 with all structural stent components must be cut from the limited lateral area of the original tube portion.


Hence, by providing notches 12e instead of eyelets 12f as additional fastening means at the lower end section of the annular collar 40, a greater number of notches 12e compared with the number of eyelets 12f can be generated. In detail, according to the second stent embodiment, the lower end sections of every supporting web 41 of the annular collar 40 is provided with a corresponding notch 12e acting as additional fastening means. In contrast, in the first embodiment of the stent (FIGS. 5a to 5e) only the lower end sections of every second supporting web 41 of the annular collar 40 can be provided with a corresponding eyelet 12f acting as additional fastening means.


In this regard, the stent design according to the second stent embodiment differs from the first stent design in that at the lower end section of every supporting web 41 of the annular collar 40 an additional fastening means is provided. This is due to the fact that, in the second embodiment of the stent 10, notches 12e are used as additional fastening means.


Hence, in the second stent embodiment, the additional fastening means to be used for fixing a heart valve prosthesis to the stent 10 are more uniformly distributed around the lower end section of the annular collar 40, thereby providing a more uniform fixation of a prosthetic heart valve to the stent. Hence, the risk of an axial displacement of the heart valve prosthesis relative to the stent may be further reduced. Each individual notch 12e provided at the lower end section of the annular collar 40 thereby serves to guide a thread or thin wire with which the tissue component(s) of the prosthetic heart valve is affixed or sewn to the lower end section of the annular collar 40 of the stent 10. In detail, the means (thread or thin wire) provided for fastening the tissue component(s) of the prosthetic heart valve 100 to the lower end section of the annular collar 40 is guided by way of the notches 12e so that a longitudinal displacement of the prosthetic heart valve relative to the stent 10 is substantially minimized. This also allows positioning of the prosthetic heart valve relative the stent 10. To this end, as can be seen in FIG. 1, the prosthetic heart valve 100 may further comprise an essentially zig-zag shaped pattern at a lower end section.


Moreover, by using corresponding notches 12e for the secure and defined fixing of the tissue component(s) of the prosthetic heart valve to the lower end section of the annular collar 40 of the stent 10, the means (threads or thin wires) used to fasten the tissue component(s) to the stent 10 are effectively prevented from being squeezed and thus degraded when the stent 10 with the prosthetic heart valve affixed thereto, i.e. the endoprosthesis 1, is compressed and brought into its collapsed shape such as to be ready for being inserted into a catheter system which is used for implanting the endoprosthesis 1. In this regard, the risk of structural deterioration in the threads or thin wires used to fasten the tissue component(s) of the prosthetic heart valve 100 to the stent 10 is reduced.


The cross-sectional shape of the notches 12e may be adapted to the cross-sectional shape of the thread or thin wire used to fasten the tissue component(s) of the prosthetic heart valve 100. This allows fixing of the tissue component(s) of the prosthetic heart valve 100 to the stent 10 at a precise predefined position relative to the stent 10. Because the fastening holes 12 are adapted to the thickness and/or the cross-sectional shape of the thread or thin wire used to affix the prosthetic heart valve 100 to the stent 10, relative movement between the stent 10 and the tissue component(s) of the prosthetic heart valve 100 due to the peristaltic motion of the heart can be effectively prevented when the endoprosthesis 1 is implanted. In the fully expanded and implanted state of the endoprosthesis 1, the tissue component(s) of the prosthetic heart valve 100 is/are thus fastened to the stent 10 with minimal play, based on which friction-induced wear of the thread or thin wire used to affix the prosthetic heart valve is minimized. As shown in, for example, in FIG. 8a, the notches 12e have a semi-circular cross-sectional shape.


As can be seen, in particular from FIGS. 8b to 8d, the stent 10 according to the second stent embodiment of the invention may further comprise at least one radial arch 32a, 32b, 32c which enables a particularly secure anchoring of the stent 10 in the site of implantation in the heart and which is substantially circumferentially aligned with at least one of the plurality of positioning arches 15a, 15b, 15c. In addition to its radial arches 32a, 32b, 32c, the stent 10 is further provided with a total of three leaflet guard arches 50a, 50b, 50c, each comprising two leaflet guard arms. It can be seen from the flat roll-out view shown in FIG. 8a that, in the structure of the stent according to the second stent embodiment, a leaflet guard arch 50a, 50b, 50c is provided in between each positioning arch 15a, 15b, 15c. Hence, in the stent according to the second stent embodiment, a leaflet guard arch 50a, 50b, 50c is allocated to each positioning arch 15a, 15b, 15c.


Referring to the flat roll-out view shown in FIG. 8a, the radial arches 32a, 32b, 32c of the stent 10 according to the second stent embodiment extend from the leaflet guard arches 50a, 50b, 50c towards the upper end 3 of the stent 10. As is shown most clearly in FIG. 8a, the stent 10 has three radial arches 32a, 32b, 32c, with each arch 32a, 32b, 32c located between the two arms of each leaflet guard arch 50a, 50b, 50c. Each radial arch 32a, 32b, 32c has a shape that is roughly inverse to each positioning arch 15a, 15b, 15c and extends in the opposite direction to each one of the positioning arches 15a, 15b, 15c.


On the other hand, each leaflet guard arch 50a, 50b, 50c has a substantially U-shaped or V-shaped structure which is closed to the lower end 2 of stent. Again, each leaflet guard arch 50a, 50b, 50c has a shape that is roughly similar to the shape of the positioning arch 15a, 15b, 15c in between the corresponding leaflet guard arch 50a, 50b, 50c is arranged. Furthermore, each leaflet guard arch 50a, 50b, 50c extends in the same direction as the positioning arch 15a, 15b, 15c.


In the stent design of the second stent embodiment, each arm of a leaflet guard arch 50a, 50b, 50c merges at about the mid-point of the length of an arm of a radial arch 32a, 32b, 32c into the arm of an opposing radial arch 32a, 32b, 32c. According to the stent design of the second stent embodiment, the leaflet guard arches 50a, 50b, 50c project in the longitudinal direction L of the stent and have a reduced length such that the positioning arches 15a, 15b, 15c can deploy during the expansion of the stent 10 and the leaflet guard arches 50a, 50b, 50c do not interfere during deployment.


The positioning arches 15a, 15b, 15c disposed on the stent 10 and also the retaining arches 16a, 16b, 16c may be curved in convex and arched fashion in the direction to the lower end section of the stent; i.e. toward the lower end 2 of the stent, whereby such a rounded form may reduce injuries to the artery as well as facilitate the unfolding during the self-expansion. Such a design may enable an easier insertion of the positioning arches 15a, 15b, 15c into the pockets of the native cardiac valve without correspondingly injuring the neighbouring tissue or blood vessels.


Although not explicitly illustrated in the flat roll-out view according to FIG. 8a, in the programming process during which the shape of the desired (expanded) stent structure is fixed, the leaflet guard arches 50a, 50b, 50c are preferably programmed so that they extend in a radial direction outside the circumference of the stent 10 when the stent 10 of the second stent embodiment is in its expanded state. In this way, an increased contact force can be applied to the leaflets of the native (diseased) cardiac valve when the stent of the second stent embodiment is in its expanded and implanted state. This, in turn, allows an increased security in the fixing of the stent in situ.


When the stent is in its expanded and implanted state, the leaflet guard arches 50a, 50b, 50c actively keep the diseased leaflets, i.e. the leaflets of the native cardiac valve, from impinging the leaflet tissue of the prosthetic heart valve 100 attached to the stent 10, when the positioning arches 15a, 15b, 15c are placed outside the native leaflets. In addition, the leaflet guard arches 50a, 50b, 50c may also provide additional anchoring and securing against migration. This feature may be unique compared to the cage known from the prior art stent designs which are not provided with positioning arches to push the diseased leaflets out of the way.


As can be seen from the roll-out view depicted in FIG. 8a, according to the stent design of the second stent embodiment, the two arms 32′, 32″ of each radial arch 32a, 32b, 32c are connected together at the upper end 3 of the stent 10 by means of a radiused connecting portion or head. This head is not only radiused but also widens at the tip so that the head abuts against the interior wall of the vessel over as large a contact area as possible when the stent 10 is in its expanded and implanted state. The heads of each radial arch 32a, 32b, 32c may also serve as additional means by which the stent 10 may be retained in a catheter before and during implantation and/or to recapture the stent after implantation.


In the programming process during which the shape of the desired (expanded) stent structure is fixed, the radial arches 32a, 32b, 32c are programmed so that they extend in a radial direction outside the circumference of the stent 10 when the stent 10 is in its expanded state. In this way an increased contact force can be applied to the vessel wall by the upper end region of the stent 10. This, in turn, allows an increased security in the fixing of the stent 10 in situ, thereby reducing the likelihood of migration of the stent 10. Therefore, in its expanded state, in addition to the clamping effect of the positioning arches 15a, 15b, 15c and in addition to the additional anchoring obtainable by the leaflet guard arches 50a, 50b, 50c, the stent 10 of the second stent embodiment is secured in place on implantation via radial forces exerted by the retaining arches 16a, 16b, 16c, the auxiliary arches 18a, 18b, 18c, the radial arches 32a, 32b, 32c, and the annular collar 40, all of which project outwards in a radial direction from the circumference of the stent 10.


It can be seen from the flat roll-out view shown in FIG. 8a that the radial arches 32a, 32b, 32c do not project in the longitudinal direction L of the stent 10 beyond the plane in which the catheter retaining means 23 or the fastening means with fastening eyelets 24 are situated. This may ensure that the catheter retaining means 23 can co-operate with corresponding means within a suitable implantation catheter without interference from the heads of the radial arches 32a, 32b, 32c. Indeed, as explained above, the heads themselves can be used as additional catheter retaining means or additional means to effect explanation of the stent 10.


In principle, the stent 10 may have more than three radial arches 32 in order to increase the radial contact force further. It is also possible to provide barb elements on all or some of the radial arches 32a, 32b, 32c, for example, to allow a still better anchoring of the stent 10 at the implantation site.


Moreover, with respect to fixing the upper area 3 of stent 10 to the wall of the blood vessel into which the stent 10 is deployed, it would be conceivable for the stent 10 to comprise barb members arranged, for example, on the eyelets 24, the tips of the barbs pointing toward the lower end 2 of stent 10.


In addition, a liner or sheath, typically a fabric, polymeric or pericardial sheet, membrane, or the like, may be provided over at least a portion of the exterior of the stent 10 to cover all or most of the surface of the outside of the stent 10, extending from a location near the lower end section of the stent to a location near the upper end section of the stent. The liner may be attached to the stent 10 at at least one end, as well as at a plurality of locations between said ends thereby forming an exterior coverage. Such exterior coverage provides a circumferential seal against the inner wall of the blood vessel lumen in order to inhibit leakage of blood flow between the stent 10 and the luminal wall thereby and to prevent a blood flow bypassing the endoprosthesis 1.


For example, the liner may be stitched or otherwise secured to the stent 10 along a plurality of circumferentially spaced-apart axial lines. Such attachment permits the liner to fold along a plurality of axial fold lines when the stent 10 is radially compressed. The liner will further be able to open and conform to the luminal wall of the tubular frame as the frame expands. Alternatively, the liner may heat welded, or ultrasonically welded to the stent 10. The liner may be secured to the plurality of independent arches (positioning arches 15a, 15b, 15c, retaining arches 16a, 16b, 16c, auxiliary arches 18a, 18b, 18c, leaflet guard arches 50a, 50b, 50c) preferably along axial lines. In addition, the liner may be secured to the annular collar 40 provided at the lower end section 2 of the stent 10. The liner will preferably be circumferentially sealed against the stent 10 at at least one end.


By covering at least a part of the outside surface of the stent 10 with the liner or sheath, thrombogenicity of the endoprosthesis 1 resulting from exposed stent elements is greatly reduced or eliminated. Such reduction of thrombogenicity is achieved while maintaining the benefits of having a stent structure which is used for spreading up a prosthetic heart valve 100 and for anchoring the prosthetic heart valve 100 in place.


As already mentioned, the stent 10 can be compressed from a relaxed, large diameter configuration to a small diameter configuration to facilitate introduction. It is necessary, of course, that the outer liner remain attached to the stent 10 both in its radially compressed configuration and in its expanded, relaxed configuration.


The liner is composed of pericardial material or conventional biological graft materials, such as polyesters, polytetrafluoroethylenes (PTFE's), polyurethanes, and the like, usually being in the form of woven fabrics, non-woven fabrics, polymeric sheets, membranes, and the like. A presently preferred fabric liner material is a plain woven polyester, such as Dacron® yarn (Dupont, Wilmington, Del.).


A third embodiment of the stent 10 according to the present invention is described in the following with reference to FIG. 9 which is a flat roll-out view of this embodiment, whereby the cardiac valve stent 10 is shown in its expanded state.


The third embodiment of the stent 10 is similar in structure and function with respect to the second embodiment. To avoid repetition, reference is therefore made to the above description of the second embodiment. In particular, the lower end section of the stent 10 is constituted by an annular collar 40 which is likewise provided with notches 12e acting as additional fastening means.


In addition, the stent 10 according to the third stent embodiment is provided with retaining arches 16a, 16b, 16c whose arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ are segmented by a plurality of bending edges 33 which are not only used for defining a bending point of two neighboring arm segments, but also as fastening notches which can be used for fixing a heart valve prosthesis 100 to the stent 10. In turn, the retaining arches 16a, 16b, 16c of the third stent embodiment are adapted to extend along the bendable transition area 104 of the prosthetic heart valve, when the endoprosthesis is assembled.


The third embodiment of the stent 10 also includes radial arches 32a, 32b, 32c extending from the positioning arches 15a, 15b, 15c towards the upper end 3 of the stent 10. As is shown in the FIG. 9, the stent 10 has three radial arches 32a, 32b, 32c, with each arch 32a, 32b, 32c located between the two arms 15a, 15a′, 15b, 15b′, 15c, 15c′ of each positioning arch 15a, 15b, 15c. Each radial arch 32a, 32b, 32c has a shape that is roughly inverse to each positioning arch 15a, 15b, 15c and extends in the opposite direction to each one of the positioning arches 15a, 15b, 15c.


Contrary to the stent design of the second stent embodiment, however, the stent design of the third embodiment is not provided with leaflet guard arches 50a, 50b, 50c. Furthermore, each arm of a radial arch 32a, 32b, 32c merges at about the mid-point of the length of the stent 10 into an arm 15a′, 15a″, 15b′, 15b″, 15c′, 15c″ of an opposing positioning arch 15a, 15b, 15c.


A fourth embodiment of the stent 10 according to the present invention is described in the following with reference to FIG. 10. In detail, FIG. 10 is a flat roll-out view of the fourth stent embodiment, whereby the cardiac valve stent 10 is shown in its expanded state.


From a comparison of FIG. 10 with FIG. 8d it is derivable that the fourth embodiment of the stent 10 is similar in structure and function with respect to the second embodiment. To avoid repetition, reference is therefore made to the above description of the second embodiment.


The fourth embodiment of the stent 10 only differs from the second stent embodiment in that the respective lower end sections of the leaflet guard arches 50a, 50b, 50c are removed. In particular, the lower end sections of the leaflet guard arches 50a, 50b, 50c between the points where each arm of a radial arch 32a, 32b, 32c merges is removed.


Another embodiment of an endoprosthesis 1 according to the present disclosure is shown by FIGS. 11a to 11c. In detail, this third embodiment of an endoprosthesis 1 includes a stent 10 according to the second stent embodiment (FIGS. 8a to 8d) and a prosthetic heart valve 100, in accordance with the second heart valve embodiment (FIGS. 3 and 4), affixed thereto.


In particular, FIG. 11a shows a first side view of the third embodiment of the endoprosthesis 1. From this first side view, the characteristic U-shape of the retaining arches 16a, 16b, 16c becomes readily apparent.


As indicated hereinbefore, this U-shape of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c is achieved by segmenting the arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″. In detail, the arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ are segmented by providing a plurality of bending edges 33. In the depicted expanded state of the stent 10, two neighboring arm segments are angled relative to each other, wherein the bending point of these two neighboring arm segments is defined by the bending edge 33 which is provided in between the both neighboring arm segments. Hence, the greater the number of bending edges 33 provided in an arm 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of a retaining arch 16a, 16b, 16c, the greater the number of arm segments which may extend in different directions in the expanded state of the stent 10. In this respect, the shape of the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c can be adapted to the shape of transition area 104 of a prosthetic heart valve 100 to be affixed to the stent 10 adapted so as to fit the retaining arches 16a, 16b, 16c to the progression of the bendable transition area 104 of the prosthetic heart valve 100.


Further to this, FIG. 11a shows the bending edges providing a number of fastening notches which are used to fix the bendable transition area 104 to stent 10. Thus, in this third endoprosthesis embodiment, there are no additional fastening holes 12a needed along the respective arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of the retaining arches 16a, 16b, 16c. Rather, the sutures 101 are wrapped around the retaining arches 16a, 16b, 16c and sewn to the bendable transition area 104, whilst being held in place by the fastening notches which extend essentially in the same direction as the bendable transition area 104 of the prosthetic heart valve. That is, the prosthetic heart valve 100 of the present third embodiment of the endoprosthesis 1 is more securely attached to the stent 10 as the fastening notches provide a greater number of attachment points compared with the number of fastening holes 12a, used in the embodiment according to FIGS. 6a and 6b of the present disclosure. In this regard, high stress concentrations at each single attachment point can be effectively avoided.


Another feature which has already been described with reference to the second embodiment of the endoprosthesis 1 depicted by FIGS. 7a and 7b, is the provision of leaflet guard arches 50a, 50b, 50c. To avoid repetition, reference is therefore made to the above description of the second endoprosthesis embodiment depicted by FIGS. 7a and 7b.



FIG. 11b shows the connection between the skirt portion 103 and the aforementioned plurality of lattice cells 70. This plurality of lattice cells 70 formed by a plurality of struts in the area between the arms 16a′, 16a″, 16b′, 16b″, 16c′, 16c″ of two neighbouring (adjacent) retaining arches 16a, 16b, 16c, provides for an additional support for the bendable transition area 104 of a prosthetic heart valve 100 to be attached to the stent 10. As depicted by FIG. 11b, the prosthetic heart valve 100 may be directly sewn to the lattice cells 70 by means of sutures 101, threads or thin wires.


As can further be derived from FIG. 11b, the prosthetic heart valve 100 according to the third embodiment of the endoprosthesis 1, comprises three separate pieces 120 being sewn together at their contiguous edges 112. FIG. 11c shows a perspective top view of the third embodiment of the endoprosthesis. In detail, FIG. 11c illustrates the attachment of the three separate pieces 120 being sewn together in a cylindrical manner along their contiguous edges 112. After the contiguous edges 112 of the separate pieces 120 are aligned and sewn together, the sleeves 111 of the separate pieces 120 are turned to the outside and attached to the commissural attachment region 11b of the stent 10. A more detailed description of this particular attachment method will be described with reference to FIGS. 19a-c and 20.


It should be noted that this third endoprosthesis embodiment is not meant to be restrictive. Of course, it is also conceivable to attach a one piece prosthetic heart valve, in accordance with the first valve embodiment (FIG. 1) of the present disclosure, to the stent 10 shown in FIGS. 8a to 8d.


In the figures of this specification, the prosthetic heart valve 100 is generally mounted to the inner surface of the stent 10. Of course, it is also conceivable to mount the prosthetic heart valve 100 to the outer surface of a support stent 10. That is, the skirt portion 102 could be in direct contact with the diseased native heart valve and could be attached to the stent 10 by means of sutures. Mounting the prosthetic heart valve 100 to the outer surface of the stent 10 supports the load transfer from the leaflet 102 to the stent 10 and reduces the stress concentration near the attachment regions 11b, 11c. This greatly reduces stresses on the leaflets 102 during closing and consequently improves the durability thereof. Also, it is possible to design the valve to obtain improved hemodynamics in the case of mounting the skirt portion to the outer surface of the stent. Additionally, the heart valve material which is in direct contact with the diseased native heart valve provides a good interface for sealing against leakage (i.e., paravalvular leakage), tissue in-growth and attachment.


An alternative second embodiment of a prosthetic heart valve 100 is shown in FIGS. 3 and 4 as well as FIGS. 19a-c and 20.


In particular, FIGS. 3 and 4 illustrate a flat pattern of the prosthetic heart valve material, which has an essentially t-shirt like shape. According to this realisation, the prosthetic heart valve 100 is made of three separate pieces 120 exhibiting the depicted t-shirt like shape. The three separate pieces 120 are connected to each other at their contiguous edges 112 by suturing, in order to form the cylindrical or conical shape of the prosthetic heart valve 100. The three separate pieces 120 may be cut from more than one pericardial sack, so as to obtain three pieces 120 having matching characteristics, e.g., tissue thickness and properties. In addition, the bendable transition area 104 is implied in the drawing of FIG. 3. That is, that each of the separate pieces 120 is intended to represent one of the three leaflets 102 of the prosthetic heart valve 100, in addition to the transition area 104 and skirt portion 103. FIG. 4 shows a top view of the three separate pieces 120 sewn together and attached to a commissure attachment regions 11b of a stent according to the further exemplary embodiment of the disclosure.


The steps for the connection of two of the three separate pieces 120 on their contiguous edges 112 are depicted in FIGS. 19a-c.


In a first step, the contiguous edges 112 are brought together and sleeves 111 of the separate pieces 120 are turned to the outside, as shown in FIG. 19a.


A reinforcement element 107.8 may then be attached to the front surface of the sleeves 111 by means of sutures 101.1, preferably applying a blanket stitch. At the same time, the continuous edges 112 are sewn together by means of the same sutures 101.1, again preferably applying a blanket stitch.


In a third step, the reinforced sleeves 111 are turned even further to the outside, so that they end up being folded rearwards onto the surface of the leaflets 102. This rearward folded position is then secured by means of lateral sutures 101.2 stitched on the outer surface of the reinforcement element 107.8.


A top view of the three separate pieces 120 sewn together and attached to the commissure attachment regions 11b of a stent 10 is illustrated in FIG. 4. As mentioned before, each of the three separated pieces 120 represents one of the three leaflets 102 of the prosthetic heart valve 100.


A detailed perspective view of the attachment of the prosthetic heart valve 100 to the commissure attachment regions 11b of the present embodiment is shown in FIG. 20. The reinforcement element 107.8 is wrapped around the rearward folded sleeves 111. This rearward folded position is held by the lateral suture 101.2 connecting the opposite ends of the reinforcement element 107.8. The material of the reinforcement element 107.8 preferably has much higher suturing retention strength than the heart valve material of the three separate pieces 120.


For this reason, the reinforcement element 107.8 is used to attach the prosthetic heart valve 100 to the commissure attachment regions 11b of the stent 10, by means of suturing 101.1. Thus, stresses due to the suturing 101.1 between the stent 10 and the prosthetic heart valve 100 are mainly introduced into the material of the reinforcement element 107.8, avoiding high stress concentrations in the prosthetic heart valve 100. Additionally, the intent of this design is to limit the leaflet travel during the opening phase by pinching the commissure area to prevent the leaflets 102 from hitting the stent 10. Also, this assembly method displaces the valve commissures inward radially from the stent post to further limit the leaflets from hitting the stent.



FIG. 21 illustrates an alternative way of attachment of the prosthetic heart valve 100 according to FIGS. 3 and 4 of the present disclosure. In detail, the sleeves 111 of adjacent separate pieces 120 are formed to enclose an inner cushion 107.2. Therefore, in turn, the leaflets 102 are displaced from the commissure attachment region 11b to limit the leaflets 102 form hitting the stent. Furthermore, the sutures 101.1 extending through the sleeves 111 and the inner cushion 107.2 are more hidden and the edges of the sleeves 111 are tucked under the inner cushion 107.2. Therefore, in this embodiment, the wear of the prosthetic heart valve 100, is significantly reduced as the leaflets 102 of the prosthetic heart valve are not in direct contact with knots of the sutures 101.1 or the edges of the sleeves 111 respectively. Of course, it is generally advantageous for any of the described embodiments, to avoid direct contact between the knots of the sutures 101 and the prosthetic heart valve material by means of reinforcement elements 107.1-107.8, in order to reduce wear.


The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many variations and alternatives to one of ordinary skill in this art. All these alternatives and variations are intended to be included within the scope of the claims where the term “comprising” means “including, but not limited to”. Those familiar with the art may recognize other equivalents to the specific embodiments described herein which equivalents are also intended to be encompassed by the claims.


Further, the particular features presented in the dependent claims can be combined with each other in other manners within the scope of the disclosure such that the disclosure should be recognized as also specifically directed to other embodiments having any other possible combination of the features of the dependent claims. For instance, for purposes of claim publication, any dependent claim which follows should be taken as alternatively written in a multiple dependent form from all prior claims which possess all antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from all previous claims). In jurisdictions where multiple dependent claim formats are restricted, the following dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim listed in such dependent claim below.


LIST OF REFERENCE NUMERALS






    • 1 endoprosthesis


    • 2 lower end of the stent/endoprosthesis


    • 3 upper end of the stent/endoprosthesis


    • 10 cardiac valve stent/stent


    • 11
      b commissure attachment region of the stent


    • 11
      c lower leaflet attachment region of the stent


    • 12
      a, 12c additional fastening holes


    • 12
      b auxiliary fastening holes


    • 15
      a-15c positioning arches


    • 15
      a′-15a″ arms of the first positioning arch


    • 15
      b′-15b″ arms of the second positioning arch


    • 15
      c′-15c″ arms of the third positioning arch


    • 16
      a-16c retaining arches


    • 16
      a′-16a″ arms of the first retaining arch


    • 16
      b′-16b″ arms of the second retaining arch


    • 16
      c′-16c″ arms of the third retaining arch


    • 17 first connecting web


    • 17
      d upper end of the first connecting web


    • 17
      p lower end of the first connecting web


    • 20 head portion of the positioning arch


    • 21 reference marker


    • 22 connecting portion between the arms of neighbouring


    • 23 positioning arches


    • 24 catheter retaining means


    • 25 eyelet


    • 30 second connecting web


    • 30 head portion/connecting portion of the retaining arch


    • 32
      a-32c radial arches


    • 33 bending edges in the arms of the retaining arches


    • 40 annular collar


    • 41 supporting web


    • 42 transversal web


    • 50
      a-50c leaflet guard arches


    • 70 structure of lattice cells


    • 100 prosthetic heart valve


    • 101 thread


    • 101.1 suture


    • 101.2 lateral suture


    • 101.3 surrounding suture


    • 101.4 clinging suture


    • 102 leaflet of the prosthetic heart valve


    • 103 skirt portion


    • 104 transition area


    • 105 commissures


    • 106 fastening holes


    • 107.1-107.8 reinforcement element


    • 108 round edge


    • 109 cavity


    • 110 slot


    • 111 sleeves


    • 112 contiguous edges


    • 120 separate piece of prosthetic heart valve

    • L longitudinal direction of the stent




Claims
  • 1. An endoprosthesis for implantation at a patient's native heart valve, the endoprosthesis comprising: a stent comprising a proximal portion and a distal portion, the proximal portion comprising a first plurality of arches around a circumference of the stent, the stent further comprising a second plurality of arches around the circumference of the stent each corresponding to one of the first plurality of arches such that each corresponding pair of arches is configured to clip a native leaflet of the native heart valve therebetween;a plurality of lattice cells extending between each one of the second plurality of arches, each of the plurality of lattice cells comprising a plurality of struts; anda plurality of prosthetic leaflets disposed within the stent, the plurality of prosthetic leaflets configured to transition from an open position to a closed position, wherein at least a portion of adjacent prosthetic leaflets join together and are configured to be coupled to an apex of an arch of the first plurality of arches.
  • 2. An endoprosthesis for implantation at a patient's native heart valve, the endoprosthesis comprising: a stent comprising a proximal portion and a distal portion, the proximal portion comprising at least one through hole and a first plurality of arches around the circumference of the stent configured to contact a native leaflet of the native heart valve;a plurality of lattice cells extending between and connecting each one of the first plurality of arches, each of the plurality of lattice cells comprising a plurality of struts; anda plurality of prosthetic leaflets disposed within the stent, the plurality of prosthetic leaflets configured to transition from an open position to a closed position, wherein at least a portion of adjacent prosthetic leaflets join together and are configured to be coupled to the stent at the at least one through hole of the stent.
  • 3. The endoprosthesis of claim 1, wherein the at least a portion of adjacent prosthetic leaflets comprises at least one tab disposed at an edge of each respective prosthetic leaflet of the plurality of prosthetic leaflets.
  • 4. The endoprosthesis of claim 2, wherein the at least a portion of adjacent prosthetic leaflets comprises at least one tab disposed at an edge of each respective prosthetic leaflet of the plurality of prosthetic leaflets.
  • 5. The endoprosthesis of claim 1, wherein the stent further comprises at least one through hole configured to couple the stent to the plurality of prosthetic leaflets.
  • 6. The endoprosthesis of claim 5, wherein the at least one through hole is disposed at a commissure attachment region.
  • 7. The endoprosthesis of claim 5, further comprising at least one suture configured to traverse the at least one through hole to couple the at least a portion of the adjacent prosthetic leaflets joined together to the stent.
  • 8. The endoprosthesis of claim 1, further comprising at least one suture configured to couple the at least a portion of the adjacent prosthetic leaflets joined together to the stent.
  • 9. The endoprosthesis of claim 3, wherein a first tab of a first prosthetic leaflet of the plurality of prosthetic leaflets is joined to a second tab of a second prosthetic leaflet of the plurality of prosthetic leaflets to form a commissure region comprising a rectangular shape.
  • 10. The endoprosthesis of claim 9, wherein at least a portion of the first tab and at least a portion of the second tab are configured to be folded to form the commissure region.
  • 11. The endoprosthesis of claim 9, further comprising at least one suture configured to couple the first tab to the second tab.
  • 12. The endoprosthesis of claim 1, wherein at least one arch of the first plurality of arches comprises a plurality of notches configured to secure at least one suture coupled to the plurality of prosthetic leaflets to the at least one arch.
  • 13. The endoprosthesis of claim 2, wherein the proximal portion of the stent comprises a second plurality of arches around a circumference of the stent each corresponding to one of the first plurality of arches such that each corresponding pair of arches is configured to clip the native leaflet of the native heart valve therebetween.
  • 14. The endoprosthesis of claim 13, wherein the at least one through hole is disposed at a commissure attachment region.
  • 15. The endoprosthesis of claim 14, further comprising at least one suture configured to traverse the at least one through hole to couple the at least a portion of the adjacent prosthetic leaflets joined together to the stent.
  • 16. The endoprosthesis of claim 13, wherein at least one arch of the first plurality of arches comprises a plurality of notches configured to secure at least one suture coupled to the plurality of prosthetic leaflets to the at least one arch.
  • 17. The endoprosthesis of claim 2, further comprising at least one suture configured to traverse the at least one through hole to couple the at least a portion of the adjacent prosthetic leaflets joined together to the stent.
  • 18. The endoprosthesis of claim 4, wherein a first tab of a first prosthetic leaflet of the plurality of prosthetic leaflets is joined to a second tab of a second prosthetic leaflet of the plurality of prosthetic leaflets to form a commissure region comprising a rectangular shape.
  • 19. The endoprosthesis of claim 18, wherein at least a portion of the first tab and at least a portion of the second tab are configured to be folded to form the commissure region.
  • 20. The endoprosthesis of claim 18, further comprising at least one suture configured to couple the first tab to the second tab.
Priority Claims (1)
Number Date Country Kind
10163831 May 2010 EP regional
Parent Case Info

This application is a continuation of U.S. application Ser. No. 15/658,955, filed on Jul. 25, 2017, now U.S. Pat. No. 10,603,164, which is a continuation of U.S. application Ser. No. 13/114,582, filed on May 24, 2011, now U.S. Pat. No. 9,744,031, which claims priority to U.S. Provisional Application No. 61/348,036 filed on May 25, 2010, and to EP Application No. 10163831.0, filed on May 25, 2010, the entire disclosures of each of which are incorporated herein by reference.

US Referenced Citations (2768)
Number Name Date Kind
15192 Peale Jun 1856 A
388776 Hall Aug 1888 A
944214 Rydquist Dec 1909 A
2121182 Benjamin Jun 1938 A
2669896 Clough Feb 1954 A
2682057 Lord Jun 1954 A
2701559 Cooper Feb 1955 A
2832078 Williams Apr 1958 A
3029819 Edward et al. Apr 1962 A
3099016 Lowell et al. Jul 1963 A
3113586 Edmark, Jr. et al. Dec 1963 A
3130418 Head et al. Apr 1964 A
3143742 Cromie Aug 1964 A
3210836 Johanson et al. Oct 1965 A
3221006 Moore et al. Nov 1965 A
3334629 Cohn Aug 1967 A
3365728 Lowell et al. Jan 1968 A
3367364 Cruz, Jr. et al. Feb 1968 A
3409013 Henry et al. Nov 1968 A
3445916 Schulte et al. May 1969 A
3540431 Mobin-Uddin et al. Nov 1970 A
3548417 Kischer et al. Dec 1970 A
3570014 Hancock et al. Mar 1971 A
3574865 Hamaker Apr 1971 A
3587115 Shiley et al. Jun 1971 A
3592184 Watkins et al. Jul 1971 A
3628535 Ostrowsky et al. Dec 1971 A
3642004 Osthagen et al. Feb 1972 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3725961 Magovern et al. Apr 1973 A
3755823 Hancock Sep 1973 A
3795246 Sturgeon Mar 1974 A
3839741 Haller Oct 1974 A
3868956 Alfidi et al. Mar 1975 A
3874388 King et al. Apr 1975 A
3983581 Angell et al. Oct 1976 A
3997923 Possis Dec 1976 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4078268 Possis Mar 1978 A
4084268 Ionescu et al. Apr 1978 A
4106126 Traenkle Aug 1978 A
4106129 Carpentier et al. Aug 1978 A
4118806 Porier et al. Oct 1978 A
4164046 Cooley Aug 1979 A
4182446 Penny Jan 1980 A
4191218 Clark et al. Mar 1980 A
4214587 Sakura, Jr. Jul 1980 A
4215871 Hirsch et al. Aug 1980 A
4222126 Boretos et al. Sep 1980 A
4233690 Akins Nov 1980 A
4261342 Aranguren Duo Apr 1981 A
4263680 Reul et al. Apr 1981 A
4265694 Boretos et al. May 1981 A
4291420 Reul Sep 1981 A
4297749 Davis et al. Nov 1981 A
4319831 Matsui et al. Mar 1982 A
RE30912 Hancock Apr 1982 E
4323358 Lentz et al. Apr 1982 A
4326306 Poler Apr 1982 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4350492 Wright et al. Sep 1982 A
4373216 Klawitter Feb 1983 A
4388735 Ionescu et al. Jun 1983 A
4406022 Roy Sep 1983 A
4423809 Mazzocco Jan 1984 A
4425908 Simon Jan 1984 A
4441215 Kaster Apr 1984 A
4441216 Ionescu et al. Apr 1984 A
4470157 Love Sep 1984 A
4484579 Meno et al. Nov 1984 A
4485816 Krumme Dec 1984 A
4491986 Gabbay Jan 1985 A
4501030 Lane Feb 1985 A
4502488 Degironimo et al. Mar 1985 A
4531943 Van Tassel et al. Jul 1985 A
4535483 Klawitter et al. Aug 1985 A
4546499 Possis et al. Oct 1985 A
4562597 Possis et al. Jan 1986 A
4574803 Storz Mar 1986 A
4580568 Gianturco Apr 1986 A
4592340 Boyles Jun 1986 A
4602911 Ahmadi et al. Jul 1986 A
4605407 Black et al. Aug 1986 A
4610688 Silvestrini et al. Sep 1986 A
4612011 Kautzky Sep 1986 A
4617932 Kornberg Oct 1986 A
4619246 Molgaard-Nielsen et al. Oct 1986 A
4643732 Pietsch et al. Feb 1987 A
4647283 Carpentier et al. Mar 1987 A
4648881 Carpentier et al. Mar 1987 A
4655218 Kulik et al. Apr 1987 A
4655771 Wallsten Apr 1987 A
4662885 DiPisa, Jr. May 1987 A
4665906 Jervis May 1987 A
4665918 Garza et al. May 1987 A
4680031 Alonso Jul 1987 A
4681908 Broderick et al. Jul 1987 A
4687483 Fisher et al. Aug 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4705516 Barone et al. Nov 1987 A
4710192 Liotta et al. Dec 1987 A
4733665 Palmaz Mar 1988 A
4755181 Igoe Jul 1988 A
4759758 Gabbay Jul 1988 A
4769029 Patel Sep 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4797901 Goerne et al. Jan 1989 A
4806595 Noishiki et al. Feb 1989 A
4819751 Shimada et al. Apr 1989 A
4829990 Thuroff et al. May 1989 A
4834755 Silvestrini et al. May 1989 A
4846830 Knoch et al. Jul 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4865600 Carpentier et al. Sep 1989 A
4872874 Taheri Oct 1989 A
4873978 Ginsburg Oct 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4885005 Nashef et al. Dec 1989 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4922905 Strecker May 1990 A
4927426 Dretler May 1990 A
4950227 Savin et al. Aug 1990 A
4953553 Tremulis Sep 1990 A
4954126 Wallsten Sep 1990 A
4966604 Reiss Oct 1990 A
4969890 Sugita et al. Nov 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5002556 Ishida et al. Mar 1991 A
5002559 Tower Mar 1991 A
5002566 Carpentier et al. Mar 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5026377 Burton et al. Jun 1991 A
5032128 Alonso Jul 1991 A
5035706 Giantureo et al. Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5053008 Bajaj Oct 1991 A
5059177 Towne et al. Oct 1991 A
5061273 Yock Oct 1991 A
5061277 Carpentier et al. Oct 1991 A
5064435 Porter Nov 1991 A
5078720 Burton et al. Jan 1992 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5094661 Levy et al. Mar 1992 A
5104399 Lazarus Apr 1992 A
5104407 Lam et al. Apr 1992 A
5108425 Hwang Apr 1992 A
5122154 Rhodes Jun 1992 A
5132473 Furutaka et al. Jul 1992 A
5141494 Danforth et al. Aug 1992 A
5143987 Hansel et al. Sep 1992 A
5147388 Yamazaki Sep 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5159937 Tremulis Nov 1992 A
5161547 Tower Nov 1992 A
5163953 Vince Nov 1992 A
5163955 Love et al. Nov 1992 A
5167628 Boyles Dec 1992 A
5178632 Hanson Jan 1993 A
5192301 Kamiya et al. Mar 1993 A
5193546 Shaknovich Mar 1993 A
5197979 Quintero et al. Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5207695 Trout, III May 1993 A
5209741 Spaeth May 1993 A
5211183 Wilson May 1993 A
5215541 Nashef et al. Jun 1993 A
5217481 Barbara Jun 1993 A
5217483 Tower Jun 1993 A
5232445 Bonzel Aug 1993 A
5234447 Kaster et al. Aug 1993 A
5234456 Silvestrini Aug 1993 A
5238004 Sahatjian et al. Aug 1993 A
5258008 Wilk Nov 1993 A
5258023 Reger Nov 1993 A
5258042 Mehta Nov 1993 A
5272909 Nguyen et al. Dec 1993 A
5275580 Yamazaki Jan 1994 A
5279612 Eberhardt Jan 1994 A
5282847 Trescony et al. Feb 1994 A
5287861 Wilk Feb 1994 A
5295958 Shturman Mar 1994 A
5327774 Nguyen et al. Jul 1994 A
5330486 Wilk Jul 1994 A
5330500 Song Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5336258 Quintero et al. Aug 1994 A
5342348 Kaplan Aug 1994 A
5344426 Lau et al. Sep 1994 A
5344427 Cottenceau et al. Sep 1994 A
5344442 Deac Sep 1994 A
5350398 Pavcnik et al. Sep 1994 A
5350399 Erlebacher et al. Sep 1994 A
5352240 Ross Oct 1994 A
5354330 Hanson et al. Oct 1994 A
5360444 Kusuhara Nov 1994 A
5368608 Levy et al. Nov 1994 A
5370685 Stevens Dec 1994 A
5380054 Galvis Jan 1995 A
5387235 Chuter Feb 1995 A
5389096 Aita et al. Feb 1995 A
5389106 Tower Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5397355 Marin et al. Mar 1995 A
5409019 Wilk Apr 1995 A
5411552 Andersen et al. May 1995 A
5415633 Lazarus et al. May 1995 A
5425739 Jessen Jun 1995 A
5425762 Muller Jun 1995 A
5429144 Wilk Jul 1995 A
5431676 Dubrul et al. Jul 1995 A
5433723 Lindenberg et al. Jul 1995 A
5443446 Shturman Aug 1995 A
5443449 Buelna Aug 1995 A
5443477 Marin et al. Aug 1995 A
5443495 Buscemi et al. Aug 1995 A
5443499 Schmitt Aug 1995 A
5449384 Johnson Sep 1995 A
5456712 Maginot Oct 1995 A
5456713 Chuter Oct 1995 A
5464449 Ryan et al. Nov 1995 A
5469868 Reger Nov 1995 A
5470320 Tiefenbrun et al. Nov 1995 A
5476506 Lunn Dec 1995 A
5476508 Amstrup Dec 1995 A
5476510 Eberhardt et al. Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5480424 Cox Jan 1996 A
5486193 Bourne et al. Jan 1996 A
5487760 Villafana Jan 1996 A
5489294 McVenes et al. Feb 1996 A
5489297 Duran Feb 1996 A
5489298 Love et al. Feb 1996 A
5496346 Horzewski et al. Mar 1996 A
5499995 Teirstein Mar 1996 A
5500014 Quijano et al. Mar 1996 A
5500015 Deac Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5509930 Love Apr 1996 A
5522881 Lentz Jun 1996 A
5527337 Stack et al. Jun 1996 A
5530949 Koda et al. Jun 1996 A
5534007 St. Germain et al. Jul 1996 A
5540712 Kleshinski et al. Jul 1996 A
5545133 Burns et al. Aug 1996 A
5545209 Roberts et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5549666 Hata et al. Aug 1996 A
5554119 Harrison et al. Sep 1996 A
5554185 Block et al. Sep 1996 A
5569274 Rapacki et al. Oct 1996 A
5571167 Maginot Nov 1996 A
5571174 Love et al. Nov 1996 A
5571175 Vanney et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5575818 Pinchuk Nov 1996 A
5580922 Park et al. Dec 1996 A
5591185 Kilmer et al. Jan 1997 A
5591195 Taheri et al. Jan 1997 A
5593434 Williams Jan 1997 A
5595571 Jaffe et al. Jan 1997 A
5596471 Hanlin Jan 1997 A
5607464 Trescony et al. Mar 1997 A
5607465 Camilli Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5613982 Goldstein Mar 1997 A
5618299 Khosravi et al. Apr 1997 A
5626553 Frassica et al. May 1997 A
5628784 Strecker May 1997 A
5632778 Goldstein May 1997 A
5634942 Chevillon et al. Jun 1997 A
5643278 Wijay Jul 1997 A
5645559 Hachtman et al. Jul 1997 A
5653684 Laptewicz et al. Aug 1997 A
5653745 Trescony et al. Aug 1997 A
5653749 Love et al. Aug 1997 A
5655548 Nelson et al. Aug 1997 A
5662124 Wilk Sep 1997 A
5662671 Barbut et al. Sep 1997 A
5662703 Yurek et al. Sep 1997 A
5665115 Cragg Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5674298 Levy et al. Oct 1997 A
5679112 Levy et al. Oct 1997 A
5681345 Euteneuer Oct 1997 A
5682906 Sterman et al. Nov 1997 A
5683451 Lenker et al. Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5693083 Baker et al. Dec 1997 A
5693088 Lazarus Dec 1997 A
5693310 Gries et al. Dec 1997 A
5695498 Tower Dec 1997 A
5697972 Kim et al. Dec 1997 A
5700269 Pinchuk et al. Dec 1997 A
5702368 Stevens et al. Dec 1997 A
5709713 Evans et al. Jan 1998 A
5713917 Leonhardt et al. Feb 1998 A
5713950 Cox Feb 1998 A
5713951 Garrison et al. Feb 1998 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson, IV et al. Feb 1998 A
5716417 Girard et al. Feb 1998 A
5718725 Sterman et al. Feb 1998 A
5720391 Dohm et al. Feb 1998 A
5720776 Chuter et al. Feb 1998 A
5725549 Lam Mar 1998 A
5725550 Nadal Mar 1998 A
5728068 Leone et al. Mar 1998 A
5728151 Garrison et al. Mar 1998 A
5733267 Del Toro Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735842 Krueger et al. Apr 1998 A
5746476 Novak et al. May 1998 A
5746709 Rom et al. May 1998 A
5746765 Kleshinski et al. May 1998 A
5746775 Levy et al. May 1998 A
5749890 Shaknovich May 1998 A
5749921 Lenker et al. May 1998 A
5755682 Knudson et al. May 1998 A
5755777 Chuter May 1998 A
5755783 Stobie et al. May 1998 A
5756476 Epstein et al. May 1998 A
5758663 Wilk et al. Jun 1998 A
5766151 Valley et al. Jun 1998 A
5769780 Hata et al. Jun 1998 A
5769812 Stevens et al. Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5769887 Brown et al. Jun 1998 A
5772609 Nguyen et al. Jun 1998 A
5776188 Shepherd et al. Jul 1998 A
5782809 Umeno et al. Jul 1998 A
5782904 White et al. Jul 1998 A
5795331 Cragg et al. Aug 1998 A
5797946 Chin Aug 1998 A
5797960 Stevens et al. Aug 1998 A
5799661 Boyd et al. Sep 1998 A
5800456 Maeda et al. Sep 1998 A
5800508 Goicoechea et al. Sep 1998 A
5800531 Cosgrove et al. Sep 1998 A
5807327 Green et al. Sep 1998 A
5807384 Mueller Sep 1998 A
5807405 Vanney et al. Sep 1998 A
5810836 Hussein et al. Sep 1998 A
5814016 Valley et al. Sep 1998 A
5817113 Gifford, III et al. Oct 1998 A
5817126 Imran Oct 1998 A
5823956 Roth et al. Oct 1998 A
5824037 Fogarty et al. Oct 1998 A
5824038 Wall Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824043 Cottone, Jr. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824055 Spiridigliozzi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824061 Quijano et al. Oct 1998 A
5824063 Cox Oct 1998 A
5824064 Taheri Oct 1998 A
5824071 Nelson et al. Oct 1998 A
5824080 Lamuraglia Oct 1998 A
5829447 Stevens et al. Nov 1998 A
5830222 Makower Nov 1998 A
5840081 Andersen et al. Nov 1998 A
5841382 Walden et al. Nov 1998 A
5843158 Lenker et al. Dec 1998 A
5843161 Solovay Dec 1998 A
5843181 Jaffe et al. Dec 1998 A
5851232 Lois Dec 1998 A
5853419 Imran Dec 1998 A
5853420 Chevillon et al. Dec 1998 A
5855210 Sterman et al. Jan 1999 A
5855597 Jayaraman Jan 1999 A
5855600 Alt Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5860966 Tower Jan 1999 A
5860996 Urban et al. Jan 1999 A
5861024 Rashidi Jan 1999 A
5861028 Angell Jan 1999 A
5865723 Love Feb 1999 A
5868783 Tower Feb 1999 A
5873812 Ciana et al. Feb 1999 A
5873906 Lau et al. Feb 1999 A
5876373 Giba et al. Mar 1999 A
5876419 Carpenter et al. Mar 1999 A
5876434 Flomenblit et al. Mar 1999 A
5876448 Thompson et al. Mar 1999 A
5878751 Hussein et al. Mar 1999 A
5880242 Hu et al. Mar 1999 A
5885228 Rosenman et al. Mar 1999 A
5885238 Stevens et al. Mar 1999 A
5885259 Berg Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5891160 Williamson, IV et al. Apr 1999 A
5891191 Stinson Apr 1999 A
5895399 Barbut et al. Apr 1999 A
5895420 Mirsch, II et al. Apr 1999 A
5899936 Goldstein May 1999 A
5906619 Olson et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5908028 Wilk Jun 1999 A
5908029 Knudson et al. Jun 1999 A
5908451 Yeo Jun 1999 A
5908452 Bokros et al. Jun 1999 A
5910144 Hayashi Jun 1999 A
5910154 Tsugita et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5911752 Dustrude et al. Jun 1999 A
5913842 Boyd et al. Jun 1999 A
5916193 Stevens et al. Jun 1999 A
5922022 Nash et al. Jul 1999 A
5924424 Stevens et al. Jul 1999 A
5925012 Murphy-Chutorian et al. Jul 1999 A
5925063 Khosravi Jul 1999 A
5928281 Huynh et al. Jul 1999 A
5931848 Saadat Aug 1999 A
5935119 Guy et al. Aug 1999 A
5935161 Robinson et al. Aug 1999 A
5935163 Gabbay Aug 1999 A
5938632 Ellis Aug 1999 A
5938697 Killion et al. Aug 1999 A
5941908 Goldsteen et al. Aug 1999 A
5944019 Knudson et al. Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
5104407 Lam et al. Sep 1999 B1
5948017 Taheri Sep 1999 A
5954764 Parodi Sep 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5961549 Nguyen et al. Oct 1999 A
5964405 Benary et al. Oct 1999 A
5964798 Imran Oct 1999 A
5968064 Selmon et al. Oct 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5968070 Bley et al. Oct 1999 A
5971993 Hussein et al. Oct 1999 A
5975949 Holliday et al. Nov 1999 A
5976153 Fischell et al. Nov 1999 A
5976155 Foreman et al. Nov 1999 A
5976174 Ruiz Nov 1999 A
5976178 Goldsteen et al. Nov 1999 A
5976192 McIntyre et al. Nov 1999 A
5976650 Campbell et al. Nov 1999 A
5979455 Maginot Nov 1999 A
5980455 Daniel et al. Nov 1999 A
5980533 Holman Nov 1999 A
5980548 Evans et al. Nov 1999 A
5984956 Tweden et al. Nov 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5984959 Robertson et al. Nov 1999 A
5984964 Roberts et al. Nov 1999 A
5987344 West Nov 1999 A
5989276 Houser et al. Nov 1999 A
5989287 Yang et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
5993481 Marcade et al. Nov 1999 A
5997525 March et al. Dec 1999 A
5997557 Barbut et al. Dec 1999 A
5997563 Kretzers Dec 1999 A
5997573 Quijano et al. Dec 1999 A
5999678 Murphy-Chutorian et al. Dec 1999 A
6001123 Lau Dec 1999 A
6001126 Nguyen-Thien-Nhon Dec 1999 A
6004261 Sinofsky et al. Dec 1999 A
6004347 McNamara et al. Dec 1999 A
6004348 Banas et al. Dec 1999 A
6007543 Ellis et al. Dec 1999 A
6010449 Selmon et al. Jan 2000 A
6010522 Barbut et al. Jan 2000 A
6010530 Goicoechea Jan 2000 A
6010531 Donlon et al. Jan 2000 A
6012457 Lesh Jan 2000 A
6013854 Moriuchi Jan 2000 A
6015431 Thornton et al. Jan 2000 A
5061277 Carpentier et al. Feb 2000 B1
6019777 Mackenzie Feb 2000 A
6019778 Wilson et al. Feb 2000 A
6022370 Tower Feb 2000 A
6026814 LaFontaine et al. Feb 2000 A
6027476 Sterman et al. Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6027525 Suh et al. Feb 2000 A
6029671 Stevens et al. Feb 2000 A
6029672 Vanney et al. Feb 2000 A
6033582 Lee et al. Mar 2000 A
6035856 LaFontaine et al. Mar 2000 A
6036677 Javier, Jr. et al. Mar 2000 A
6036697 DiCaprio Mar 2000 A
6042554 Rosenman et al. Mar 2000 A
6042581 Ryan et al. Mar 2000 A
6042589 Marianne Mar 2000 A
6042598 Tsugita et al. Mar 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6045565 Ellis et al. Apr 2000 A
6051014 Jang Apr 2000 A
6051104 Oriaran et al. Apr 2000 A
6053924 Hussein Apr 2000 A
6053942 Eno et al. Apr 2000 A
6056743 Ellis et al. May 2000 A
6059809 Amor et al. May 2000 A
6059827 Fenton, Jr. May 2000 A
6066160 Colvin et al. May 2000 A
6067988 Mueller May 2000 A
6068638 Makower May 2000 A
6071292 Makower et al. Jun 2000 A
6074416 Berg et al. Jun 2000 A
6074417 Peredo Jun 2000 A
6074418 Buchanan et al. Jun 2000 A
6076529 Vanney et al. Jun 2000 A
6076742 Benary Jun 2000 A
6077297 Robinson et al. Jun 2000 A
6079414 Roth Jun 2000 A
6080163 Hussein et al. Jun 2000 A
6080170 Nash et al. Jun 2000 A
6083257 Taylor et al. Jul 2000 A
6091042 Benary Jul 2000 A
6092526 LaFontaine et al. Jul 2000 A
6092529 Cox Jul 2000 A
6093166 Knudson et al. Jul 2000 A
6093177 Javier, Jr. et al. Jul 2000 A
6093185 Ellis et al. Jul 2000 A
6093203 Uflacker Jul 2000 A
6093530 McLlroy et al. Jul 2000 A
6096074 Pedros Aug 2000 A
6102941 Tweden et al. Aug 2000 A
6102944 Huynh et al. Aug 2000 A
6106550 Magovern et al. Aug 2000 A
6110191 Dehdashtian et al. Aug 2000 A
6110198 Fogarty et al. Aug 2000 A
6110201 Quijano et al. Aug 2000 A
6113612 Swanson et al. Sep 2000 A
6113630 Vanney et al. Sep 2000 A
6113823 Eno Sep 2000 A
6117169 Moe Sep 2000 A
6120520 Saadat et al. Sep 2000 A
6120534 Ruiz Sep 2000 A
6123682 Knudson et al. Sep 2000 A
6123723 Konya et al. Sep 2000 A
6125852 Stevens et al. Oct 2000 A
6126649 Vantassel et al. Oct 2000 A
6126654 Giba et al. Oct 2000 A
6126685 Lenker et al. Oct 2000 A
6126686 Badylak et al. Oct 2000 A
6132451 Payne et al. Oct 2000 A
6132473 Williams et al. Oct 2000 A
6132986 Pathak et al. Oct 2000 A
6139510 Palermo Oct 2000 A
6139541 Vanney et al. Oct 2000 A
6142987 Tsugita Nov 2000 A
6143021 Staehle Nov 2000 A
6143987 Makita Nov 2000 A
6146366 Schachar Nov 2000 A
6146415 Fitz Nov 2000 A
6146417 Ischinger Nov 2000 A
6152937 Peterson et al. Nov 2000 A
6152956 Pierce Nov 2000 A
6155264 Ressemann et al. Dec 2000 A
6156031 Aita et al. Dec 2000 A
6156055 Ravenscroft Dec 2000 A
6156531 Pathak et al. Dec 2000 A
6157852 Selmon et al. Dec 2000 A
6159225 Makower Dec 2000 A
6159239 Greenhalgh Dec 2000 A
6162208 Hipps Dec 2000 A
6162245 Jayaraman Dec 2000 A
6165185 Shennib et al. Dec 2000 A
6165188 Saadat et al. Dec 2000 A
6165200 Tsugita et al. Dec 2000 A
6165209 Patterson et al. Dec 2000 A
6167605 Morales Jan 2001 B1
6168579 Tsugita Jan 2001 B1
6168614 Andersen et al. Jan 2001 B1
6168616 Brown, III Jan 2001 B1
6171251 Mueller et al. Jan 2001 B1
6171327 Daniel et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6177514 Pathak et al. Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6182664 Cosgrove Feb 2001 B1
6182668 Tweden et al. Feb 2001 B1
6183481 Lee et al. Feb 2001 B1
6186972 Nelson et al. Feb 2001 B1
6187016 Hedges et al. Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6190393 Bevier et al. Feb 2001 B1
6190405 Culombo et al. Feb 2001 B1
6193726 Vanney Feb 2001 B1
6193734 Bolduc et al. Feb 2001 B1
6196230 Hall et al. Mar 2001 B1
6197050 Eno et al. Mar 2001 B1
6197053 Cosgrove et al. Mar 2001 B1
6197296 Davies et al. Mar 2001 B1
6197324 Crittenden Mar 2001 B1
6200311 Danek et al. Mar 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6203550 Olson Mar 2001 B1
6203556 Evans et al. Mar 2001 B1
6206888 Bicek et al. Mar 2001 B1
6206911 Milo Mar 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6210957 Carpentier et al. Apr 2001 B1
6213126 LaFontaine et al. Apr 2001 B1
6214036 Letendre et al. Apr 2001 B1
6214041 Tweden et al. Apr 2001 B1
6214054 Cunanan et al. Apr 2001 B1
6214055 Simionescu et al. Apr 2001 B1
6217527 Selmon et al. Apr 2001 B1
6217549 Selmon et al. Apr 2001 B1
6217575 DeVore et al. Apr 2001 B1
6217609 Haverkost Apr 2001 B1
6218662 Tchakarov et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221049 Selmon et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6221100 Strecker Apr 2001 B1
6223752 Vanney et al. May 2001 B1
6224584 March et al. May 2001 B1
6231544 Tsugita et al. May 2001 B1
6231546 Milo et al. May 2001 B1
6231551 Barbut May 2001 B1
6231587 Makower May 2001 B1
6231602 Carpentier et al. May 2001 B1
6235000 Milo et al. May 2001 B1
6237607 Vanney et al. May 2001 B1
6238406 Ellis et al. May 2001 B1
6241667 Vetter et al. Jun 2001 B1
6241738 Dereume Jun 2001 B1
6241741 Duhaylongsod et al. Jun 2001 B1
6241757 An et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6245103 Stinson Jun 2001 B1
6245105 Nguyen et al. Jun 2001 B1
6248112 Gambale et al. Jun 2001 B1
6248116 Chevillon et al. Jun 2001 B1
6250305 Tweden Jun 2001 B1
6251079 Gambale et al. Jun 2001 B1
6251104 Kesten et al. Jun 2001 B1
6251116 Shennib et al. Jun 2001 B1
6251135 Stinson et al. Jun 2001 B1
6251418 Ahern et al. Jun 2001 B1
6253768 Wilk Jul 2001 B1
6253769 LaFontaine et al. Jul 2001 B1
6254564 Wilk et al. Jul 2001 B1
6254635 Schroeder et al. Jul 2001 B1
6254636 Peredo Jul 2001 B1
6257634 Wei Jul 2001 B1
6258052 Milo Jul 2001 B1
6258087 Edwards et al. Jul 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258119 Hussein et al. Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6258129 Dybdal et al. Jul 2001 B1
6258150 Mackellar Jul 2001 B1
6261304 Hall et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6269819 Oz et al. Aug 2001 B1
6270513 Tsugita et al. Aug 2001 B1
6270521 Fischell et al. Aug 2001 B1
6270526 Cox Aug 2001 B1
6273876 Klima et al. Aug 2001 B1
6273895 Pinchuk et al. Aug 2001 B1
6276661 Laird Aug 2001 B1
6277555 Duran et al. Aug 2001 B1
6283127 Sterman et al. Sep 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6283983 Makower et al. Sep 2001 B1
6283995 Moe et al. Sep 2001 B1
6285903 Rosenthal et al. Sep 2001 B1
6287317 Makower et al. Sep 2001 B1
6287334 Moll et al. Sep 2001 B1
6287338 Sarnowski et al. Sep 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6290709 Ellis et al. Sep 2001 B1
6290728 Phelps et al. Sep 2001 B1
6296662 Caffey Oct 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302875 Makower et al. Oct 2001 B1
6302892 Wilk Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6306164 Kujawski Oct 2001 B1
6309382 Garrison et al. Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6311693 Sterman et al. Nov 2001 B1
6312465 Griffin et al. Nov 2001 B1
6319281 Patel Nov 2001 B1
6322548 Payne et al. Nov 2001 B1
6322593 Pathak et al. Nov 2001 B1
6325067 Sterman et al. Dec 2001 B1
6327772 Zadno-Azizi et al. Dec 2001 B1
6330884 Kim Dec 2001 B1
6331189 Wolinsky et al. Dec 2001 B1
6334873 Lane et al. Jan 2002 B1
6336934 Gilson et al. Jan 2002 B1
6336937 Vonesh et al. Jan 2002 B1
6338735 Stevens Jan 2002 B1
6338740 Carpentier Jan 2002 B1
6342070 Nguyen-Thien-Nhon Jan 2002 B1
6344044 Fulkerson et al. Feb 2002 B1
6346074 Roth Feb 2002 B1
6346116 Brooks et al. Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6350248 Knudson et al. Feb 2002 B1
6350277 Kocur Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6352547 Brown et al. Mar 2002 B1
6352554 De Paulis Mar 2002 B2
6352708 Duran et al. Mar 2002 B1
6357104 Myers Mar 2002 B1
6358277 Duran Mar 2002 B1
6361519 Knudson et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6363938 Saadat et al. Apr 2002 B2
6363939 Wilk Apr 2002 B1
6364895 Greenhalgh Apr 2002 B1
6368338 Konya et al. Apr 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6375615 Flaherty et al. Apr 2002 B1
6378221 Ekholm, Jr. et al. Apr 2002 B1
6379319 Garibotto et al. Apr 2002 B1
6379365 Diaz Apr 2002 B1
6379372 Dehdashtian et al. Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6379740 Rinaldi et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6383193 Cathcart et al. May 2002 B1
6387119 Wolf et al. May 2002 B2
6387122 Cragg May 2002 B1
6390098 LaFontaine et al. May 2002 B1
6391051 Sullivan, III et al. May 2002 B2
6391538 Vyavahare et al. May 2002 B1
6395208 Herweck et al. May 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6401720 Stevens et al. Jun 2002 B1
6402736 Brown et al. Jun 2002 B1
6402740 Ellis et al. Jun 2002 B1
6406488 Tweden et al. Jun 2002 B1
6406491 Vanney Jun 2002 B1
6406493 Tu et al. Jun 2002 B1
6409697 Eno et al. Jun 2002 B2
6409750 Hyodoh et al. Jun 2002 B1
6409751 Hall et al. Jun 2002 B1
6409755 Vrba Jun 2002 B1
6409759 Peredo Jun 2002 B1
6413275 Nguyen et al. Jul 2002 B1
6416490 Ellis et al. Jul 2002 B1
6416510 Altman et al. Jul 2002 B1
6423089 Gingras et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6432119 Saadat Aug 2002 B1
6432126 Gambale et al. Aug 2002 B1
6432127 Kim et al. Aug 2002 B1
6432132 Cottone et al. Aug 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6443158 LaFontaine et al. Sep 2002 B1
6447522 Gambale et al. Sep 2002 B2
6447539 Nelson et al. Sep 2002 B1
6451025 Jervis Sep 2002 B1
6451054 Stevens Sep 2002 B1
6454760 Vanney Sep 2002 B2
6454794 Knudson et al. Sep 2002 B1
6454799 Schreck Sep 2002 B1
6458092 Gambale et al. Oct 2002 B1
6458140 Akin et al. Oct 2002 B2
6458153 Bailey et al. Oct 2002 B1
6458323 Boekstegers Oct 2002 B1
6461382 Cao Oct 2002 B1
6464709 Shennib et al. Oct 2002 B2
6468303 Amplatz et al. Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6471723 Ashworth et al. Oct 2002 B1
6475169 Ferrera Nov 2002 B2
6475226 Belef et al. Nov 2002 B1
6475239 Campbell et al. Nov 2002 B1
6475244 Herweck et al. Nov 2002 B2
6478819 Moe Nov 2002 B2
6479079 Pathak et al. Nov 2002 B1
6482220 Mueller Nov 2002 B1
6482228 Norred Nov 2002 B1
6485501 Green Nov 2002 B1
6485502 Don Michael et al. Nov 2002 B2
6485513 Fan Nov 2002 B1
6485524 Strecker Nov 2002 B2
6487581 Spence et al. Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6491689 Ellis et al. Dec 2002 B1
6491707 Makower et al. Dec 2002 B2
6494211 Boyd et al. Dec 2002 B1
6494897 Sterman et al. Dec 2002 B2
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6508496 Huang Jan 2003 B1
6508803 Horikawa et al. Jan 2003 B1
6508825 Selmon et al. Jan 2003 B1
6508833 Pavcnik et al. Jan 2003 B2
6509145 Torrianni Jan 2003 B1
6511458 Milo et al. Jan 2003 B2
6511491 Grudem et al. Jan 2003 B2
6514217 Selmon et al. Feb 2003 B1
6514271 Evans et al. Feb 2003 B2
6517527 Gambale et al. Feb 2003 B2
6517558 Gittings et al. Feb 2003 B2
6517573 Pollock et al. Feb 2003 B1
6521179 Girardot et al. Feb 2003 B1
6524323 Nash et al. Feb 2003 B1
6524335 Hartley et al. Feb 2003 B1
6527800 McGuckin, Jr. et al. Mar 2003 B1
6530949 Konya et al. Mar 2003 B2
6530952 Vesely Mar 2003 B2
6533807 Wolinsky et al. Mar 2003 B2
6537297 Tsugita et al. Mar 2003 B2
6537310 Palmaz et al. Mar 2003 B1
6540768 Diaz et al. Apr 2003 B1
6540782 Snyders Apr 2003 B1
6544230 Flaherty et al. Apr 2003 B1
6547827 Carpentier et al. Apr 2003 B2
6551303 Van Tassel et al. Apr 2003 B1
6558318 Daniel et al. May 2003 B1
6558417 Peredo May 2003 B2
6558418 Carpentier et al. May 2003 B2
6558429 Taylor May 2003 B2
6559132 Holmer May 2003 B1
6561998 Roth et al. May 2003 B1
6562031 Chandrasekaran et al. May 2003 B2
6562058 Seguin et al. May 2003 B2
6562063 Euteneuer et al. May 2003 B1
6562069 Cai et al. May 2003 B2
6564805 Garrison et al. May 2003 B2
6565528 Mueller May 2003 B1
6565594 Herweck et al. May 2003 B1
6569145 Shmulewitz et al. May 2003 B1
6569147 Evans et al. May 2003 B1
6569196 Vesely May 2003 B1
6572642 Rinaldi et al. Jun 2003 B2
6572643 Gharibadeh Jun 2003 B1
6572652 Shaknovich Jun 2003 B2
6575168 LaFontaine et al. Jun 2003 B2
6579311 Makower Jun 2003 B1
6582444 Wilk Jun 2003 B2
6582460 Cryer Jun 2003 B1
6582462 Andersen et al. Jun 2003 B1
6585756 Strecker Jul 2003 B1
6585758 Chouinard et al. Jul 2003 B1
6585766 Huynh et al. Jul 2003 B1
6589279 Anderson et al. Jul 2003 B1
6592546 Barbut et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6599304 Selmon et al. Jul 2003 B1
6600803 Bruder et al. Jul 2003 B2
6605053 Kamm et al. Aug 2003 B1
6605112 Moll et al. Aug 2003 B1
6605113 Wilk Aug 2003 B2
6608040 Lin et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6610085 Lazarus Aug 2003 B1
6610100 Phelps et al. Aug 2003 B2
6613069 Boyd et al. Sep 2003 B2
6613077 Gilligan et al. Sep 2003 B2
6613079 Wolinsky et al. Sep 2003 B1
6613081 Kim et al. Sep 2003 B2
6613086 Moe et al. Sep 2003 B1
6616675 Evard et al. Sep 2003 B1
6616682 Joergensen et al. Sep 2003 B2
6622604 Chouinard et al. Sep 2003 B1
6623491 Thompson Sep 2003 B2
6623518 Thompson et al. Sep 2003 B2
6623521 Steinke et al. Sep 2003 B2
6626938 Butaric et al. Sep 2003 B1
6626939 Burnside et al. Sep 2003 B1
6632241 Hancock et al. Oct 2003 B1
6632243 Zadno-Azizi et al. Oct 2003 B1
6632470 Morra et al. Oct 2003 B2
6635068 Dubrul et al. Oct 2003 B1
6635079 Unsworth et al. Oct 2003 B2
6635080 Lauterjung et al. Oct 2003 B1
6635085 Caffey et al. Oct 2003 B1
6638237 Guiles et al. Oct 2003 B1
6638247 Selmon et al. Oct 2003 B1
6638293 Makower et al. Oct 2003 B1
6641610 Wolf et al. Nov 2003 B2
6651670 Rapacki et al. Nov 2003 B2
6651672 Roth Nov 2003 B2
6652540 Cole et al. Nov 2003 B1
6652546 Nash et al. Nov 2003 B1
6652555 Vantassel et al. Nov 2003 B1
6652571 White et al. Nov 2003 B1
6652578 Bailey et al. Nov 2003 B2
6655386 Makower et al. Dec 2003 B1
6656213 Solem Dec 2003 B2
6660003 DeVore et al. Dec 2003 B1
6660024 Flaherty et al. Dec 2003 B1
6663588 DuBois et al. Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6663667 Dehdashtian et al. Dec 2003 B2
6666863 Wentzel et al. Dec 2003 B2
6669709 Cohn et al. Dec 2003 B1
6669724 Park et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673101 Fitzgerald et al. Jan 2004 B1
6673106 Mitelberg et al. Jan 2004 B2
6673109 Cox Jan 2004 B2
6676668 Mercereau et al. Jan 2004 B2
6676692 Rabkin et al. Jan 2004 B2
6676693 Belding et al. Jan 2004 B1
6676698 McGuckin, Jr. et al. Jan 2004 B2
6679268 Stevens et al. Jan 2004 B2
6682543 Barbut et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685648 Flaherty et al. Feb 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6692512 Jang Feb 2004 B2
6692513 Streeter et al. Feb 2004 B2
6694983 Wolf et al. Feb 2004 B2
6695864 Macoviak et al. Feb 2004 B2
6695865 Boyle et al. Feb 2004 B2
6695875 Stelter et al. Feb 2004 B2
6695878 McGuckin, Jr. et al. Feb 2004 B2
6699274 Stinson Mar 2004 B2
6701932 Knudson et al. Mar 2004 B2
6702851 Chinn et al. Mar 2004 B1
6709425 Gambale et al. Mar 2004 B2
6709444 Makower Mar 2004 B1
6712842 Gifford, III et al. Mar 2004 B1
6712843 Elliott Mar 2004 B2
6714842 Ito Mar 2004 B1
6719770 Laufer et al. Apr 2004 B2
6719787 Cox Apr 2004 B2
6719788 Cox Apr 2004 B2
6719789 Cox Apr 2004 B2
6723116 Taheri Apr 2004 B2
6723122 Yang et al. Apr 2004 B2
6726677 Flaherty et al. Apr 2004 B1
6729356 Baker et al. May 2004 B1
6730118 Spenser et al. May 2004 B2
6730121 Ortiz et al. May 2004 B2
6730377 Wang May 2004 B2
6733513 Boyle et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6736827 McAndrew et al. May 2004 B1
6736839 Cummings May 2004 B2
6736845 Marquez et al. May 2004 B2
6736846 Cox May 2004 B2
6743252 Bates et al. Jun 2004 B1
6746464 Makower Jun 2004 B1
6752828 Thornton Jun 2004 B2
6755854 Gillick et al. Jun 2004 B2
6755855 Yurek et al. Jun 2004 B2
6758855 Fulton, III et al. Jul 2004 B2
6764503 Ishimaru Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6767345 St. Germain et al. Jul 2004 B2
6767362 Schreck Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6773454 Wholey et al. Aug 2004 B2
6773455 Allen et al. Aug 2004 B2
6773456 Gordon et al. Aug 2004 B1
6774278 Ragheb et al. Aug 2004 B1
6776791 Stallings et al. Aug 2004 B1
6786925 Schoon et al. Sep 2004 B1
6786929 Gambale et al. Sep 2004 B2
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790237 Stinson Sep 2004 B2
6792979 Konya et al. Sep 2004 B2
6797000 Simpson et al. Sep 2004 B2
6797002 Spence et al. Sep 2004 B2
6802319 Stevens et al. Oct 2004 B2
6802858 Gambale et al. Oct 2004 B2
6805711 Quijano et al. Oct 2004 B2
6808498 Laroya et al. Oct 2004 B2
6808504 Schorgl et al. Oct 2004 B2
6808529 Fulkerson Oct 2004 B2
6814746 Thompson et al. Nov 2004 B2
6814754 Greenhalgh Nov 2004 B2
6820676 Palmaz et al. Nov 2004 B2
6821211 Otten et al. Nov 2004 B2
6821297 Snyders Nov 2004 B2
6824041 Grieder et al. Nov 2004 B2
6824970 Vyavahare et al. Nov 2004 B2
6830568 Kesten et al. Dec 2004 B1
6830575 Stenzel et al. Dec 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof et al. Dec 2004 B1
6830586 Quijano et al. Dec 2004 B2
6837901 Rabkin et al. Jan 2005 B2
6837902 Nguyen et al. Jan 2005 B2
6840957 DiMatteo et al. Jan 2005 B2
6843802 Villalobos et al. Jan 2005 B1
6846325 Liddicoat Jan 2005 B2
6849084 Rabkin et al. Feb 2005 B2
6849085 Marton Feb 2005 B2
6854467 Boekstegers Feb 2005 B2
6860898 Stack et al. Mar 2005 B2
6861211 Levy et al. Mar 2005 B2
6863668 Gillespie et al. Mar 2005 B2
6863684 Kim et al. Mar 2005 B2
6863688 Ralph et al. Mar 2005 B2
6866650 Stevens et al. Mar 2005 B2
6866669 Buzzard et al. Mar 2005 B2
6872223 Roberts et al. Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6881199 Wilk et al. Apr 2005 B2
6881220 Edwin et al. Apr 2005 B2
6883522 Spence et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890330 Streeter et al. May 2005 B2
6890340 Duane May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6899704 Sterman et al. May 2005 B2
6905743 Chen et al. Jun 2005 B1
6908481 Cribier Jun 2005 B2
6911036 Douk et al. Jun 2005 B2
6911040 Johnson et al. Jun 2005 B2
6911043 Myers et al. Jun 2005 B2
6913021 Knudson et al. Jul 2005 B2
6913600 Valley et al. Jul 2005 B2
6916304 Eno et al. Jul 2005 B2
6920674 Thornton Jul 2005 B2
6920732 Mårtensson Jul 2005 B2
6926690 Renati Aug 2005 B2
6926732 Derus et al. Aug 2005 B2
6929009 Makower et al. Aug 2005 B2
6929011 Knudson et al. Aug 2005 B2
6929653 Strecter Aug 2005 B2
6936058 Forde et al. Aug 2005 B2
6936066 Palmaz et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6939352 Buzzard et al. Sep 2005 B2
6939359 Tu et al. Sep 2005 B2
6939365 Fogarty et al. Sep 2005 B1
6939370 Hartley et al. Sep 2005 B2
6942682 Vrba et al. Sep 2005 B2
6945949 Wilk Sep 2005 B2
6945997 Huynh et al. Sep 2005 B2
6949080 Wolf et al. Sep 2005 B2
6949118 Kohler et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6953332 Kurk et al. Oct 2005 B1
6953481 Phelps et al. Oct 2005 B2
6955175 Stevens et al. Oct 2005 B2
6955681 Evans et al. Oct 2005 B2
6964652 Guiles et al. Nov 2005 B2
6964673 Tsugita et al. Nov 2005 B2
6964676 Gerberding et al. Nov 2005 B1
6969395 Eskuri Nov 2005 B2
6972025 Wasdyke Dec 2005 B2
6972029 Mayrhofer et al. Dec 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6976990 Mowry Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6984242 Campbell et al. Jan 2006 B2
6984244 Perez et al. Jan 2006 B2
6986742 Hart et al. Jan 2006 B2
6986784 Weiser et al. Jan 2006 B1
6988949 Wang Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6991649 Sievers Jan 2006 B2
7001425 McCullagh et al. Feb 2006 B2
7004176 Lau Feb 2006 B2
7008397 Tweden et al. Mar 2006 B2
7011095 Wolf et al. Mar 2006 B2
7011681 Vesely Mar 2006 B2
7014655 Barbarash et al. Mar 2006 B2
7018401 Hyodoh et al. Mar 2006 B1
7018406 Seguin et al. Mar 2006 B2
7018408 Bailey et al. Mar 2006 B2
7022134 Quijano et al. Apr 2006 B1
7025773 Gittings et al. Apr 2006 B2
7025780 Gabbay Apr 2006 B2
7025791 Levine et al. Apr 2006 B2
7028692 Sterman et al. Apr 2006 B2
7037331 Mitelberg et al. May 2006 B2
7037333 Myers et al. May 2006 B2
7041128 McGuckin, Jr. et al. May 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7048014 Hyodoh et al. May 2006 B2
7048757 Shaknovich May 2006 B2
7050276 Nishiyama May 2006 B2
7074236 Rabkin et al. Jul 2006 B2
7078163 Torrianni Jul 2006 B2
7081132 Cook et al. Jul 2006 B2
7097658 Oktay Aug 2006 B2
7097659 Woolfson et al. Aug 2006 B2
7101396 Artof et al. Sep 2006 B2
7105016 Shiu et al. Sep 2006 B2
7108715 Lawrence-Brown et al. Sep 2006 B2
7115141 Menz et al. Oct 2006 B2
7118585 Addis Oct 2006 B2
7122020 Mogul Oct 2006 B2
7125418 Duran et al. Oct 2006 B2
7128759 Osborne et al. Oct 2006 B2
7137184 Schreck et al. Nov 2006 B2
7141063 White et al. Nov 2006 B2
7141064 Scott et al. Nov 2006 B2
7143312 Wang et al. Nov 2006 B1
7147662 Pollock et al. Dec 2006 B1
7147663 Berg et al. Dec 2006 B1
7153324 Case et al. Dec 2006 B2
7160319 Chouinard et al. Jan 2007 B2
7163556 Xie et al. Jan 2007 B2
7166097 Barbut Jan 2007 B2
7175652 Cook et al. Feb 2007 B2
7175653 Gaber Feb 2007 B2
7175654 Bonsignore et al. Feb 2007 B2
7175656 Khairkhahan Feb 2007 B2
7179290 Cao Feb 2007 B2
7186265 Sharkawy et al. Mar 2007 B2
7189258 Johnson et al. Mar 2007 B2
7189259 Simionescu et al. Mar 2007 B2
7191018 Gielen et al. Mar 2007 B2
7191406 Barber et al. Mar 2007 B1
7195641 Palmaz et al. Mar 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201761 Woolfson et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7214344 Carpentier et al. May 2007 B2
7217287 Wilson et al. May 2007 B2
7235092 Banas et al. Jun 2007 B2
7235093 Gregorich Jun 2007 B2
7238200 Lee et al. Jul 2007 B2
7241257 Ainsworth et al. Jul 2007 B1
7252682 Seguin Aug 2007 B2
7258696 Rabkin et al. Aug 2007 B2
7258891 Pacetti et al. Aug 2007 B2
7261732 Justino Aug 2007 B2
7264632 Wright et al. Sep 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7285130 Austin Oct 2007 B2
7297150 Cartledge et al. Nov 2007 B2
7300457 Palmaz Nov 2007 B2
7300463 Liddicoat Nov 2007 B2
7311730 Gabbay Dec 2007 B2
7314449 Pfeiffer et al. Jan 2008 B2
7314485 Mathis Jan 2008 B2
7314880 Chang et al. Jan 2008 B2
7316706 Bloom et al. Jan 2008 B2
7316712 Peredo Jan 2008 B2
7317005 Hoekstra et al. Jan 2008 B2
7317942 Brown Jan 2008 B2
7317950 Lee Jan 2008 B2
7318278 Zhang et al. Jan 2008 B2
7318998 Goldstein et al. Jan 2008 B2
7319096 Malm et al. Jan 2008 B2
7320692 Bender et al. Jan 2008 B1
7320704 Lashinski et al. Jan 2008 B2
7320705 Quintessenza Jan 2008 B2
7320706 Al-Najjar Jan 2008 B2
7322932 Xie et al. Jan 2008 B2
7323006 Andreas et al. Jan 2008 B2
7323066 Budron Jan 2008 B1
7326174 Cox et al. Feb 2008 B2
7326219 Mowry et al. Feb 2008 B2
7326236 Andreas et al. Feb 2008 B2
7327862 Murphy et al. Feb 2008 B2
7329278 Seguin et al. Feb 2008 B2
7329279 Haug et al. Feb 2008 B2
7329280 Bolling et al. Feb 2008 B2
7329777 Harter et al. Feb 2008 B2
7331991 Kheradvar et al. Feb 2008 B2
7331993 White Feb 2008 B2
7333643 Murphy et al. Feb 2008 B2
7335158 Taylor Feb 2008 B2
7335213 Hyde et al. Feb 2008 B1
7335218 Wilson et al. Feb 2008 B2
7335490 Van Gilst et al. Feb 2008 B2
7338484 Schoon et al. Mar 2008 B2
7338520 Bailey et al. Mar 2008 B2
7361189 Case et al. Apr 2008 B2
7361190 Shaoulian et al. Apr 2008 B2
7364588 Mathis et al. Apr 2008 B2
7371258 Woo et al. May 2008 B2
7374560 Ressemann et al. May 2008 B2
7374571 Pease et al. May 2008 B2
7377895 Spence et al. May 2008 B2
7377938 Sarac et al. May 2008 B2
7377940 Ryan et al. May 2008 B2
7381210 Zarbatany et al. Jun 2008 B2
7381216 Buzzard et al. Jun 2008 B2
7381218 Schreck Jun 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7381220 Macoviak et al. Jun 2008 B2
7384411 Condado Jun 2008 B1
7387640 Cummings Jun 2008 B2
7389874 Quest et al. Jun 2008 B2
7390325 Wang et al. Jun 2008 B2
7393358 Malewicz Jul 2008 B2
7393360 Spenser et al. Jul 2008 B2
7396364 Moaddeb et al. Jul 2008 B2
7399315 Iobbi Jul 2008 B2
7402171 Osborne et al. Jul 2008 B2
7404792 Spence et al. Jul 2008 B2
7404793 Lau et al. Jul 2008 B2
7405259 Frye et al. Jul 2008 B2
7410499 Bicer Aug 2008 B2
7412274 Mejia Aug 2008 B2
7412290 Janke et al. Aug 2008 B2
7415861 Sokel Aug 2008 B2
7416530 Turner et al. Aug 2008 B2
7422603 Lane Sep 2008 B2
7422606 Ung-Chhun et al. Sep 2008 B2
7423032 Ozaki et al. Sep 2008 B2
7426413 Balczewski et al. Sep 2008 B2
7427279 Frazier et al. Sep 2008 B2
7427287 Turovskiy et al. Sep 2008 B2
7427291 Liddicoat et al. Sep 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7430448 Zimmer et al. Sep 2008 B1
7430484 Ohara Sep 2008 B2
7431691 Wilk Oct 2008 B1
7431733 Knight Oct 2008 B2
7435059 Smith et al. Oct 2008 B2
7435257 Lashinski et al. Oct 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
RE40570 Carpentier et al. Nov 2008 E
7445630 Lashinski et al. Nov 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7445632 McGuckin, Jr. et al. Nov 2008 B2
7452371 Pavcnik et al. Nov 2008 B2
7455689 Johnson Nov 2008 B2
7462156 Mitrev Dec 2008 B2
7462184 Worley et al. Dec 2008 B2
7462191 Spenser et al. Dec 2008 B2
7468050 Kantrowitz Dec 2008 B1
7470284 Lambrecht et al. Dec 2008 B2
7470285 Nugent et al. Dec 2008 B2
7473271 Gunderson Jan 2009 B2
7473275 Marquez Jan 2009 B2
7473417 Zeltinger et al. Jan 2009 B2
7476196 Spence et al. Jan 2009 B2
7476199 Spence et al. Jan 2009 B2
7476200 Tal Jan 2009 B2
7476244 Buzzard et al. Jan 2009 B2
7481838 Carpentier et al. Jan 2009 B2
7485088 Murphy et al. Feb 2009 B2
7485143 Webler et al. Feb 2009 B2
7488346 Navia Feb 2009 B2
7491232 Bolduc et al. Feb 2009 B2
7493869 Foster et al. Feb 2009 B1
7497824 Taylor Mar 2009 B2
7500949 Gottlieb et al. Mar 2009 B2
7500989 Solem et al. Mar 2009 B2
7503929 Johnson et al. Mar 2009 B2
7503930 Sharkawy et al. Mar 2009 B2
7507199 Wang et al. Mar 2009 B2
7510572 Gabbay Mar 2009 B2
7510574 Lê et al. Mar 2009 B2
7510575 Spenser et al. Mar 2009 B2
7510577 Moaddeb et al. Mar 2009 B2
7513863 Bolling et al. Apr 2009 B2
7513909 Lane et al. Apr 2009 B2
7522950 Fuimaono et al. Apr 2009 B2
7524330 Berreklouw Apr 2009 B2
7530253 Spenser et al. May 2009 B2
7530995 Quijano et al. May 2009 B2
7534261 Friedman May 2009 B2
7544206 Cohn Jun 2009 B2
7547322 Sarac et al. Jun 2009 B2
7553324 Andreas et al. Jun 2009 B2
7556386 Smith Jul 2009 B2
7556646 Yang et al. Jul 2009 B2
7569071 Haverkost et al. Aug 2009 B2
7578828 Gittings et al. Aug 2009 B2
7585321 Cribier Sep 2009 B2
7591848 Allen Sep 2009 B2
7594974 Cali et al. Sep 2009 B2
7601159 Ewers et al. Oct 2009 B2
7601195 Ichikawa Oct 2009 B2
7608099 Johnson et al. Oct 2009 B2
7611534 Kapadia et al. Nov 2009 B2
7618446 Andersen et al. Nov 2009 B2
7622276 Cunanan et al. Nov 2009 B2
7625403 Krivoruchko Dec 2009 B2
7628802 White et al. Dec 2009 B2
7628803 Pavcnik et al. Dec 2009 B2
7632296 Malewicz Dec 2009 B2
7632298 Hijlkema et al. Dec 2009 B2
7635386 Gammie Dec 2009 B1
7641687 Chinn et al. Jan 2010 B2
7651519 Dittman Jan 2010 B2
7655034 Mitchell et al. Feb 2010 B2
7674282 Wu et al. Mar 2010 B2
7682390 Seguin Mar 2010 B2
7704222 Wilk et al. Apr 2010 B2
7704277 Zakay et al. Apr 2010 B2
7712606 Salahieh et al. May 2010 B2
7717955 Lane et al. May 2010 B2
7722638 Deyette, Jr. et al. May 2010 B2
7722662 Steinke et al. May 2010 B2
7722666 Lafontaine May 2010 B2
7722671 Carlyle et al. May 2010 B1
7731742 Schlick et al. Jun 2010 B2
7735493 Van Der Burg et al. Jun 2010 B2
7736327 Wilk et al. Jun 2010 B2
7736388 Goldfarb et al. Jun 2010 B2
7743481 Lafont et al. Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7758625 Wu et al. Jul 2010 B2
7763065 Schmid et al. Jul 2010 B2
7771463 Ton et al. Aug 2010 B2
7771467 Svensson Aug 2010 B2
7776083 Vesely Aug 2010 B2
7780725 Haug et al. Aug 2010 B2
7780726 Seguin Aug 2010 B2
7785360 Freitag Aug 2010 B2
7794487 Majercak et al. Sep 2010 B2
7799046 White et al. Sep 2010 B2
7799065 Pappas Sep 2010 B2
7803185 Gabbay Sep 2010 B2
7806919 Bloom et al. Oct 2010 B2
7823267 Bolduc Nov 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7833262 McGuckin, Jr. et al. Nov 2010 B2
7837727 Goetz et al. Nov 2010 B2
7846203 Cribier Dec 2010 B2
7846204 Letac et al. Dec 2010 B2
7854758 Taheri Dec 2010 B2
7857845 Stacchino et al. Dec 2010 B2
7862602 Licata et al. Jan 2011 B2
7867274 Hill et al. Jan 2011 B2
7887583 Macoviak Feb 2011 B2
7892276 Stocker et al. Feb 2011 B2
7892292 Stack et al. Feb 2011 B2
7896913 Damm et al. Mar 2011 B2
7896915 Guyenot et al. Mar 2011 B2
7914569 Nguyen et al. Mar 2011 B2
7914574 Schmid et al. Mar 2011 B2
7914575 Guyenot et al. Mar 2011 B2
7918880 Austin Apr 2011 B2
7927363 Perouse Apr 2011 B2
7938851 Olson et al. May 2011 B2
7947071 Schmid et al. May 2011 B2
7947075 Goetz et al. May 2011 B2
7951189 Haverkost et al. May 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7967853 Eidenschink et al. Jun 2011 B2
7972359 Kreidler Jul 2011 B2
7972376 Dove et al. Jul 2011 B1
7972378 Tabor et al. Jul 2011 B2
7988724 Salahieh et al. Aug 2011 B2
7993386 Elliott Aug 2011 B2
8002824 Jenson et al. Aug 2011 B2
8002825 Letac et al. Aug 2011 B2
8012198 Hill et al. Sep 2011 B2
8021421 Fogarty et al. Sep 2011 B2
RE42818 Cali et al. Oct 2011 E
RE42857 Cali et al. Oct 2011 E
8038704 Sherburne Oct 2011 B2
8038709 Palasis et al. Oct 2011 B2
8043450 Cali et al. Oct 2011 B2
8048153 Salahieh et al. Nov 2011 B2
8052715 Quinn et al. Nov 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8052750 Tuval et al. Nov 2011 B2
8057540 Letac et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8062536 Liu et al. Nov 2011 B2
8062537 Tuominen et al. Nov 2011 B2
8062749 Shelestak et al. Nov 2011 B2
8070799 Righini et al. Dec 2011 B2
8075641 Aravanis et al. Dec 2011 B2
8083788 Acosta et al. Dec 2011 B2
8092518 Schreck Jan 2012 B2
8092520 Quadri Jan 2012 B2
8092521 Figulla et al. Jan 2012 B2
8128676 Cummings Mar 2012 B2
8128681 Shoemaker et al. Mar 2012 B2
8133217 Stokes et al. Mar 2012 B2
8133270 Khe et al. Mar 2012 B2
8136659 Salahieh et al. Mar 2012 B2
8137394 Stocker et al. Mar 2012 B2
8137398 Tuval et al. Mar 2012 B2
8147534 Berez et al. Apr 2012 B2
8157853 Laske et al. Apr 2012 B2
8167894 Miles et al. May 2012 B2
8172896 McNamara et al. May 2012 B2
8182528 Salahieh et al. May 2012 B2
8192351 Fishler et al. Jun 2012 B2
8206437 Bonhoeffer et al. Jun 2012 B2
8211107 Parks et al. Jul 2012 B2
8216174 Wilk et al. Jul 2012 B2
8216301 Bonhoeffer et al. Jul 2012 B2
8221493 Boyle et al. Jul 2012 B2
8226707 White Jul 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8231670 Salahieh et al. Jul 2012 B2
8236049 Rowe et al. Aug 2012 B2
8236241 Carpentier et al. Aug 2012 B2
8246675 Zegdi Aug 2012 B2
8246678 Salahieh et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8277500 Schmid et al. Oct 2012 B2
8287584 Salahieh et al. Oct 2012 B2
8303653 Bonhoeffer et al. Nov 2012 B2
8308798 Pintor et al. Nov 2012 B2
8317858 Straubinger et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8328868 Paul et al. Dec 2012 B2
8343136 How et al. Jan 2013 B2
8343213 Salahieh et al. Jan 2013 B2
8348995 Tuval et al. Jan 2013 B2
8348996 Tuval et al. Jan 2013 B2
8348999 Kheradvar et al. Jan 2013 B2
8357387 Dove et al. Jan 2013 B2
8366767 Zhang Feb 2013 B2
8372134 Schlick et al. Feb 2013 B2
8376865 Forster et al. Feb 2013 B2
8377117 Keidar et al. Feb 2013 B2
8382822 Pavcnik et al. Feb 2013 B2
8398704 Straubinger et al. Mar 2013 B2
8398708 Meiri et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8414641 Stocker et al. Apr 2013 B2
8414643 Tuval et al. Apr 2013 B2
8414644 Quadri et al. Apr 2013 B2
8414645 Dwork et al. Apr 2013 B2
8439961 Jagger et al. May 2013 B2
8445278 Everaerts et al. May 2013 B2
8460365 Haverkost et al. Jun 2013 B2
8465540 Straubinger et al. Jun 2013 B2
8468667 Straubinger et al. Jun 2013 B2
8470023 Eidenschink et al. Jun 2013 B2
8491650 Wiemeyer et al. Jul 2013 B2
8512394 Schmid et al. Aug 2013 B2
8512399 LaFontaine Aug 2013 B2
8512400 Tran et al. Aug 2013 B2
8512401 Murray, III et al. Aug 2013 B2
8523936 Schmid et al. Sep 2013 B2
8535368 Headley, Jr. et al. Sep 2013 B2
8540762 Schmid et al. Sep 2013 B2
8545547 Schmid et al. Oct 2013 B2
8551160 Figulla et al. Oct 2013 B2
8556880 Freyman et al. Oct 2013 B2
8556966 Jenson Oct 2013 B2
8568475 Nguyen Oct 2013 B2
8579962 Salahieh et al. Nov 2013 B2
8579965 Bonhoeffer et al. Nov 2013 B2
8585756 Bonhoeffer et al. Nov 2013 B2
8585759 Bumbalough Nov 2013 B2
8591570 Revuelta et al. Nov 2013 B2
8597226 Wilk et al. Dec 2013 B2
8603159 Seguin et al. Dec 2013 B2
8603160 Salahieh et al. Dec 2013 B2
8617235 Schmid et al. Dec 2013 B2
8617236 Paul et al. Dec 2013 B2
8623074 Ryan Jan 2014 B2
8623075 Murray, III et al. Jan 2014 B2
8623076 Salahieh et al. Jan 2014 B2
8623078 Salahieh et al. Jan 2014 B2
8628562 Cummings Jan 2014 B2
8628571 Hacohen et al. Jan 2014 B1
8647381 Essinger et al. Feb 2014 B2
8668733 Haug et al. Mar 2014 B2
8672997 Drasler et al. Mar 2014 B2
8679174 Ottma et al. Mar 2014 B2
8685077 Laske et al. Apr 2014 B2
8696743 Holecek Apr 2014 B2
8721713 Tower et al. May 2014 B2
8721717 Shoemaker et al. May 2014 B2
8734508 Hastings et al. May 2014 B2
8758430 Ferrari et al. Jun 2014 B2
8764818 Gregg Jul 2014 B2
8778020 Gregg Jul 2014 B2
8790395 Straubinger et al. Jul 2014 B2
8795305 Martin et al. Aug 2014 B2
8795356 Quadri et al. Aug 2014 B2
8808356 Braido et al. Aug 2014 B2
8808364 Palasis et al. Aug 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8828079 Thielen et al. Sep 2014 B2
8840662 Salahieh et al. Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8845721 Braido et al. Sep 2014 B2
8851286 Chang et al. Oct 2014 B2
8852272 Gross et al. Oct 2014 B2
8858620 Salahieh et al. Oct 2014 B2
8894703 Salahieh et al. Nov 2014 B2
8932349 Jenson et al. Jan 2015 B2
8940014 Gamarra et al. Jan 2015 B2
8951243 Crisostomo et al. Feb 2015 B2
8951299 Paul et al. Feb 2015 B2
8956383 Aklog et al. Feb 2015 B2
8992608 Haug et al. Mar 2015 B2
8998976 Gregg et al. Apr 2015 B2
9005273 Salahieh et al. Apr 2015 B2
9011521 Haug et al. Apr 2015 B2
9023099 Duffy et al. May 2015 B2
9028542 Hill et al. May 2015 B2
9039756 White May 2015 B2
9044318 Straubinger et al. Jun 2015 B2
9131926 Crisostomo et al. Sep 2015 B2
9149358 Tabor et al. Oct 2015 B2
9168130 Straubinger et al. Oct 2015 B2
9168131 Yohanan et al. Oct 2015 B2
9168136 Yang et al. Oct 2015 B2
9180005 Lashinski et al. Nov 2015 B1
9186482 Dorn Nov 2015 B2
9211266 Iwazawa et al. Dec 2015 B2
9216082 Von Segesser et al. Dec 2015 B2
9248037 Roeder et al. Feb 2016 B2
9265608 Miller et al. Feb 2016 B2
9277991 Salahieh et al. Mar 2016 B2
9277993 Gamarra et al. Mar 2016 B2
9301840 Nguyen et al. Apr 2016 B2
9301843 Richardson et al. Apr 2016 B2
9308085 Salahieh et al. Apr 2016 B2
9320599 Salahieh et al. Apr 2016 B2
9326853 Olson et al. May 2016 B2
9358106 Salahieh et al. Jun 2016 B2
9358110 Paul et al. Jun 2016 B2
9370419 Hill et al. Jun 2016 B2
9370421 Crisostomo et al. Jun 2016 B2
9387076 Paul et al. Jul 2016 B2
9393094 Salahieh et al. Jul 2016 B2
9393113 Salahieh et al. Jul 2016 B2
9393114 Sutton et al. Jul 2016 B2
9393115 Tabor et al. Jul 2016 B2
9415567 Sogard et al. Aug 2016 B2
9421083 Eidenschink et al. Aug 2016 B2
9439759 Straubinger et al. Sep 2016 B2
9463084 Stinson Oct 2016 B2
9474598 Gregg et al. Oct 2016 B2
9474609 Haverkost et al. Oct 2016 B2
9492276 Lee et al. Nov 2016 B2
9510945 Sutton et al. Dec 2016 B2
9526609 Salahieh et al. Dec 2016 B2
9532872 Salahieh et al. Jan 2017 B2
9539091 Yang et al. Jan 2017 B2
9554924 Schlick et al. Jan 2017 B2
9597432 Nakamura Mar 2017 B2
9649212 Fargahi May 2017 B2
9717593 Alkhatib et al. Aug 2017 B2
D800908 Hariton et al. Oct 2017 S
9775709 Miller et al. Oct 2017 B2
9788945 Ottma et al. Oct 2017 B2
9861476 Salahieh et al. Jan 2018 B2
9867694 Girard et al. Jan 2018 B2
9867699 Straubinger et al. Jan 2018 B2
9872768 Paul et al. Jan 2018 B2
9889002 Bonhoeffer et al. Feb 2018 B2
9901445 Backus et al. Feb 2018 B2
9949824 Bonhoeffer et al. Apr 2018 B2
9956075 Salahieh et al. May 2018 B2
9987133 Straubinger et al. Jun 2018 B2
10092324 Gillespie et al. Oct 2018 B2
10143552 Wallace et al. Dec 2018 B2
10154901 Straubinger et al. Dec 2018 B2
10321987 Wang et al. Jun 2019 B2
10363134 Figulla Jul 2019 B2
10543084 Guyenot et al. Jan 2020 B2
10702382 Straubinger et al. Jul 2020 B2
10709555 Schreck et al. Jul 2020 B2
11266497 Cao Mar 2022 B2
20010000041 Selmon et al. Mar 2001 A1
20010001314 Davison et al. May 2001 A1
20010002445 Vesely May 2001 A1
20010004683 Gambale et al. Jun 2001 A1
20010004690 Gambale et al. Jun 2001 A1
20010004699 Gittings et al. Jun 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010008969 Evans et al. Jul 2001 A1
20010010017 Letac et al. Jul 2001 A1
20010011187 Pavcnik et al. Aug 2001 A1
20010011189 Drasler et al. Aug 2001 A1
20010012948 Vanney Aug 2001 A1
20010014813 Saadat et al. Aug 2001 A1
20010016700 Eno et al. Aug 2001 A1
20010018596 Selmon et al. Aug 2001 A1
20010020172 Selmon et al. Sep 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025196 Chinn et al. Sep 2001 A1
20010025643 Foley Oct 2001 A1
20010027287 Shmulewitz et al. Oct 2001 A1
20010027338 Greenberg Oct 2001 A1
20010027339 Boatman et al. Oct 2001 A1
20010029385 Shennib et al. Oct 2001 A1
20010032013 Marton Oct 2001 A1
20010034547 Hall et al. Oct 2001 A1
20010037117 Gambale et al. Nov 2001 A1
20010037141 Yee et al. Nov 2001 A1
20010037149 Wilk Nov 2001 A1
20010039426 Makower et al. Nov 2001 A1
20010039445 Hall et al. Nov 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041902 Lepulu et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010041930 Globerman et al. Nov 2001 A1
20010044631 Akin et al. Nov 2001 A1
20010044634 Don Michael et al. Nov 2001 A1
20010044647 Pinchuk et al. Nov 2001 A1
20010044652 Moore Nov 2001 A1
20010044656 Williamson, IV et al. Nov 2001 A1
20010047165 Makower et al. Nov 2001 A1
20010049523 DeVore et al. Dec 2001 A1
20010051822 Stack et al. Dec 2001 A1
20010053932 Phelps et al. Dec 2001 A1
20020002349 Flaherty et al. Jan 2002 A1
20020002396 Fulkerson Jan 2002 A1
20020002401 McGuckin, Jr. et al. Jan 2002 A1
20020004662 Wilk Jan 2002 A1
20020004663 Gittings et al. Jan 2002 A1
20020007138 Wilk et al. Jan 2002 A1
20020010489 Gayzel et al. Jan 2002 A1
20020010508 Chobotov Jan 2002 A1
20020026233 Shaknovich Feb 2002 A1
20020029014 Jayaraman Mar 2002 A1
20020029079 Kim et al. Mar 2002 A1
20020029981 Nigam Mar 2002 A1
20020032476 Gambale et al. Mar 2002 A1
20020032478 Boekstegers et al. Mar 2002 A1
20020032480 Spence et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020035390 Schaldach et al. Mar 2002 A1
20020035396 Heath Mar 2002 A1
20020042650 Vardi et al. Apr 2002 A1
20020042651 Liddicoat et al. Apr 2002 A1
20020045846 Kaplon et al. Apr 2002 A1
20020045928 Boekstegers Apr 2002 A1
20020045929 Diaz Apr 2002 A1
20020049486 Knudson et al. Apr 2002 A1
20020052651 Myers May 2002 A1
20020055767 Forde et al. May 2002 A1
20020055769 Wang May 2002 A1
20020055772 McGuckin, Jr. et al. May 2002 A1
20020055774 Liddicoat May 2002 A1
20020055775 Carpentier et al. May 2002 A1
20020058897 Renati May 2002 A1
20020058987 Butaric et al. May 2002 A1
20020058993 Landau et al. May 2002 A1
20020058995 Stevens May 2002 A1
20020062146 Makower et al. May 2002 A1
20020065478 Knudson et al. May 2002 A1
20020065485 DuBois et al. May 2002 A1
20020072699 Knudson et al. Jun 2002 A1
20020072789 Hackett et al. Jun 2002 A1
20020077566 Laroya et al. Jun 2002 A1
20020077654 Javier, Jr. et al. Jun 2002 A1
20020077696 Zadno-Azizi et al. Jun 2002 A1
20020082584 Rosenman et al. Jun 2002 A1
20020082609 Green Jun 2002 A1
20020092535 Wilk Jul 2002 A1
20020092536 LaFontaine et al. Jul 2002 A1
20020095111 Tweden et al. Jul 2002 A1
20020095173 Mazzocchi et al. Jul 2002 A1
20020095206 Addonizio et al. Jul 2002 A1
20020095209 Zadno-Azizi et al. Jul 2002 A1
20020099439 Schwartz et al. Jul 2002 A1
20020100484 Hall et al. Aug 2002 A1
20020103533 Langberg et al. Aug 2002 A1
20020107565 Greenhalgh Aug 2002 A1
20020111627 Vincent-Prestigiacomo Aug 2002 A1
20020111665 Lauterjung Aug 2002 A1
20020111668 Smith Aug 2002 A1
20020111672 Kim et al. Aug 2002 A1
20020111674 Chouinard et al. Aug 2002 A1
20020117789 Childers et al. Aug 2002 A1
20020120322 Thompson et al. Aug 2002 A1
20020120323 Thompson et al. Aug 2002 A1
20020120328 Pathak et al. Aug 2002 A1
20020123698 Garibotto et al. Sep 2002 A1
20020123786 Gittings et al. Sep 2002 A1
20020123790 White et al. Sep 2002 A1
20020123802 Snyders Sep 2002 A1
20020133183 Lentz et al. Sep 2002 A1
20020133226 Marquez et al. Sep 2002 A1
20020138087 Shennib et al. Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020143285 Eno et al. Oct 2002 A1
20020143289 Ellis et al. Oct 2002 A1
20020143387 Soetikno et al. Oct 2002 A1
20020144696 Sharkawy et al. Oct 2002 A1
20020151913 Berg et al. Oct 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020156522 Ivancev et al. Oct 2002 A1
20020161377 Rabkin Oct 2002 A1
20020161383 Akin et al. Oct 2002 A1
20020161390 Mouw Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020161424 Rapacki et al. Oct 2002 A1
20020161426 Iancea Oct 2002 A1
20020165479 Wilk Nov 2002 A1
20020165576 Boyle et al. Nov 2002 A1
20020165606 Wolf et al. Nov 2002 A1
20020173842 Buchanan Nov 2002 A1
20020177766 Mogul Nov 2002 A1
20020177772 Altman et al. Nov 2002 A1
20020177840 Farnholtz Nov 2002 A1
20020177894 Acosta et al. Nov 2002 A1
20020179098 Makower et al. Dec 2002 A1
20020183716 Herweck et al. Dec 2002 A1
20020183781 Casey et al. Dec 2002 A1
20020186558 Plank et al. Dec 2002 A1
20020188341 Elliott Dec 2002 A1
20020188344 Bolea et al. Dec 2002 A1
20020193782 Ellis et al. Dec 2002 A1
20020193871 Beyersdorf et al. Dec 2002 A1
20020198594 Schreck Dec 2002 A1
20030004541 Linder et al. Jan 2003 A1
20030004560 Chobotov et al. Jan 2003 A1
20030009189 Gilson et al. Jan 2003 A1
20030014104 Cribier Jan 2003 A1
20030018377 Berg et al. Jan 2003 A1
20030018379 Knudson et al. Jan 2003 A1
20030023300 Bailey et al. Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030027332 Lafrance et al. Feb 2003 A1
20030028213 Thill et al. Feb 2003 A1
20030028247 Cali Feb 2003 A1
20030033001 Igaki Feb 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030036795 Andersen et al. Feb 2003 A1
20030040736 Stevens et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030040791 Oktay Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030042186 Boyle Mar 2003 A1
20030044315 Boekstegers Mar 2003 A1
20030045828 Wilk Mar 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055371 Wolf et al. Mar 2003 A1
20030055495 Pease Mar 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030060844 Borillo et al. Mar 2003 A1
20030065386 Weadock Apr 2003 A1
20030069492 Abrams et al. Apr 2003 A1
20030069646 Stinson Apr 2003 A1
20030070944 Nigam Apr 2003 A1
20030073973 Evans et al. Apr 2003 A1
20030074058 Sherry Apr 2003 A1
20030078561 Gambale et al. Apr 2003 A1
20030078652 Sutherland Apr 2003 A1
20030083730 Stinson May 2003 A1
20030093145 Lawrence-Brown et al. May 2003 A1
20030100918 Duane May 2003 A1
20030100919 Hopkins et al. May 2003 A1
20030100920 Akin et al. May 2003 A1
20030105514 Phelps et al. Jun 2003 A1
20030109924 Cribier Jun 2003 A1
20030109930 Bluni et al. Jun 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030120195 Milo et al. Jun 2003 A1
20030125795 Pavcnik et al. Jul 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20030130727 Drasler et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030130746 Ashworth et al. Jul 2003 A1
20030135257 Taheri Jul 2003 A1
20030139796 Sequin et al. Jul 2003 A1
20030139798 Brown et al. Jul 2003 A1
20030139803 Sequin et al. Jul 2003 A1
20030139804 Hankh et al. Jul 2003 A1
20030144657 Bowe et al. Jul 2003 A1
20030144732 Cosgrove et al. Jul 2003 A1
20030149474 Becker Aug 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149477 Gabbay Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030153971 Chandrasekaran Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030158573 Gittings et al. Aug 2003 A1
20030158595 Randall et al. Aug 2003 A1
20030163193 Widenhouse Aug 2003 A1
20030163198 Morra et al. Aug 2003 A1
20030165352 Ibrahim et al. Sep 2003 A1
20030171803 Shimon Sep 2003 A1
20030171805 Berg et al. Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030181938 Roth et al. Sep 2003 A1
20030181942 Sutton et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030191449 Nash et al. Oct 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030191519 Lombardi et al. Oct 2003 A1
20030191526 Van Tassel et al. Oct 2003 A1
20030195457 LaFontaine et al. Oct 2003 A1
20030195458 Phelps et al. Oct 2003 A1
20030195609 Berenstein et al. Oct 2003 A1
20030195620 Huynh et al. Oct 2003 A1
20030198722 Johnston, Jr. et al. Oct 2003 A1
20030199759 Richard Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199963 Tower et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030199972 Zadno-Azizi et al. Oct 2003 A1
20030204160 Kamm et al. Oct 2003 A1
20030204249 Letort Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030212410 Stenzel et al. Nov 2003 A1
20030212413 Wilk Nov 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212452 Zadno-Azizi et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030216678 March et al. Nov 2003 A1
20030216679 Wolf et al. Nov 2003 A1
20030216774 Larson Nov 2003 A1
20030220661 Mowry et al. Nov 2003 A1
20030220667 Van Der Burg et al. Nov 2003 A1
20030225445 Derus et al. Dec 2003 A1
20030229366 Reggie et al. Dec 2003 A1
20030229390 Ashton et al. Dec 2003 A1
20030233117 Adams et al. Dec 2003 A1
20030236542 Makower Dec 2003 A1
20030236567 Elliot Dec 2003 A1
20030236568 Hojeibane et al. Dec 2003 A1
20030236570 Cook et al. Dec 2003 A1
20040004926 Maeda Jan 2004 A1
20040006298 Wilk Jan 2004 A1
20040006380 Buck et al. Jan 2004 A1
20040015225 Kim et al. Jan 2004 A1
20040015228 Lombardi et al. Jan 2004 A1
20040018651 Nadeau Jan 2004 A1
20040019348 Stevens et al. Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040026389 Kessler et al. Feb 2004 A1
20040033364 Spiridigliozzi et al. Feb 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040037946 Morra et al. Feb 2004 A1
20040039343 Eppstein et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040044361 Frazier et al. Mar 2004 A1
20040044392 Von Oepen Mar 2004 A1
20040044400 Cheng et al. Mar 2004 A1
20040044402 Jung et al. Mar 2004 A1
20040049204 Harari et al. Mar 2004 A1
20040049207 Goldfarb et al. Mar 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049226 Keegan et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040058097 Weder Mar 2004 A1
20040059280 Makower et al. Mar 2004 A1
20040059407 Escamilla et al. Mar 2004 A1
20040059409 Stenzel Mar 2004 A1
20040059429 Amin et al. Mar 2004 A1
20040073157 Knudson et al. Apr 2004 A1
20040073198 Gilson et al. Apr 2004 A1
20040073238 Makower Apr 2004 A1
20040073289 Hartley et al. Apr 2004 A1
20040077987 Rapacki et al. Apr 2004 A1
20040077988 Tweden et al. Apr 2004 A1
20040077990 Knudson et al. Apr 2004 A1
20040078950 Schreck et al. Apr 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040082967 Broome et al. Apr 2004 A1
20040082989 Cook et al. Apr 2004 A1
20040087982 Eskuri May 2004 A1
20040088042 Kim et al. May 2004 A1
20040088045 Cox May 2004 A1
20040092858 Wilson et al. May 2004 A1
20040092989 Wilson et al. May 2004 A1
20040093005 Durcan May 2004 A1
20040093016 Root et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040093063 Wright et al. May 2004 A1
20040093070 Hojeibane et al. May 2004 A1
20040093075 Kuehne May 2004 A1
20040097788 Mourlas et al. May 2004 A1
20040098022 Barone May 2004 A1
20040098098 McGuckin, Jr. et al. May 2004 A1
20040098099 McCullagh et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040102855 Shank May 2004 A1
20040106931 Guiles et al. Jun 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040106990 Spence et al. Jun 2004 A1
20040107004 Levine et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040113306 Rapacki et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040116999 Ledergerber Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040118415 Hall et al. Jun 2004 A1
20040122318 Flaherty et al. Jun 2004 A1
20040122347 Knudson et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127847 DuBois et al. Jul 2004 A1
20040127912 Rabkin et al. Jul 2004 A1
20040127936 Salahieh et al. Jul 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040133154 Flaherty et al. Jul 2004 A1
20040133225 Makower Jul 2004 A1
20040133274 Webler et al. Jul 2004 A1
20040138694 Tran et al. Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040138745 Macoviak et al. Jul 2004 A1
20040147868 Bardsley et al. Jul 2004 A1
20040147869 Wolf et al. Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040148021 Cartledge et al. Jul 2004 A1
20040153094 Dunfee et al. Aug 2004 A1
20040153145 Simionescu et al. Aug 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040158143 Flaherty et al. Aug 2004 A1
20040158277 Lowe et al. Aug 2004 A1
20040163094 Matsui et al. Aug 2004 A1
20040167444 Laroya et al. Aug 2004 A1
20040167565 Beulke et al. Aug 2004 A1
20040167573 Williamson, IV et al. Aug 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040168691 Sharkawy et al. Sep 2004 A1
20040176791 Lim et al. Sep 2004 A1
20040181140 Falwell et al. Sep 2004 A1
20040186507 Hall et al. Sep 2004 A1
20040186557 Gambale et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186587 Ahern Sep 2004 A1
20040193180 Buzzard et al. Sep 2004 A1
20040193244 Hartley et al. Sep 2004 A1
20040193252 Perez et al. Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040197695 Aono Oct 2004 A1
20040199245 Lauterjung Oct 2004 A1
20040204683 McGuckin, Jr. et al. Oct 2004 A1
20040204755 Robin Oct 2004 A1
20040206363 McCarthy et al. Oct 2004 A1
20040210104 Lau et al. Oct 2004 A1
20040210190 Kohler et al. Oct 2004 A1
20040210240 Saint Oct 2004 A1
20040210301 Obermiller et al. Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210306 Quijano et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215317 Cummings Oct 2004 A1
20040215331 Chew et al. Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040219180 Gambale et al. Nov 2004 A1
20040220598 Bolduc et al. Nov 2004 A1
20040220655 Swanson et al. Nov 2004 A1
20040225321 Krolik et al. Nov 2004 A1
20040225353 McGuckin, Jr. et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20040236418 Stevens Nov 2004 A1
20040243143 Corcoran et al. Dec 2004 A1
20040243221 Fawzi et al. Dec 2004 A1
20040249343 Cioanta Dec 2004 A1
20040254594 Alfaro Dec 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260390 Sarac et al. Dec 2004 A1
20040260393 Rahdert et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20040267357 Allen et al. Dec 2004 A1
20050000858 Roovers Jan 2005 A1
20050004505 Phelps et al. Jan 2005 A1
20050004558 Gambale et al. Jan 2005 A1
20050004648 Boekstegers Jan 2005 A1
20050008589 Legrand et al. Jan 2005 A1
20050009000 Wilhelm et al. Jan 2005 A1
20050010246 Streeter et al. Jan 2005 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak et al. Jan 2005 A1
20050015112 Cohn et al. Jan 2005 A1
20050021136 Xie et al. Jan 2005 A1
20050025857 Schoenherr et al. Feb 2005 A1
20050027305 Shiu et al. Feb 2005 A1
20050027348 Case et al. Feb 2005 A1
20050033220 Wilk et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050033402 Cully et al. Feb 2005 A1
20050038495 Greenan Feb 2005 A1
20050038509 Ashe Feb 2005 A1
20050043585 Datta et al. Feb 2005 A1
20050043711 Corcoran et al. Feb 2005 A1
20050043757 Arad et al. Feb 2005 A1
20050043759 Chanduszko Feb 2005 A1
20050043760 Fogarty et al. Feb 2005 A1
20050043781 Foley Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050049674 Berra et al. Mar 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050049696 Siess et al. Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050060016 Wu et al. Mar 2005 A1
20050060018 Dittman Mar 2005 A1
20050060029 Le et al. Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050065594 DiMatteo et al. Mar 2005 A1
20050070794 Deal et al. Mar 2005 A1
20050070957 Das Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075717 Nguyen et al. Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075720 Nguyen et al. Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050075725 Rowe Apr 2005 A1
20050075726 Svanidze et al. Apr 2005 A1
20050075727 Wheatley Apr 2005 A1
20050075730 Myers et al. Apr 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050075776 Cho Apr 2005 A1
20050084595 Shukla et al. Apr 2005 A1
20050085841 Eversull et al. Apr 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050090890 Wu et al. Apr 2005 A1
20050096568 Kato May 2005 A1
20050096692 Linder et al. May 2005 A1
20050096724 Stenzel et al. May 2005 A1
20050096726 Sequin et al. May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050096768 Huang et al. May 2005 A1
20050098547 Cali et al. May 2005 A1
20050100580 Osborne et al. May 2005 A1
20050101903 Kohler et al. May 2005 A1
20050101904 Wilk May 2005 A1
20050101968 Dadourian May 2005 A1
20050107822 Wasdyke May 2005 A1
20050107871 Realyvasquez et al. May 2005 A1
20050113902 Geiser et al. May 2005 A1
20050113904 Shank et al. May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050119688 Bergheim Jun 2005 A1
20050119728 Sarac Jun 2005 A1
20050119736 Zilla et al. Jun 2005 A1
20050125075 Meade et al. Jun 2005 A1
20050131438 Cohn Jun 2005 A1
20050137499 Sheets et al. Jun 2005 A1
20050137609 Guiraudon Jun 2005 A1
20050137681 Shoemaker et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050137683 Hezi-Yamit et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137693 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050138689 Aukerman Jun 2005 A1
20050143804 Haverkost Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050148997 Valley et al. Jul 2005 A1
20050149159 Andreas et al. Jul 2005 A1
20050149166 Schaeffer et al. Jul 2005 A1
20050149181 Eberhardt Jul 2005 A1
20050150775 Zhang et al. Jul 2005 A1
20050159726 Evans et al. Jul 2005 A1
20050165352 Henry et al. Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050165479 Drews et al. Jul 2005 A1
20050171597 Boatman et al. Aug 2005 A1
20050171598 Schaeffer Aug 2005 A1
20050177227 Heim et al. Aug 2005 A1
20050182483 Osborne et al. Aug 2005 A1
20050182486 Gabbay Aug 2005 A1
20050186349 Loper et al. Aug 2005 A1
20050187616 Realyvasquez Aug 2005 A1
20050192527 Gharib et al. Sep 2005 A1
20050192665 Spenser et al. Sep 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203605 Dolan Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050203818 Rotman et al. Sep 2005 A9
20050209580 Freyman Sep 2005 A1
20050214342 Tweden et al. Sep 2005 A1
20050222664 Parker Oct 2005 A1
20050222668 Schaeffer et al. Oct 2005 A1
20050222674 Paine Oct 2005 A1
20050228334 Knudson et al. Oct 2005 A1
20050228472 Case et al. Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050228496 Mensah et al. Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240262 White Oct 2005 A1
20050240263 Fogarty et al. Oct 2005 A1
20050251243 Seppala et al. Nov 2005 A1
20050251250 Verhoeven et al. Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050251252 Stobie Nov 2005 A1
20050256532 Nayak et al. Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267523 Devellian et al. Dec 2005 A1
20050267560 Bates Dec 2005 A1
20050267567 Shalev Dec 2005 A1
20050267573 Macoviak et al. Dec 2005 A9
20050283231 Haug et al. Dec 2005 A1
20050283962 Boudjemline Dec 2005 A1
20050288627 Mogul Dec 2005 A1
20050288685 Gulles et al. Dec 2005 A1
20050288706 Widomski et al. Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060004469 Sokel Jan 2006 A1
20060009841 McGuckin, Jr. et al. Jan 2006 A1
20060009842 Huynh et al. Jan 2006 A1
20060015168 Gunderson Jan 2006 A1
20060025855 Lashinski et al. Feb 2006 A1
20060025857 Bergheim Feb 2006 A1
20060028766 Khizroev Feb 2006 A1
20060041218 Phelps et al. Feb 2006 A1
20060047338 Jenson et al. Mar 2006 A1
20060047343 Oviatt et al. Mar 2006 A1
20060052736 Tweden et al. Mar 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060058775 Stevens et al. Mar 2006 A1
20060058864 Schaeffer et al. Mar 2006 A1
20060058871 Zakay et al. Mar 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060064151 Guterman et al. Mar 2006 A1
20060069424 Acosta et al. Mar 2006 A1
20060074477 Berthiaume et al. Apr 2006 A1
20060074484 Huber Apr 2006 A1
20060074485 Realyvasquez Apr 2006 A1
20060077447 Sojian et al. Apr 2006 A1
20060085060 Campbell Apr 2006 A1
20060089711 Dolan Apr 2006 A1
20060100685 Seguin et al. May 2006 A1
20060111770 Pavcnik et al. May 2006 A1
20060116757 Lashinski et al. Jun 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060135961 Rosenman et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060136034 Modesitt et al. Jun 2006 A1
20060142846 Pavcnik et al. Jun 2006 A1
20060142848 Gabbay Jun 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060155312 Levine et al. Jul 2006 A1
20060155363 LaDuca et al. Jul 2006 A1
20060155366 LaDuca et al. Jul 2006 A1
20060161248 Case et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060161265 Levine et al. Jul 2006 A1
20060167474 Bloom et al. Jul 2006 A1
20060167543 Bailey et al. Jul 2006 A1
20060173524 Salahieh et al. Aug 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060190070 Dieck et al. Aug 2006 A1
20060193885 Neethling et al. Aug 2006 A1
20060195134 Crittenden Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060195186 Drews et al. Aug 2006 A1
20060206192 Tower et al. Sep 2006 A1
20060206202 Bonhoeffer et al. Sep 2006 A1
20060210597 Hiles Sep 2006 A1
20060212110 Osborne et al. Sep 2006 A1
20060212111 Case et al. Sep 2006 A1
20060217802 Ruiz et al. Sep 2006 A1
20060224183 Freudenthal Oct 2006 A1
20060229561 Huszar Oct 2006 A1
20060229718 Marquez Oct 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060246584 Covelli Nov 2006 A1
20060247570 Pokorney Nov 2006 A1
20060247763 Slater Nov 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265043 Mandrusov et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060270958 George Nov 2006 A1
20060271149 Berez et al. Nov 2006 A1
20060271161 Meyer et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060271175 Woolfson et al. Nov 2006 A1
20060276873 Sato Dec 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060276882 Case et al. Dec 2006 A1
20060276887 Brady et al. Dec 2006 A1
20060282161 Huynh et al. Dec 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20060287719 Rowe et al. Dec 2006 A1
20060290027 O'Connor et al. Dec 2006 A1
20060293745 Carpentier et al. Dec 2006 A1
20070005129 Damm et al. Jan 2007 A1
20070005131 Taylor Jan 2007 A1
20070005132 Simionescu et al. Jan 2007 A1
20070010876 Salahieh et al. Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070010878 Rafiee et al. Jan 2007 A1
20070010887 Williams et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070016288 Gurskis et al. Jan 2007 A1
20070020248 Everaerts et al. Jan 2007 A1
20070021826 Case et al. Jan 2007 A1
20070027518 Case et al. Feb 2007 A1
20070027520 Sherburne Feb 2007 A1
20070027533 Douk Feb 2007 A1
20070027535 Purdy, Jr. et al. Feb 2007 A1
20070032856 Limon Feb 2007 A1
20070038291 Case et al. Feb 2007 A1
20070038295 Case et al. Feb 2007 A1
20070043420 Lostetter Feb 2007 A1
20070043424 Pryor Feb 2007 A1
20070043431 Melsheimer Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070050014 Johnson Mar 2007 A1
20070051377 Douk et al. Mar 2007 A1
20070055340 Pryor Mar 2007 A1
20070056346 Spenser et al. Mar 2007 A1
20070060998 Butterwick et al. Mar 2007 A1
20070061002 Paul, Jr. et al. Mar 2007 A1
20070061008 Salahieh et al. Mar 2007 A1
20070073389 Bolduc et al. Mar 2007 A1
20070073392 Heyninck-Jantz et al. Mar 2007 A1
20070078504 Mialhe Apr 2007 A1
20070078509 Lotfy Apr 2007 A1
20070078510 Ryan Apr 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070093869 Bloom et al. Apr 2007 A1
20070093887 Case et al. Apr 2007 A1
20070100427 Perouse May 2007 A1
20070100435 Case et al. May 2007 A1
20070100439 Cangialosi et al. May 2007 A1
20070100440 Figulla et al. May 2007 A1
20070100449 O'Neil et al. May 2007 A1
20070112355 Salahieh et al. May 2007 A1
20070112358 Abbott et al. May 2007 A1
20070112415 Bartlett May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070118214 Salahieh et al. May 2007 A1
20070123700 Ueda et al. May 2007 A1
20070123979 Perier et al. May 2007 A1
20070135889 Moore et al. Jun 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070142907 Moaddeb et al. Jun 2007 A1
20070155010 Farnsworth et al. Jul 2007 A1
20070156233 Kapadia et al. Jul 2007 A1
20070162102 Ryan et al. Jul 2007 A1
20070162103 Case et al. Jul 2007 A1
20070162107 Haug et al. Jul 2007 A1
20070162113 Sharkawy et al. Jul 2007 A1
20070173918 Dreher et al. Jul 2007 A1
20070173932 Cali et al. Jul 2007 A1
20070179592 Schaeffer Aug 2007 A1
20070179600 Vardi Aug 2007 A1
20070185513 Woolfson et al. Aug 2007 A1
20070185565 Schwammenthal et al. Aug 2007 A1
20070185571 Kapadia et al. Aug 2007 A1
20070198078 Berra et al. Aug 2007 A1
20070198097 Zegdi Aug 2007 A1
20070203391 Bloom et al. Aug 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070203560 Forster et al. Aug 2007 A1
20070203576 Lee et al. Aug 2007 A1
20070208550 Cali et al. Sep 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070225681 House Sep 2007 A1
20070225802 Forsell Sep 2007 A1
20070232898 Huynh et al. Oct 2007 A1
20070233222 Roeder et al. Oct 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070233237 Krivoruchko Oct 2007 A1
20070233238 Huynh et al. Oct 2007 A1
20070238979 Huynh et al. Oct 2007 A1
20070239254 Chia et al. Oct 2007 A1
20070239265 Birdsall Oct 2007 A1
20070239266 Birdsall Oct 2007 A1
20070239269 Dolan et al. Oct 2007 A1
20070239271 Nguyen Oct 2007 A1
20070239273 Allen Oct 2007 A1
20070244543 Mitchell Oct 2007 A1
20070244544 Birdsall et al. Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070244546 Francis Oct 2007 A1
20070244551 Stobie Oct 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070244553 Rafiee et al. Oct 2007 A1
20070244554 Rafiee et al. Oct 2007 A1
20070244555 Rafiee et al. Oct 2007 A1
20070244556 Rafiee et al. Oct 2007 A1
20070244557 Rafiee et al. Oct 2007 A1
20070250151 Pereira Oct 2007 A1
20070250160 Rafiee Oct 2007 A1
20070255386 Tenne Nov 2007 A1
20070255390 Ducke et al. Nov 2007 A1
20070255394 Ryan Nov 2007 A1
20070255396 Douk et al. Nov 2007 A1
20070260301 Chuter et al. Nov 2007 A1
20070260327 Case et al. Nov 2007 A1
20070265701 Gurskis et al. Nov 2007 A1
20070270751 Stangenes et al. Nov 2007 A1
20070270943 Solem et al. Nov 2007 A1
20070273813 Yoshida et al. Nov 2007 A1
20070282436 Pinchuk Dec 2007 A1
20070287717 Fanning et al. Dec 2007 A1
20070288000 Bonan Dec 2007 A1
20070288087 Fearnot et al. Dec 2007 A1
20070288089 Gurskis et al. Dec 2007 A1
20080004688 Spenser et al. Jan 2008 A1
20080004696 Vesely Jan 2008 A1
20080009934 Schneider et al. Jan 2008 A1
20080009940 Cribier Jan 2008 A1
20080015671 Bonhoeffer Jan 2008 A1
20080021546 Patz et al. Jan 2008 A1
20080021552 Gabbay Jan 2008 A1
20080022504 Melsheimer Jan 2008 A1
20080033534 Cook et al. Feb 2008 A1
20080033541 Gelbart et al. Feb 2008 A1
20080039925 Ishimaru et al. Feb 2008 A1
20080039934 Styrc Feb 2008 A1
20080045921 Anderson et al. Feb 2008 A1
20080048656 Tan et al. Feb 2008 A1
20080065001 DiNucci et al. Mar 2008 A1
20080065011 Marchand et al. Mar 2008 A1
20080065206 Liddicoat Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071368 Tuval Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080077227 Ouellette et al. Mar 2008 A1
20080077234 Styrc Mar 2008 A1
20080077236 Letac et al. Mar 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080086205 Gordy et al. Apr 2008 A1
20080097586 Pavcnik et al. Apr 2008 A1
20080102439 Tian et al. May 2008 A1
20080109070 Wagner et al. May 2008 A1
20080125859 Salahieh et al. May 2008 A1
20080127707 Kokish et al. Jun 2008 A1
20080133002 Gelbart et al. Jun 2008 A1
20080133003 Seguin et al. Jun 2008 A1
20080140188 Rahdert et al. Jun 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080147105 Wilson et al. Jun 2008 A1
20080147180 Ghione et al. Jun 2008 A1
20080147181 Ghione et al. Jun 2008 A1
20080147182 Righini et al. Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080161909 Kheradvar et al. Jul 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080161911 Revuelta et al. Jul 2008 A1
20080172119 Yamasaki et al. Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080183273 Mesana et al. Jul 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080195193 Purdy et al. Aug 2008 A1
20080195199 Kheradvar et al. Aug 2008 A1
20080200977 Paul et al. Aug 2008 A1
20080208209 Fischer et al. Aug 2008 A1
20080208327 Rowe Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080215143 Seguin Sep 2008 A1
20080215144 Ryan et al. Sep 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080221703 Que et al. Sep 2008 A1
20080228254 Ryan Sep 2008 A1
20080228263 Ryan Sep 2008 A1
20080234443 Kiss et al. Sep 2008 A1
20080234797 Styrc Sep 2008 A1
20080234814 Salahieh et al. Sep 2008 A1
20080243246 Ryan et al. Oct 2008 A1
20080255651 Dwork Oct 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080262590 Murray Oct 2008 A1
20080262592 Jordan et al. Oct 2008 A1
20080262593 Ryan et al. Oct 2008 A1
20080262602 Wilk et al. Oct 2008 A1
20080264102 Berra Oct 2008 A1
20080269878 Lobbi Oct 2008 A1
20080275549 Rowe Nov 2008 A1
20080275550 Kheradvar et al. Nov 2008 A1
20080288054 Pulnev et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090012356 Dann et al. Jan 2009 A1
20090012600 Styrc et al. Jan 2009 A1
20090030512 Thielen et al. Jan 2009 A1
20090048656 Wen Feb 2009 A1
20090054968 Bonhoeffer et al. Feb 2009 A1
20090054969 Salahieh et al. Feb 2009 A1
20090054976 Tuval et al. Feb 2009 A1
20090062908 Bonhoeffer et al. Mar 2009 A1
20090069886 Suri et al. Mar 2009 A1
20090069887 Righini et al. Mar 2009 A1
20090069889 Suri Mar 2009 A1
20090069890 Suri Mar 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090082844 Zacharias et al. Mar 2009 A1
20090082858 Nugent et al. Mar 2009 A1
20090085900 Weiner Apr 2009 A1
20090093876 Nitzan et al. Apr 2009 A1
20090093877 Keidar et al. Apr 2009 A1
20090099640 Weng Apr 2009 A1
20090099641 Wu et al. Apr 2009 A1
20090099643 Hyodoh et al. Apr 2009 A1
20090099653 Suri et al. Apr 2009 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20090157175 Benichou Jun 2009 A1
20090163951 Simmons et al. Jun 2009 A1
20090164004 Cohn Jun 2009 A1
20090164006 Seguin et al. Jun 2009 A1
20090171432 Von Segesser et al. Jul 2009 A1
20090171447 Von Segesser et al. Jul 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090182405 Arnault De La Menardiere et al. Jul 2009 A1
20090192585 Bloom et al. Jul 2009 A1
20090192586 Tabor et al. Jul 2009 A1
20090192591 Ryan et al. Jul 2009 A1
20090192601 Rafiee et al. Jul 2009 A1
20090198316 Laske et al. Aug 2009 A1
20090198323 Johnson et al. Aug 2009 A1
20090210052 Forster et al. Aug 2009 A1
20090216310 Straubinger et al. Aug 2009 A1
20090216312 Straubinger et al. Aug 2009 A1
20090216313 Straubinger Aug 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090222082 Lock et al. Sep 2009 A1
20090234407 Hastings et al. Sep 2009 A1
20090234443 Ottma et al. Sep 2009 A1
20090240264 Tuval et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090248143 Laham Oct 2009 A1
20090259306 Rowe Oct 2009 A1
20090264759 Byrd Oct 2009 A1
20090264997 Salahieh et al. Oct 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090287290 Macaulay et al. Nov 2009 A1
20090287296 Manasse Nov 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20090299462 Fawzi et al. Dec 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20100004739 Vesely Jan 2010 A1
20100004740 Seguin et al. Jan 2010 A1
20100011564 Millwee et al. Jan 2010 A1
20100030328 Seguin et al. Feb 2010 A1
20100036479 Hill et al. Feb 2010 A1
20100036485 Seguin Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100057051 How et al. Mar 2010 A1
20100057185 Melsheimer et al. Mar 2010 A1
20100069852 Kelley Mar 2010 A1
20100069916 Cully et al. Mar 2010 A1
20100070027 Bonhoeffer et al. Mar 2010 A1
20100082089 Quadri et al. Apr 2010 A1
20100082094 Quadri et al. Apr 2010 A1
20100087913 Rabkin et al. Apr 2010 A1
20100094399 Dorn et al. Apr 2010 A1
20100094411 Tuval et al. Apr 2010 A1
20100100167 Bortlein et al. Apr 2010 A1
20100121434 Paul et al. May 2010 A1
20100131054 Tuval et al. May 2010 A1
20100131057 Subramanian et al. May 2010 A1
20100137979 Tuval et al. Jun 2010 A1
20100145439 Seguin et al. Jun 2010 A1
20100152840 Seguin et al. Jun 2010 A1
20100160725 Kiser et al. Jun 2010 A1
20100161045 Righini Jun 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100174362 Straubinger et al. Jul 2010 A1
20100185275 Richter et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100191320 Straubinger et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100198346 Keogh et al. Aug 2010 A1
20100210991 Wilk et al. Aug 2010 A1
20100219092 Salahieh et al. Sep 2010 A1
20100234932 Arbefeuille et al. Sep 2010 A1
20100234940 Dolan Sep 2010 A1
20100239917 Lee et al. Sep 2010 A1
20100249908 Chau et al. Sep 2010 A1
20100249915 Zhang Sep 2010 A1
20100249916 Zhang Sep 2010 A1
20100249917 Zhang Sep 2010 A1
20100249918 Zhang Sep 2010 A1
20100256723 Murray Oct 2010 A1
20100262231 Tuval et al. Oct 2010 A1
20100268332 Tuval et al. Oct 2010 A1
20100280459 Werner Nov 2010 A1
20100280495 Paul et al. Nov 2010 A1
20100286768 Alkhatib Nov 2010 A1
20100292779 Straubinger et al. Nov 2010 A1
20100292780 Straubinger et al. Nov 2010 A1
20100292785 Seguin et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110004297 Sogard et al. Jan 2011 A1
20110015616 Straubinger et al. Jan 2011 A1
20110022157 Essinger et al. Jan 2011 A1
20110029066 Gilad et al. Feb 2011 A1
20110034852 Hausler et al. Feb 2011 A1
20110040366 Goetz et al. Feb 2011 A1
20110040374 Goetz et al. Feb 2011 A1
20110071613 Wood et al. Mar 2011 A1
20110093007 Abbott et al. Apr 2011 A1
20110098805 Dwork et al. Apr 2011 A1
20110106244 Ferrari et al. May 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110166637 Irwin et al. Jul 2011 A1
20110190862 Bashiri et al. Aug 2011 A1
20110190874 Celermajer et al. Aug 2011 A1
20110208290 Straubinger et al. Aug 2011 A1
20110208297 Tuval et al. Aug 2011 A1
20110224780 Tabor et al. Sep 2011 A1
20110238159 Guyenot et al. Sep 2011 A1
20110238167 Dove et al. Sep 2011 A1
20110257729 Spenser et al. Oct 2011 A1
20110257733 Dwork Oct 2011 A1
20110257735 Salahieh et al. Oct 2011 A1
20110264191 Rothstein Oct 2011 A1
20110264196 Savage et al. Oct 2011 A1
20110264203 Dwork et al. Oct 2011 A1
20110276121 Levine Nov 2011 A1
20110276129 Salahieh et al. Nov 2011 A1
20110288626 Straubinger et al. Nov 2011 A1
20110288634 Tuval et al. Nov 2011 A1
20110295363 Girard et al. Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20120016469 Salahieh et al. Jan 2012 A1
20120016471 Salahieh et al. Jan 2012 A1
20120022633 Olson et al. Jan 2012 A1
20120022642 Haug et al. Jan 2012 A1
20120029627 Salahieh et al. Feb 2012 A1
20120035719 Forster et al. Feb 2012 A1
20120035720 Cali et al. Feb 2012 A1
20120041547 Duffy et al. Feb 2012 A1
20120041549 Salahieh et al. Feb 2012 A1
20120041550 Salahieh et al. Feb 2012 A1
20120046740 Paul et al. Feb 2012 A1
20120053683 Salahieh et al. Mar 2012 A1
20120059447 Zilla et al. Mar 2012 A1
20120065464 Ellis et al. Mar 2012 A1
20120078347 Braido et al. Mar 2012 A1
20120078357 Conklin Mar 2012 A1
20120078360 Rafiee Mar 2012 A1
20120089224 Haug et al. Apr 2012 A1
20120100182 Mooney et al. Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120116496 Chuter et al. May 2012 A1
20120123515 Hosford et al. May 2012 A1
20120123529 Levi et al. May 2012 A1
20120130468 Khosravi et al. May 2012 A1
20120132547 Salahieh et al. May 2012 A1
20120136430 Sochman et al. May 2012 A1
20120165957 Everland et al. Jun 2012 A1
20120172982 Stacchino et al. Jul 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120185030 Igaki et al. Jul 2012 A1
20120197379 Laske et al. Aug 2012 A1
20120209374 Bonhoeffer et al. Aug 2012 A1
20120209376 Hauser et al. Aug 2012 A1
20120221100 Huber Aug 2012 A1
20120226341 Schreck et al. Sep 2012 A1
20120283715 Mihalik et al. Nov 2012 A1
20120283823 Bonhoeffer et al. Nov 2012 A1
20120303113 Benichou et al. Nov 2012 A1
20120303116 Gorman, III et al. Nov 2012 A1
20120305441 Murray et al. Dec 2012 A1
20120310332 Murray et al. Dec 2012 A1
20120316637 Holm et al. Dec 2012 A1
20120330408 Hillukka et al. Dec 2012 A1
20120330409 Haug et al. Dec 2012 A1
20130013057 Salahieh et al. Jan 2013 A1
20130018457 Gregg et al. Jan 2013 A1
20130030519 Tran et al. Jan 2013 A1
20130030520 Lee et al. Jan 2013 A1
20130046373 Cartledge et al. Feb 2013 A1
20130053949 Pintor et al. Feb 2013 A1
20130066342 Dell et al. Mar 2013 A1
20130066419 Gregg Mar 2013 A1
20130071441 Iwazawa et al. Mar 2013 A1
20130073037 Gregg et al. Mar 2013 A1
20130079867 Hoffman et al. Mar 2013 A1
20130079869 Straubinger et al. Mar 2013 A1
20130089655 Gregg Apr 2013 A1
20130090728 Solem Apr 2013 A1
20130090729 Gregg et al. Apr 2013 A1
20130096664 Goetz et al. Apr 2013 A1
20130116778 Gregg et al. May 2013 A1
20130118949 Chang et al. May 2013 A1
20130123757 Crisostomo et al. May 2013 A1
20130123795 Gamarra et al. May 2013 A1
20130123796 Sutton et al. May 2013 A1
20130123898 Tung et al. May 2013 A1
20130138207 Quadri et al. May 2013 A1
20130144203 Wilk et al. Jun 2013 A1
20130144276 Crisostomo et al. Jun 2013 A1
20130158653 Gamarra et al. Jun 2013 A1
20130158655 Sutton et al. Jun 2013 A1
20130158656 Sutton et al. Jun 2013 A1
20130166017 Cartledge et al. Jun 2013 A1
20130178930 Straubinger et al. Jul 2013 A1
20130184813 Quadri et al. Jul 2013 A1
20130190865 Anderson Jul 2013 A1
20130204359 Thubrikar et al. Aug 2013 A1
20130231735 Deem et al. Sep 2013 A1
20130245752 Goetz et al. Sep 2013 A1
20130253342 Griswold et al. Sep 2013 A1
20130253635 Straubinger et al. Sep 2013 A1
20130253640 Meiri et al. Sep 2013 A1
20130268067 Forster et al. Oct 2013 A1
20130274865 Haverkost et al. Oct 2013 A1
20130274870 Lombardi et al. Oct 2013 A1
20130289698 Wang et al. Oct 2013 A1
20130296999 Burriesci et al. Nov 2013 A1
20130304199 Sutton et al. Nov 2013 A1
20130310917 Richter et al. Nov 2013 A1
20130310923 Kheradvar et al. Nov 2013 A1
20130310928 Morriss et al. Nov 2013 A1
20130325101 Goetz et al. Dec 2013 A1
20130338755 Goetz et al. Dec 2013 A1
20130345799 Lafontaine Dec 2013 A1
20140012368 Sugimoto et al. Jan 2014 A1
20140012370 Bonhoeffer et al. Jan 2014 A1
20140018911 Zhou et al. Jan 2014 A1
20140052239 Kong et al. Feb 2014 A1
20140058501 Bonhoeffer et al. Feb 2014 A1
20140083190 Kaack et al. Mar 2014 A1
20140088680 Costello et al. Mar 2014 A1
20140094904 Salahieh et al. Apr 2014 A1
20140114390 Tobis et al. Apr 2014 A1
20140114405 Paul et al. Apr 2014 A1
20140114406 Salahieh et al. Apr 2014 A1
20140114407 Rajamannan Apr 2014 A1
20140121763 Duffy et al. May 2014 A1
20140121766 Salahieh et al. May 2014 A1
20140128969 Hill et al. May 2014 A1
20140135912 Salahieh et al. May 2014 A1
20140207229 Shoemaker et al. Jul 2014 A1
20140222142 Kovalsky et al. Aug 2014 A1
20140236287 Clague et al. Aug 2014 A1
20140243962 Wilson et al. Aug 2014 A1
20140243963 Sheps et al. Aug 2014 A1
20140243967 Salahieh et al. Aug 2014 A1
20140249621 Eidenschink Sep 2014 A1
20140257473 Rajamannan Sep 2014 A1
20140277414 Kheradvar Sep 2014 A1
20140296962 Cartledge et al. Oct 2014 A1
20140309732 Solem Oct 2014 A1
20140316518 Kheradvar et al. Oct 2014 A1
20140330371 Gloss et al. Nov 2014 A1
20140343669 Lane et al. Nov 2014 A1
20140379068 Thielen et al. Dec 2014 A1
20150012085 Salahieh et al. Jan 2015 A1
20150032056 Okamura et al. Jan 2015 A1
20150073540 Salahieh et al. Mar 2015 A1
20150073541 Salahieh et al. Mar 2015 A1
20150088252 Jenson et al. Mar 2015 A1
20150094804 Bonhoeffer et al. Apr 2015 A1
20150105857 Bonhoeffer et al. Apr 2015 A1
20150127092 Straubinger et al. May 2015 A1
20150127094 Salahieh et al. May 2015 A1
20150142102 Lafontaine et al. May 2015 A1
20150209142 Paul et al. Jul 2015 A1
20150209146 Hill et al. Jul 2015 A1
20150223933 Haug et al. Aug 2015 A1
20150238315 Rabito et al. Aug 2015 A1
20150245909 Salahieh et al. Sep 2015 A1
20150272731 Racchini et al. Oct 2015 A1
20150320557 Sutton et al. Nov 2015 A1
20150335423 Gregg et al. Nov 2015 A1
20150352252 Nakamura et al. Dec 2015 A1
20150359997 Crisostomo et al. Dec 2015 A1
20160022418 Salahieh et al. Jan 2016 A1
20160045306 Agrawal et al. Feb 2016 A1
20160045307 Yohanan et al. Feb 2016 A1
20160051362 Cooper et al. Feb 2016 A1
20160067040 Agrawal et al. Mar 2016 A1
20160120645 Alon May 2016 A1
20160135951 Salahieh et al. May 2016 A1
20160143731 Backus et al. May 2016 A1
20160158003 Wallace et al. Jun 2016 A1
20160166384 Olson et al. Jun 2016 A1
20160199184 Ma et al. Jul 2016 A1
20160206423 O'Connor et al. Jul 2016 A1
20160213467 Backus et al. Jul 2016 A1
20160220359 Backus et al. Aug 2016 A1
20160220360 Lin et al. Aug 2016 A1
20160220365 Backus et al. Aug 2016 A1
20160250024 Hill et al. Sep 2016 A1
20160256271 Backus et al. Sep 2016 A1
20160262878 Backus et al. Sep 2016 A1
20160346107 Matthison-Hansen et al. Dec 2016 A1
20160354203 Tuval et al. Dec 2016 A1
20160374793 Lafontaine et al. Dec 2016 A1
20160376063 Salahieh et al. Dec 2016 A1
20170000609 Gross et al. Jan 2017 A1
20170007400 Sogard et al. Jan 2017 A1
20170027693 Paul et al. Feb 2017 A1
20170049563 Straubinger et al. Feb 2017 A1
20170049568 Straubinger et al. Feb 2017 A1
20170056172 Salahieh et al. Mar 2017 A1
20170065410 Straubinger et al. Mar 2017 A1
20170095595 Nakamura Apr 2017 A1
20170333230 Folan et al. Nov 2017 A1
20170348013 Mottola et al. Dec 2017 A1
20180368976 Bonhoeffer et al. Dec 2018 A1
20190328522 Straubinger et al. Oct 2019 A1
20200054449 Min et al. Feb 2020 A1
20210322153 Tuval Oct 2021 A1
20220304803 Guyenot Sep 2022 A1
Foreign Referenced Citations (894)
Number Date Country
757647 Feb 2003 AU
776895 Sep 2004 AU
777443 Oct 2004 AU
778831 Dec 2004 AU
2004231189 Dec 2004 AU
2004242527 Jan 2005 AU
2001281277 Sep 2005 AU
2006328896 Jun 2007 AU
2002329324 Jul 2007 AU
2007294199 Mar 2008 AU
2009200985 Apr 2009 AU
2006328896 Aug 2013 AU
2378589 Feb 2001 CA
2381192 Feb 2001 CA
2385662 Mar 2001 CA
2407987 Nov 2001 CA
2418958 Feb 2002 CA
2435962 Aug 2002 CA
2457755 Feb 2003 CA
2436258 Jan 2005 CA
2848485 Jan 2005 CA
2848490 Jan 2005 CA
2595233 Jul 2006 CA
2627409 May 2007 CA
2627555 May 2007 CA
2634358 Jun 2007 CA
2657839 Mar 2008 CA
2659690 Mar 2008 CA
1338951 Mar 2002 CN
1342443 Apr 2002 CN
1745727 Mar 2006 CN
2762776 Mar 2006 CN
1897892 Jan 2007 CN
2933337 Aug 2007 CN
101011298 Aug 2007 CN
101431963 May 2009 CN
101605509 Dec 2009 CN
101623217 Jan 2010 CN
101700199 May 2010 CN
101720211 Jun 2010 CN
102271626 Dec 2011 CN
102413793 Apr 2012 CN
103118630 May 2013 CN
2815756 Oct 1979 DE
3640745 Jun 1987 DE
3920657 Jan 1991 DE
3640745 Mar 1992 DE
4316971 Nov 1994 DE
19532846 Mar 1997 DE
19 546 692 Jun 1997 DE
19633901 Feb 1998 DE
19 857 887 Jul 2000 DE
19907646 Aug 2000 DE
10034105 Apr 2002 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
10048814 May 2002 DE
10049812 Jun 2004 DE
10335948 Jul 2004 DE
10049815 Oct 2005 DE
102005003632 Aug 2006 DE
20221871 Sep 2008 DE
69937568 Sep 2008 DE
1112042 Feb 2008 DK
200800058 Jun 2008 DK
200800058 Jul 2008 DK
1259195 Feb 2009 DK
1281375 May 2012 DK
0 084 395 Jul 1983 EP
0103546 Mar 1984 EP
0103546 May 1988 EP
0144167 Nov 1989 EP
0 402 036 Dec 1990 EP
0 402 176 Dec 1990 EP
0411118 Feb 1991 EP
0 458 877 Apr 1991 EP
0 515 324 Nov 1992 EP
0 547 135 Jun 1993 EP
0579523 Jan 1994 EP
0402176 Apr 1994 EP
0592410 Apr 1994 EP
0597967 May 1994 EP
0597967 Dec 1994 EP
0458877 May 1995 EP
0657147 Jun 1995 EP
0 592 410 Nov 1995 EP
0696447 Feb 1996 EP
0402036 Apr 1996 EP
0 729 364 Sep 1996 EP
0732088 Sep 1996 EP
0409929 Apr 1997 EP
0 756 498 May 1997 EP
0 778 775 Jun 1997 EP
0786970 Aug 1997 EP
0792624 Sep 1997 EP
0797957 Oct 1997 EP
0797958 Oct 1997 EP
0799604 Oct 1997 EP
0801928 Oct 1997 EP
0815798 Jan 1998 EP
0826346 Mar 1998 EP
0829239 Mar 1998 EP
0836834 Apr 1998 EP
0850607 Jul 1998 EP
0853921 Jul 1998 EP
0858779 Aug 1998 EP
0871414 Oct 1998 EP
0876796 Nov 1998 EP
0876803 Nov 1998 EP
0778775 Jan 1999 EP
0888142 Jan 1999 EP
0888750 Jan 1999 EP
0895752 Feb 1999 EP
0896813 Feb 1999 EP
0903122 Mar 1999 EP
0876796 May 1999 EP
0 928 615 Jul 1999 EP
0657147 Aug 1999 EP
0934728 Aug 1999 EP
0938877 Sep 1999 EP
0943302 Sep 1999 EP
0597967 Dec 1999 EP
0696447 Jan 2000 EP
0971649 Jan 2000 EP
0 986 348 Mar 2000 EP
1000590 May 2000 EP
1011523 Jun 2000 EP
1020166 Jul 2000 EP
1027870 Aug 2000 EP
1 041 942 Oct 2000 EP
1 041 943 Oct 2000 EP
1051204 Nov 2000 EP
1057459 Dec 2000 EP
1057460 Dec 2000 EP
1078610 Feb 2001 EP
1088529 Apr 2001 EP
1089676 Apr 2001 EP
1093771 Apr 2001 EP
1097676 May 2001 EP
1 117 446 Jul 2001 EP
1112042 Jul 2001 EP
1112097 Jul 2001 EP
1158937 Dec 2001 EP
0547135 Jan 2002 EP
0729364 Jan 2002 EP
1164976 Jan 2002 EP
1166721 Jan 2002 EP
1171061 Jan 2002 EP
1 206 179 May 2002 EP
0756498 Jul 2002 EP
1233731 Aug 2002 EP
0986348 Sep 2002 EP
1235537 Sep 2002 EP
1 251 804 Oct 2002 EP
1248655 Oct 2002 EP
1251805 Oct 2002 EP
1255510 Nov 2002 EP
1257305 Nov 2002 EP
1259193 Nov 2002 EP
1259195 Nov 2002 EP
0 971 649 Dec 2002 EP
0959815 Dec 2002 EP
1262201 Dec 2002 EP
1264582 Dec 2002 EP
1 281 375 Feb 2003 EP
1281357 Feb 2003 EP
0888142 May 2003 EP
1112097 Jun 2003 EP
1330213 Jul 2003 EP
1 017 868 Sep 2003 EP
0937439 Sep 2003 EP
1340473 Sep 2003 EP
1347785 Oct 2003 EP
1354569 Oct 2003 EP
1356793 Oct 2003 EP
1281375 Dec 2003 EP
1340473 Feb 2004 EP
1041943 Mar 2004 EP
1356793 Mar 2004 EP
1395208 Mar 2004 EP
1401359 Mar 2004 EP
0871414 Apr 2004 EP
1406561 Apr 2004 EP
1408882 Apr 2004 EP
1042045 May 2004 EP
1414295 May 2004 EP
0819013 Jun 2004 EP
1430853 Jun 2004 EP
1347785 Jul 2004 EP
1435878 Jul 2004 EP
1435879 Jul 2004 EP
1439800 Jul 2004 EP
1441672 Aug 2004 EP
1 452 153 Sep 2004 EP
0954248 Sep 2004 EP
0 987 998 Oct 2004 EP
1206179 Oct 2004 EP
1469797 Oct 2004 EP
1 087 727 Nov 2004 EP
1115452 Nov 2004 EP
1117446 Nov 2004 EP
1472996 Nov 2004 EP
1477202 Nov 2004 EP
1 233 731 Dec 2004 EP
1107710 Dec 2004 EP
1484081 Dec 2004 EP
1 499 366 Jan 2005 EP
1494616 Jan 2005 EP
1143879 Mar 2005 EP
1516599 Mar 2005 EP
1518518 Mar 2005 EP
1 253 875 Apr 2005 EP
1229864 Apr 2005 EP
1519697 Apr 2005 EP
1521414 Apr 2005 EP
1522278 Apr 2005 EP
1 251 803 Jun 2005 EP
1088529 Jun 2005 EP
1093771 Jun 2005 EP
1430853 Jun 2005 EP
1539047 Jun 2005 EP
1547533 Jun 2005 EP
1059894 Jul 2005 EP
1551274 Jul 2005 EP
1551336 Jul 2005 EP
1000590 Aug 2005 EP
1027013 Aug 2005 EP
1078610 Aug 2005 EP
1560542 Aug 2005 EP
1562515 Aug 2005 EP
1570809 Sep 2005 EP
1576937 Sep 2005 EP
0943302 Oct 2005 EP
1267753 Oct 2005 EP
1582178 Oct 2005 EP
1582179 Oct 2005 EP
1011523 Nov 2005 EP
1067869 Nov 2005 EP
1589902 Nov 2005 EP
1598031 Nov 2005 EP
1600110 Nov 2005 EP
1600121 Nov 2005 EP
0786970 Dec 2005 EP
1156757 Dec 2005 EP
1603493 Dec 2005 EP
1605871 Dec 2005 EP
1021141 Jan 2006 EP
1614400 Jan 2006 EP
1616531 Jan 2006 EP
1616536 Jan 2006 EP
1041942 Jun 2006 EP
1441672 Jun 2006 EP
1663070 Jun 2006 EP
1667614 Jun 2006 EP
1494616 Jul 2006 EP
1 690 515 Aug 2006 EP
1702247 Sep 2006 EP
1051204 Dec 2006 EP
1734902 Dec 2006 EP
1395208 Jan 2007 EP
1 251 805 Mar 2007 EP
1 255 510 Mar 2007 EP
1499366 Jul 2007 EP
1600121 Jul 2007 EP
1835948 Sep 2007 EP
1 112 042 Nov 2007 EP
1251797 Nov 2007 EP
1616531 Dec 2007 EP
1863545 Dec 2007 EP
1 878 407 Jan 2008 EP
1 886 649 Feb 2008 EP
1 900 343 Mar 2008 EP
1406561 Mar 2008 EP
1893132 Mar 2008 EP
1901681 Mar 2008 EP
1435878 Apr 2008 EP
1886649 Apr 2008 EP
1251804 Jul 2008 EP
EP-1605871 Jul 2008 EP
1968491 Sep 2008 EP
1 259 195 Oct 2008 EP
1 980 220 Oct 2008 EP
2 000 115 Dec 2008 EP
1994913 Dec 2008 EP
1560542 Jan 2009 EP
1408882 Feb 2009 EP
1255510 Mar 2009 EP
1330213 Mar 2009 EP
2033593 Mar 2009 EP
2047824 Apr 2009 EP
2059192 May 2009 EP
2074964 Jul 2009 EP
1401359 Aug 2009 EP
1968491 Jul 2010 EP
1259193 Nov 2010 EP
2257242 Dec 2010 EP
2266503 Dec 2010 EP
2266504 Dec 2010 EP
1893132 Mar 2011 EP
2266503 Apr 2011 EP
2266504 Apr 2011 EP
2059192 Jul 2011 EP
1441672 Sep 2011 EP
2364669 Sep 2011 EP
2387977 Nov 2011 EP
1603493 Dec 2011 EP
1281375 Feb 2012 EP
2364669 Mar 2012 EP
2047824 May 2012 EP
2474287 Jul 2012 EP
2387977 Nov 2013 EP
1551274 Dec 2014 EP
2874812 May 2015 EP
2749254 Jun 2015 EP
1702247 Aug 2015 EP
2926766 Oct 2015 EP
1519697 Nov 2015 EP
1863545 Nov 2015 EP
1835948 Feb 2016 EP
1734902 Jun 2016 EP
3028668 Jun 2016 EP
1539047 Nov 2016 EP
1667614 Dec 2016 EP
3181096 Jun 2017 EP
2659861 Mar 2019 EP
1667614 Apr 2020 EP
2293734 Mar 2008 ES
2313954 Mar 2009 ES
2353733 Mar 2011 ES
2381337 May 2012 ES
2421438 Sep 2013 ES
2432305 Feb 1980 FR
2788217 Jul 2000 FR
2815844 May 2002 FR
2826863 Jan 2003 FR
2874812 Mar 2006 FR
2828263 May 2007 FR
2018950 Oct 1979 GB
2056023 Mar 1981 GB
2316322 Feb 1998 GB
2316322 Oct 1998 GB
2398214 Aug 2004 GB
2398245 Aug 2004 GB
2398245 Mar 2007 GB
2433700 Jul 2007 GB
2433700 Dec 2007 GB
2440809 Feb 2008 GB
2440809 Aug 2011 GB
1053600 Jul 2012 HK
S5286296 Jul 1977 JP
S54137896 Sep 1979 JP
S62227352 Oct 1987 JP
S6449571 Feb 1989 JP
H0447576 Aug 1992 JP
H04505866 Oct 1992 JP
H06505187 Jun 1994 JP
H06343703 Dec 1994 JP
H07504091 May 1995 JP
H07505803 Jun 1995 JP
H07265339 Oct 1995 JP
H0833715 Feb 1996 JP
H1049571 Feb 1998 JP
H10507673 Jul 1998 JP
2001000460 Jan 2001 JP
2001504016 Mar 2001 JP
2001526574 Dec 2001 JP
2002525168 Aug 2002 JP
2002525169 Aug 2002 JP
2002536115 Oct 2002 JP
2003515386 May 2003 JP
2003518984 Jun 2003 JP
2003-524504 Aug 2003 JP
2004504111 Feb 2004 JP
2004130068 Apr 2004 JP
2004514467 May 2004 JP
2004255186 Sep 2004 JP
2004267750 Sep 2004 JP
2004283461 Oct 2004 JP
2005505343 Feb 2005 JP
2007521125 Aug 2007 JP
2007298375 Nov 2007 JP
2007534381 Nov 2007 JP
2007536003 Dec 2007 JP
2008506497 Mar 2008 JP
2008514345 May 2008 JP
2008535572 Sep 2008 JP
2008539985 Nov 2008 JP
2008541865 Nov 2008 JP
2009034529 Feb 2009 JP
2009061293 Mar 2009 JP
2009509635 Mar 2009 JP
4246433 Apr 2009 JP
2009520535 May 2009 JP
2009131397 Jun 2009 JP
4295460 Jul 2009 JP
2009528905 Aug 2009 JP
2009534157 Sep 2009 JP
2010525896 Jul 2010 JP
2010526609 Aug 2010 JP
4636794 Feb 2011 JP
2011509805 Mar 2011 JP
4739223 Aug 2011 JP
2012500665 Jan 2012 JP
4904362 Mar 2012 JP
4912395 Apr 2012 JP
2012518446 Aug 2012 JP
2013520260 Jun 2013 JP
2013521884 Jun 2013 JP
2013526388 Jun 2013 JP
5341455 Nov 2013 JP
2013540495 Nov 2013 JP
6144009 Jun 2017 JP
6449571 Jan 2019 JP
1112042 Jan 2008 PT
1259195 Dec 2008 PT
1259193 Jan 2011 PT
1281375 Mar 2012 PT
1994913 Aug 2013 PT
2149037 May 2000 RU
7901667 Oct 1979 SE
WO-8402266 Jun 1984 WO
WO 9009102 Aug 1990 WO
WO-9014804 Dec 1990 WO
WO-9117720 Nov 1991 WO
WO-9203990 Mar 1992 WO
WO-9212690 Aug 1992 WO
WO-9214419 Sep 1992 WO
WO-9217118 Oct 1992 WO
WO-9301768 Feb 1993 WO
WO-9315693 Aug 1993 WO
WO-9320757 Oct 1993 WO
WO-9504556 Feb 1995 WO
WO 9511055 Apr 1995 WO
WO-9504556 Apr 1995 WO
WO 9524873 Sep 1995 WO
WO 9528183 Oct 1995 WO
WO-9528899 Nov 1995 WO
WO-9529640 Nov 1995 WO
WO-9529713 Nov 1995 WO
WO 9613227 May 1996 WO
WO-9614032 May 1996 WO
WO-9624306 Aug 1996 WO
WO-9630072 Oct 1996 WO
WO-9632972 Oct 1996 WO
WO-9635469 Nov 1996 WO
WO-9639962 Dec 1996 WO
WO-9639964 Dec 1996 WO
WO-9639965 Dec 1996 WO
WO-9640012 Dec 1996 WO
WO-9713463 Apr 1997 WO
WO-9713471 Apr 1997 WO
WO-9724082 Jul 1997 WO
WO-9727893 Aug 1997 WO
WO-9727897 Aug 1997 WO
WO-9727898 Aug 1997 WO
WO-9728839 Aug 1997 WO
WO 9732615 Sep 1997 WO
WO-9732551 Sep 1997 WO
WO-9743961 Nov 1997 WO
WO-9748350 Dec 1997 WO
WO-9803118 Jan 1998 WO
WO-9806356 Feb 1998 WO
WO-9808456 Mar 1998 WO
WO-9810714 Mar 1998 WO
WO-9811846 Mar 1998 WO
WO-9814137 Apr 1998 WO
WO-9816161 Apr 1998 WO
WO-9819633 May 1998 WO
WO-9824373 Jun 1998 WO
WO-9825533 Jun 1998 WO
WO-9825549 Jun 1998 WO
WO-9829057 Jul 1998 WO
WO-9836790 Aug 1998 WO
WO-9838916 Sep 1998 WO
WO-9838925 Sep 1998 WO
WO-9838939 Sep 1998 WO
WO-9838941 Sep 1998 WO
WO-9839038 Sep 1998 WO
WO 9843556 Oct 1998 WO
WO 9846165 Oct 1998 WO
WO-9844869 Oct 1998 WO
WO-9846115 Oct 1998 WO
WO-9846119 Oct 1998 WO
WO-9849964 Nov 1998 WO
WO-9850103 Nov 1998 WO
WO-9853759 Dec 1998 WO
WO-9853761 Dec 1998 WO
WO-9855027 Dec 1998 WO
WO-9855047 Dec 1998 WO
WO-9857590 Dec 1998 WO
WO-9857591 Dec 1998 WO
WO-9857592 Dec 1998 WO
WO-9857599 Dec 1998 WO
WO-9907296 Feb 1999 WO
WO-9908624 Feb 1999 WO
WO-9915112 Apr 1999 WO
WO-9915220 Apr 1999 WO
WO-9917671 Apr 1999 WO
WO-9917683 Apr 1999 WO
WO-9921490 May 1999 WO
WO-9921510 May 1999 WO
WO-9922655 May 1999 WO
WO-9922656 May 1999 WO
WO-9922658 May 1999 WO
WO-9925273 May 1999 WO
WO-9927985 Jun 1999 WO
WO 9937337 Jul 1999 WO
WO-9933414 Jul 1999 WO
WO-9935977 Jul 1999 WO
WO-9935979 Jul 1999 WO
WO-9935980 Jul 1999 WO
WO-9936000 Jul 1999 WO
WO-9936001 Jul 1999 WO
WO-9938459 Aug 1999 WO
WO-9940853 Aug 1999 WO
WO-9940868 Aug 1999 WO
WO-9940963 Aug 1999 WO
WO-9940964 Aug 1999 WO
WO-9942058 Aug 1999 WO
WO-9944524 Sep 1999 WO
WO-9944540 Sep 1999 WO
WO-9944542 Sep 1999 WO
WO-9947071 Sep 1999 WO
WO-9947075 Sep 1999 WO
WO-9948545 Sep 1999 WO
WO-9948549 Sep 1999 WO
WO-9949793 Oct 1999 WO
WO-9949910 Oct 1999 WO
WO-9951162 Oct 1999 WO
WO-9951165 Oct 1999 WO
WO-9953863 Oct 1999 WO
WO-9953987 Oct 1999 WO
WO-9955406 Nov 1999 WO
WO 9966863 Dec 1999 WO
WO-9960941 Dec 1999 WO
WO-9962430 Dec 1999 WO
WO-0002503 Jan 2000 WO
WO-0009059 Feb 2000 WO
WO-0009195 Feb 2000 WO
WO 0015148 Mar 2000 WO
WO-0010623 Mar 2000 WO
WO-0012029 Mar 2000 WO
WO-0013722 Mar 2000 WO
WO-0015146 Mar 2000 WO
WO-0015147 Mar 2000 WO
WO-0015149 Mar 2000 WO
WO-0015275 Mar 2000 WO
WO-0016848 Mar 2000 WO
WO 0018445 Apr 2000 WO
WO-0018302 Apr 2000 WO
WO-0018323 Apr 2000 WO
WO-0018325 Apr 2000 WO
WO-0018326 Apr 2000 WO
WO-0018330 Apr 2000 WO
WO-0018331 Apr 2000 WO
WO-0018333 Apr 2000 WO
WO-0018462 Apr 2000 WO
WO-0021436 Apr 2000 WO
WO-0021461 Apr 2000 WO
WO-0021463 Apr 2000 WO
WO-0021464 Apr 2000 WO
WO 200025702 May 2000 WO
WO-0024449 May 2000 WO
WO-0028922 May 2000 WO
WO-0028924 May 2000 WO
WO-0033725 Jun 2000 WO
WO-0035376 Jun 2000 WO
WO-0036997 Jun 2000 WO
WO-0041632 Jul 2000 WO
WO-0041633 Jul 2000 WO
WO-0041652 Jul 2000 WO
WO-0043051 Jul 2000 WO
WO-0044211 Jul 2000 WO
WO 0047139 Aug 2000 WO
WO-0044308 Aug 2000 WO
WO-0044311 Aug 2000 WO
WO-0044313 Aug 2000 WO
WO-0044331 Aug 2000 WO
WO-0045711 Aug 2000 WO
WO-0045874 Aug 2000 WO
WO-0045886 Aug 2000 WO
WO-0047136 Aug 2000 WO
WO-0048531 Aug 2000 WO
WO-0049952 Aug 2000 WO
WO-0049954 Aug 2000 WO
WO-0049956 Aug 2000 WO
WO-0049970 Aug 2000 WO
WO 0053125 Sep 2000 WO
WO-0053122 Sep 2000 WO
WO-0054660 Sep 2000 WO
WO-0054661 Sep 2000 WO
WO-0056224 Sep 2000 WO
WO-0056225 Sep 2000 WO
WO-0056387 Sep 2000 WO
WO 0062714 Oct 2000 WO
WO-0060995 Oct 2000 WO
WO-0066007 Nov 2000 WO
WO-0066009 Nov 2000 WO
WO-0066035 Nov 2000 WO
WO-0067661 Nov 2000 WO
WO-0069345 Nov 2000 WO
WO-0069367 Nov 2000 WO
WO-0069504 Nov 2000 WO
WO-0071195 Nov 2000 WO
WO-0078226 Dec 2000 WO
WO-0105331 Jan 2001 WO
WO 0110209 Feb 2001 WO
WO-0106959 Feb 2001 WO
WO-0108566 Feb 2001 WO
WO-0108596 Feb 2001 WO
WO-0108602 Feb 2001 WO
WO-0110320 Feb 2001 WO
WO-0110340 Feb 2001 WO
WO-0110341 Feb 2001 WO
WO-0110343 Feb 2001 WO
WO-0110347 Feb 2001 WO
WO-0110348 Feb 2001 WO
WO-0110349 Feb 2001 WO
WO-0110350 Feb 2001 WO
WO-0117440 Mar 2001 WO
WO-0117456 Mar 2001 WO
WO 200135870 May 2001 WO
WO-0135864 May 2001 WO
WO-0136870 May 2001 WO
WO 0141679 Jun 2001 WO
WO-0139700 Jun 2001 WO
WO 0151104 Jul 2001 WO
WO-0149185 Jul 2001 WO
WO-0149187 Jul 2001 WO
WO-0149213 Jul 2001 WO
WO 0154625 Aug 2001 WO
WO 0158503 Aug 2001 WO
WO 0162189 Aug 2001 WO
WO 0164137 Sep 2001 WO
WO-0047139 Sep 2001 WO
WO-0176510 Oct 2001 WO
WO-0182837 Nov 2001 WO
WO-0197715 Dec 2001 WO
WO-0211647 Feb 2002 WO
WO-0219926 Mar 2002 WO
WO-0222054 Mar 2002 WO
WO-0224118 Mar 2002 WO
WO 200236048 May 2002 WO
WO-0241789 May 2002 WO
WO-0243620 Jun 2002 WO
WO-0247575 Jun 2002 WO
WO-0249540 Jun 2002 WO
WO-02051489 Jul 2002 WO
WO-02056798 Jul 2002 WO
WO-02056955 Jul 2002 WO
WO 02058745 Aug 2002 WO
WO-02060509 Aug 2002 WO
WO-02067782 Sep 2002 WO
WO-02069842 Sep 2002 WO
WO-02076349 Oct 2002 WO
WO 02100301 Dec 2002 WO
WO 02102286 Dec 2002 WO
WO-02100297 Dec 2002 WO
WO 03007795 Jan 2003 WO
WO 2003003949 Jan 2003 WO
WO-03003943 Jan 2003 WO
WO 03009785 Feb 2003 WO
WO 03013239 Feb 2003 WO
WO 2003011195 Feb 2003 WO
WO-03015851 Feb 2003 WO
WO 03028592 Apr 2003 WO
WO-03030776 Apr 2003 WO
WO-03032869 Apr 2003 WO
WO-03032870 Apr 2003 WO
WO-03037222 May 2003 WO
WO-03037227 May 2003 WO
WO 03047468 Jun 2003 WO
WO-03047460 Jun 2003 WO
WO-03047648 Jun 2003 WO
WO-03051231 Jun 2003 WO
WO-03063729 Aug 2003 WO
WO 03079928 Oct 2003 WO
WO-03079932 Oct 2003 WO
WO-03079933 Oct 2003 WO
WO-03088873 Oct 2003 WO
WO 2003096935 Nov 2003 WO
WO-03015851 Nov 2003 WO
WO-03063729 Nov 2003 WO
WO-03092554 Nov 2003 WO
WO-03094793 Nov 2003 WO
WO-03094797 Nov 2003 WO
WO-03096932 Nov 2003 WO
WO-03101195 Dec 2003 WO
WO-03103949 Dec 2003 WO
WO 2004004597 Jan 2004 WO
WO-03003949 Jan 2004 WO
WO-2004006803 Jan 2004 WO
WO-2004006804 Jan 2004 WO
WO 2004016200 Feb 2004 WO
WO 2004016201 Feb 2004 WO
WO-2004014256 Feb 2004 WO
WO 2004019825 Mar 2004 WO
WO-2004019811 Mar 2004 WO
WO-2004019817 Mar 2004 WO
WO-2004021922 Mar 2004 WO
WO-2004023980 Mar 2004 WO
WO 2004026117 Apr 2004 WO
WO 2004026173 Apr 2004 WO
WO 2004028399 Apr 2004 WO
WO-2004019811 Apr 2004 WO
WO-2004030515 Apr 2004 WO
WO 2004043301 May 2004 WO
WO-2004041126 May 2004 WO
WO-2004043293 May 2004 WO
WO-2004047681 Jun 2004 WO
WO-2004058106 Jul 2004 WO
WO-2004062980 Jul 2004 WO
WO-2004058106 Aug 2004 WO
WO-2004064671 Aug 2004 WO
WO-2004066876 Aug 2004 WO
WO-2004071352 Aug 2004 WO
WO 2004082527 Sep 2004 WO
WO 2004082528 Sep 2004 WO
WO-2004082536 Sep 2004 WO
WO-2004089250 Oct 2004 WO
WO-2004089253 Oct 2004 WO
WO 2004096100 Nov 2004 WO
WO-2004093728 Nov 2004 WO
WO-2004103162 Dec 2004 WO
WO-2004105651 Dec 2004 WO
WO-2005002466 Jan 2005 WO
WO-2005004753 Jan 2005 WO
WO-2005007343 Jan 2005 WO
WO-2005009285 Feb 2005 WO
WO-2005011534 Feb 2005 WO
WO-2005011535 Feb 2005 WO
WO 2005021063 Mar 2005 WO
WO-2005023155 Mar 2005 WO
WO-2005027790 Mar 2005 WO
WO-2005027797 Mar 2005 WO
WO 2005034812 Apr 2005 WO
WO-2005032622 Apr 2005 WO
WO-2005010215 May 2005 WO
WO-2005046528 May 2005 WO
WO-2005046529 May 2005 WO
WO-2005048883 Jun 2005 WO
WO 2005062980 Jul 2005 WO
WO-2005063980 Jul 2005 WO
WO-2005065585 Jul 2005 WO
WO-2005065594 Jul 2005 WO
WO 2005072654 Aug 2005 WO
WO-2005070343 Aug 2005 WO
WO-2005076890 Aug 2005 WO
WO-2005084595 Sep 2005 WO
WO-2005087140 Sep 2005 WO
WO-2005096993 Oct 2005 WO
WO-2005102015 Nov 2005 WO
WO-2005110240 Nov 2005 WO
WO-2005112779 Dec 2005 WO
WO-2006005015 Jan 2006 WO
WO-2006009690 Jan 2006 WO
WO-2006026371 Mar 2006 WO
WO-2006027499 Mar 2006 WO
WO-2005062980 May 2006 WO
WO 2006066327 Jun 2006 WO
WO-2006058163 Jun 2006 WO
WO-2006065949 Jun 2006 WO
WO-2006068944 Jun 2006 WO
WO 2006076890 Jul 2006 WO
WO-2006070372 Jul 2006 WO
WO-2006083763 Aug 2006 WO
WO-2006086135 Aug 2006 WO
WO-2006086736 Aug 2006 WO
WO-2006089517 Aug 2006 WO
WO 2006102063 Sep 2006 WO
WO-2006093795 Sep 2006 WO
WO 2006108090 Oct 2006 WO
WO 2006124649 Nov 2006 WO
WO 2006127756 Nov 2006 WO
WO 2006127765 Nov 2006 WO
WO-2006118766 Nov 2006 WO
WO 2006132948 Dec 2006 WO
WO-2006129441 Dec 2006 WO
WO-2006133959 Dec 2006 WO
WO-2006138173 Dec 2006 WO
WO-2006138391 Dec 2006 WO
WO-2007009117 Jan 2007 WO
WO-2007009609 Jan 2007 WO
WO-2007013999 Feb 2007 WO
WO-2007033093 Mar 2007 WO
WO-2007035471 Mar 2007 WO
WO 2007047488 Apr 2007 WO
WO 2007047945 Apr 2007 WO
WO-2005102015 Apr 2007 WO
WO-2006138391 Apr 2007 WO
WO-2007044285 Apr 2007 WO
WO 2007048529 May 2007 WO
WO 2007051620 May 2007 WO
WO 2007059252 May 2007 WO
WO-2007053243 May 2007 WO
WO-2007058847 May 2007 WO
WO 2007071436 Jun 2007 WO
WO-2006086736 Jun 2007 WO
WO 2007098232 Aug 2007 WO
WO-2007092354 Aug 2007 WO
WO-2007097983 Aug 2007 WO
WO-2007053243 Sep 2007 WO
WO 2007120543 Oct 2007 WO
WO-2007071436 Nov 2007 WO
WO-2007123658 Nov 2007 WO
WO-2007123956 Nov 2007 WO
WO-2007033093 Jan 2008 WO
WO-2007071436 Jan 2008 WO
WO 2008028569 Mar 2008 WO
WO 2008035337 Mar 2008 WO
WO-2008031103 Mar 2008 WO
WO 2008045949 Apr 2008 WO
WO-2008040555 Apr 2008 WO
WO-2008047354 Apr 2008 WO
WO-2008051554 May 2008 WO
WO 2008070797 Jun 2008 WO
WO-2008070442 Jun 2008 WO
WO 2008079962 Jul 2008 WO
WO 2008101083 Aug 2008 WO
WO-2008098191 Aug 2008 WO
WO-2008100599 Aug 2008 WO
WO 2008125153 Oct 2008 WO
WO 2008138584 Nov 2008 WO
WO-2008137603 Nov 2008 WO
WO 2008150529 Dec 2008 WO
WO-2009002548 Dec 2008 WO
WO-2009024859 Feb 2009 WO
WO-2009029199 Mar 2009 WO
WO-2009042196 Apr 2009 WO
WO-2009045334 Apr 2009 WO
WO-2009045338 Apr 2009 WO
WO-2009053497 Apr 2009 WO
WO-2009054397 Apr 2009 WO
WO-2007044285 May 2009 WO
WO-2009061389 May 2009 WO
WO-2009085206 Jul 2009 WO
WO-2009091509 Jul 2009 WO
WO-2009094188 Jul 2009 WO
WO-2009094501 Jul 2009 WO
WO-2009100198 Aug 2009 WO
WO-2009106545 Sep 2009 WO
WO-2009108615 Sep 2009 WO
WO-2009111241 Sep 2009 WO
WO-2009149462 Dec 2009 WO
WO-2009155561 Dec 2009 WO
WO-2010022138 Feb 2010 WO
WO-2010042950 Apr 2010 WO
WO-2010043950 Apr 2010 WO
WO-2010044851 Apr 2010 WO
WO-2010045238 Apr 2010 WO
WO-2010045297 Apr 2010 WO
WO-2010049160 May 2010 WO
WO-2010083558 Jul 2010 WO
WO-2010086460 Aug 2010 WO
WO-2010098857 Sep 2010 WO
WO-2010104638 Sep 2010 WO
WO-2010045238 Oct 2010 WO
WO-2010141626 Dec 2010 WO
WO-2011008812 Jan 2011 WO
WO-2011008853 Jan 2011 WO
WO-2011051043 May 2011 WO
WO-2011057087 May 2011 WO
WO-2011060386 May 2011 WO
WO-2011102968 Aug 2011 WO
WO-2011104269 Sep 2011 WO
WO-2011120050 Sep 2011 WO
WO-2011133368 Oct 2011 WO
WO-2011144351 Nov 2011 WO
WO 2011147849 Dec 2011 WO
WO-2012002228 Jan 2012 WO
WO-2012023980 Feb 2012 WO
WO-2012036742 Mar 2012 WO
WO-2012038550 Mar 2012 WO
WO-2012039748 Mar 2012 WO
WO-2012082952 Jun 2012 WO
WO-2012106491 Aug 2012 WO
WO-2012116368 Aug 2012 WO
WO-2012142189 Oct 2012 WO
WO-2012145546 Oct 2012 WO
WO-2012162228 Nov 2012 WO
WO-2013009975 Jan 2013 WO
WO-2013028387 Feb 2013 WO
WO-2013033791 Mar 2013 WO
WO-2013074671 May 2013 WO
WO-2013096545 Jun 2013 WO
WO-2013134214 Sep 2013 WO
WO-2014056644 Apr 2014 WO
WO-2014072439 May 2014 WO
WO-2014072439 Jul 2014 WO
WO-2015028209 Mar 2015 WO
WO-2016093877 Jun 2016 WO
WO-2016126511 Aug 2016 WO
Non-Patent Literature Citations (251)
Entry
US 6,331,185 B1, 12/2001, Gambale et al. (withdrawn)
US 8,062,356 B2, 11/2011, Salahieh et al. (withdrawn)
US 8,062,357 B2, 11/2011, Salahieh et al. (withdrawn)
US 8,075,614 B2, 12/2011, Salahieh et al. (withdrawn)
US 8,133,271 B2, 03/2012, Salahieh et al. (withdrawn)
US 8,211,170 B2, 07/2012, Paul et al. (withdrawn)
Akins C.W., et al., “Risk of Reoperative Valve Replacement for Failed Mitral and Aortic Bioprostheses,” The Annals of Thoracic Surgery, 65:545-1552 (Jan. 1998). Retrieved from the Internet: URL: http://ats.ctsnetjournals.org/cgi/contenUfull/65/6/1545 (Jan. 1998).
Allen et al., “What are the characteristics of the ideal endovascular graft for abdominal aortic aneurysm exclusion?”, J. Endovasc. Surg., vol. 4(2), May 1997, pp. 195-202.
Anabtawi I.N., et al., “Experimental evaluation of myocardial tunnelization as a method of myocardial revascularization,” Journal of Thoracic and Cardiovascular Surgery, 58(5):638-646 (Nov. 1969).
Andersen et al., “Transluminal implantation of artificial heart valves, Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs,” Euro. Heart J., vol. 13, May 1992, pp. 704-708.
Archie J.P., et al., “Intramyocardial Pressure: Effect of Preload on Transmural Distribution of Systolic Coronary Blood Flow,” The American Journal of Cardiology, 35(6):904-911 (Jun. 1975).
Baba H., et al., “Hemodynamic effects of venous valves in aorta-coronary bypass grafts,” The Journal of Thoracic and Cardiovascular Surgery, 71(5):774-778 (May 1976).
Block et al., “Percutaneous Approaches to Valvular Heart Disease,” Current Cardiology Reports, 7(2):108-113 ( Mar. 2005).
Blum et al., “Endoluminal Stent-Grafts for Intrarenal Abdominal Aortic Aneurysms.” New Engl. J. Med., 336:13-20 (Jan. 1997).
Bonhoeffer et al., “Percutaneous Insertion of the Pulmonary Valve,” J. Am. Coll. Cardiol., vol. 39, May 15, 2002, pp. 1664-1669.
Bonhoeffer et al., “Percutaneous Mitral Valve Dilatation with the Multi-Track System,” Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiograhy & Interventions, United States (Oct. 1999), pp. 178-183.
Bonhoeffer et al., “Percutaneous replacement of pulmonary valve in a right ventricle to pulmonary-artery prosthetic conduit with valve dysfunction”, The Lancet, Oct. 21, 2000, vol. 356, pp. 1403-1405.
Bonhoeffer et al., “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study,” Circulation, vol. 102, Aug. 15, 2000, pp. 813-816.
Bonhoeffer P., et al., “Technique and Results of Percutaneous Mitral Valvuloplasty With the Multi-Track System,” Journal of Interventional Cadiology, 13(4):263-268 (Aug. 2000).
Boudjemline et al., “Percutaneous Implantation of a Biological Valve in Aortic Position: Preliminary Results in a Sheep Study,” European Heart Journal, vol. 22, p. 630, Abstract Only (Sep. 2001).
Boudjemline et al., “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study.” Med Sci. Monit., 8:4:BR113-116 (Apr. 2002).
Boudjemline et al., “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs.” Euro. Heart J., Jul. 2002, 23, pp. 1045-1049.
Boudjemline et al., “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study.” Journal of the American College of Cardiology, 43(6):1082-1087 (Mar. 2004).
Boudjemline et al., “Percutaneous Valve Insertion: A New Approach?”, J. of Thoracic and Cardio. Surg, 125(3):741-743, Mar. 2003.
Boudjemline et al., “Stent Implantation Combined with a Valve Replacement to Treat Degenerated Right Ventricle to Pulmonary Artery Prosthetic Conduits,” European Heart Journal, vol. 22, p. 355, Abstract Only (Sep. 2001).
Boudjemline et al., “Steps Toward Percutaneous Aortic Valve Replacement.” Circulation, Feb. 12, 2002, vol. 105, pp. 775-778.
Boudjemline et al., “The Percutaneous Implantable Heart Valve,” Progress in Pediatric Cardiology, vol. 14, pp. 89-93, (Nov. 2001).
Boudjemline Y., et al., “Images in Cardiovascular Medicine, Percutaneous Aortic Valve Replacement in Animals,” Circulation, vol. 109:e161, United States, Mar. 16, 2004, 1 page.
Boudjemline Y., et al., “Is Percutaneous Implantation of a Bovine Venous Valve in the Inferior Vena Cava a Reliable Technique to Treat Chronic Venous Insufficiency Syndrome?” Medical Science Monitor-International Medical Journal of Experimental and Clinical Research, Poland, Mar. 2004, pp. BR61-66.
Boudjemline Y., et al., “Off-pump Replacement of the Pulmonary Valve in Large Right Ventricular Outflow Tracts: A Hybrid Approach,” Journal of Thoracic and Cardiovascular Surgery, United States, vol. 129, No. 4, Apr. 2005, pp. 831-837.
Boudjemline Y., et al., “Percutaneous Aortic Valve Replacement: Will We Get There?” Heart, British Cardiac Society, England, Dec. 2001, pp. 705-706.
Boudjemline Y., et al., “Transcatheter Reconstruction of the Right Heart,” Cardiology in the Young, England, Jun. 2003, pp. 308-311.
Bruce C.J., et al., “Right-sided Valve Disease Deserves Little More Respect,” Circulation, 119(2):2726-2734 (May 2009).
Coats L., et al., “The Potential Impact of Percutaneous Pulmonary Valve Stent Implantation on Right Ventricular Outflow Tract Re-Intervention,” European Journal of Cardio-Thoracic Surgery, vol. 27, England, Apr. 2005, pp. 536-543.
Commeau P et al., “Percutaneous Balloon Dilatation of calcific aortic Valve Stenosis: Anatomical and Haemodynamic Evaluation,” British Heart Journal, 59:227-238 (Feb. 1988).
Cribier et al., “Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis”, J. of Am. Coll. of Cardio, Feb. 18, 2004, 43(4), pp. 698-703.
Cribier et al., “Percutaneous Transluminal Valvuloplasty of Acquired Aortic Stenosis in Elderly Patients: An Alternative to Valve Replacement?”, The Lancet, Jan. 11, 1986, pp. 63-67.
Cunanan et al., “Tissue Characterization and Calcification Potential of Commercial Bioprosthetic Heart Valves.” Ann. Thorac. Surg., May 15, 2001, pp. S417-S421.
Cunliffe et al., “Glutaraldehyde Inactivation of Exotic Animal Viruses in Swine Heart Tissue,” Applied and Environmental Microbiology, Greenport, New York, vol. 37, No. 5, May 1979, pp. 1044-1046.
Dake et al., “Transluminal Placement of Endovascular Stent-Grafts for the Treatment of Descending Thoracic Aortic Aneurysms.” New Engl. J. of Med., 331(26):1729-34 (Dec. 1994).
Dalby et al., “Non-Surgical Aortic Valve Replacement” Br. J. Cardiol., 10(6):450-452 (Nov. 2003).
Davidson et al., “Percutaneous therapies for valvular heart disease,” Cardiovascular Pathology 15:123-129 (Jan. 2006).
Dewey et al., “Transapical aortic valve implantation: An Animal Feasibility Study”, The annals of thoracic surgery, 82:110-116 (Feb. 2006).
Dhasmana et al., “Factors Associated With Periprosthetic Leakage Following Primary Mitral Valve Replacement: With Special Consideration of Suture Technique.” Annals of Thorac. Surg., (Feb. 1983), 35(2), pp. 170-178.
Dotter, “Transluminally-Placed Coilspring Endarterial Tube Grafts,” Investigative Radiology, pp. 329-332 (Oct. 1969).
Emery et al., “Replacement of the Aortic Valve in Patients Under 50 Years of Age: Long-Term Follow-Up of the St. Jude Medical Prosthesis.” Ann. Thorac. Surg., 75:1815-1819 (Jun. 2003).
European Search Report dated Aug. 10, 2011 for EP Application No. 06824992.9.
European Search Report for EP Patent Appl. Serial No. 12179049.7 (1257), dated Oct. 30, 2012, 4 pages.
European Search Report for EP Patent Appl. Serial No. 12179075.2 (1257), dated Oct. 29, 2012, 3 pages.
European Search Report for EP Patent Appl. Serial No. 12179141.2 (1257), dated Nov. 2, 2012, 3 pages.
European Search Report for EP Patent Appl. Serial No. 12179146.1 (1257), dated Nov. 7, 2012, 8 pages.
European Search Report for EP Patent Appl. Serial No. 12179330.1 (1257), dated Nov. 22, 2012, 3 pages.
European Search Report for EP Patent Appl. Serial No. 12179338.4 (1257), dated Nov. 2, 2012, 3 pages.
European Search Report for EP Patent Appl. Serial No. 12179339.2 (1257), dated Oct. 29, 2012, 4 pages.
European Search Report for EP Patent Appl. Serial No. 12179914.2 (1257), dated Nov. 7, 2012, 6 pages.
European Search Report for EP Patent Appl. Serial No. 13150337.7 (1257), dated Jul. 9, 2013, 3 pages.
European Search Report for EP Patent Appl. Serial No. 13183134.9 (1651), dated Nov. 19, 2013, 3 pages.
European Search Report for EP Patent Appl. Serial No. 14159630.4 (1651), dated May 22, 2014, 3 pages.
European Search Report for EP Patent Appl. Serial No. 14161991.6 (1651), dated Jun. 3, 2014, 3 pages.
European Search Report for EP Patent Appl. Serial No. 15167832.3 (1651), dated Jul. 23, 2015, 3 pages.
European Search Report for EP Patent Appl. Serial No. 15167847.1 (1651), dated Jul. 23, 2015, 3 pages.
European Search Report for EP Patent Appl. Serial No. 17196833.2, dated Mar. 6, 2018, 4 pages.
European Search Report for EP Patent Appl. Serial No. 18164490.7, dated Sep. 17, 2018 5 pages.
European Search Report from EP Patent Office for EP Application No. 15177718.2, dated Jan. 18, 2016, 4 pages.
European Search Report from EP Patent Office for EP Application No. 15177731.5, dated Apr. 14, 2016, 4 pages.
European Search Report from EP Patent Office for EP Application No. 16151726.3, dated Feb. 25, 2016, 4 pages.
Extended European Search Report dated Apr. 11, 2008 in EP Patent Appl. Serial No. 081630410, 5 pages.
Extended EP Search Report dated Sep. 24, 2020 in EP Patent Appl. Serial No. 20165841.6 (JVT-0280).
Extended European Search Report for Application No. 10183946.2.4-2320 dated Feb. 14, 2012, 7 pages.
Extended European Search Report dated Aug. 9, 2018 in EP Patent Appl. Serial No. 18158901.1 (1113).
Extended European Search Report dated Jun. 12, 2018 in EP Patent Appl. Serial No. 17209326.2 (1113).
Extended European Search Report dated May 16, 2012 in EP Patent Appl. Serial No. 11178135.7 (1257).
Extended European Search Report for Application No. 11178076.3-1257 dated Feb. 29, 2012, 5 pages.
Extended European Search Report from EP Patent Office for EP Application No. 17162616.1, dated Jul. 27, 2017, 7 pages.
Extended European Search Report dated Apr. 9, 2014 in EP Patent Appl. Serial No. 14164683.6.
Extended European Search Report dated May 9, 2013 in EP Patent Appl. Serial No. 130178309.4,4 pages.
Extended European Search Report dated Aug. 19, 2011 in EP Patent Appl. Serial No. 07827132.7.
Extended European Search Report dated Feb. 27, 2017 in EP Patent Appl. Serial No. 16186773,6 pages.
Extended European Search Report dated Sep. 29, 2014 in EP Patent Appl. Serial No. 14166480, 5 pages.
Extended European Search Report for Application No. 07116242.4-2310 dated Mar. 31, 2008, 10 pages.
Extended European Search Report for Application No. 09154935.2, dated May 29, 2009, 7 pages.
Extended European Search Report for Application No. 10012198.7 dated Mar. 23, 2011, 7 pages.
Extended European Search Report for Application No. 10168525.3-1257 dated Feb. 3, 2011, 13 pages.
Extended European Search Report for Application No. 11153142.2-1257 dated Aug. 3, 2011, 10 pages.
Extended European Search Report for Application No. 11165093.3-1257 dated Aug. 30, 2011, 6 pages.
Extended European Search Report for Application No. 11178073.0-1257 dated Oct. 14, 2011, 5 pages.
Extended European Search Report for Application No. 11178145.6-1257 dated Feb. 29, 2012, 5 pages.
Extended European Search Report for Application No. 13188858.8-1651 dated Jan. 13, 2014, 6 pages.
Extended European Search Report for Application No. 19195062 dated Jan. 2, 2020, 7 pages.
ExtendedEuropean Search Report for EP Patent Appl. Serial No. 06827630.2 dated Jun. 7, 2010, 5 pages.
Extended European Search Report for EP Patent Appl. Serial No. 07110318.8, dated May 29, 2008, 10 pages.
Extended European Search Report for EP Patent Appl. Serial No. 10163478.0, dated Mar. 22, 2011, 9 pages.
Extended European Search Report for EP Patent Appl. Serial No. 10184842.2, dated Mar. 23, 2011, 7 pages.
Extended European Search Report for EP Patent Appl. Serial No. 11162971.3, dated Jun. 30, 2011, 5 pages.
Extended European Search Report for EP Patent Appl. Serial No. 13163918.9, dated Jul. 24, 2013, 8 pages.
Extended European Search Report for EP Patent Appl. Serial No. 14179639.1, dated Mar. 9, 2015, 7 pages.
Extended European Search Report for EP Patent Appl. Serial No. 16201320.5, dated May 19, 2017, 6 pages.
Extended European Search Report for EP Patent Appl. Serial No. 18200191.7, dated May 6, 2019, 8 pages.
Ferrari, “Entwicklung eines Verfahrens zum transvaskularen Aortenklappenersatz,” Habilitationsschrift, Medizinische Fakultat der Friedrich-Schiller-Universitat Jena, Sep. 2003, pp. 1-159. (With English Translation).
Ferrari, “Entwicklung eines Verfahrens zum transvaskularen Aortenklappenersatz,” Habilitationsschrift, Medizinische Fakultät der Friedrich-Schiller-Universität Jena, Sep. 2003, pp. 49-52. (With English Translation).
Ferrari M.W., “Transarterial Aortic Valve Replacement with a Self Expanding Stent in Pigs,” Heart, vol. 90, No. 11, doi:10.1136/hrt.2003.028951, ISSN 1355-6037, XP055137208, Nov. 2004, pp. 1326-1331.
Filsoufi F., et al., “Long-term Outcomes of Tricuspid Valve Replacement in the Current Era,” Ann. Thorac. Surg., 8(3):845-850 (Sep. 2005).
Fluency Vascular Stent Graft Instructions for Use, May 2014, 20 pages.
Greeenberg, “Abdominal Aortic Endografting: Fixation and Sealing.” J. Am. Coll. Surg., 194(1):S79-S87 (Jan. 2002).
Grossi A.E et al., “Impact of Minimally Invasive Valvular Heart Surgery: A Case-Control Study”, Ann. Thorac. Surg., 71:807-810 (Mar. 2001).
Heinrich R.S., et al., “Experimental analysis of fluid mechanical energy losses in aortic valve stenosis: importance of pressure recovery”, Ann Biomed Eng., Nov.-Dec. 1996, vol. 24(6), pp. 685-694.
Hijazi Z.M., “Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins”, J. of Am. College of Cardio., Nov. 6, 2004, vol. 43, No. 6, pp. 1088-1089.
Hourihan M., et al., “Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks”, JACC, Boston, Massachusetts, 20(6):1371-1377 (Nov. 1992).
Huber H.C., et al., “Direct-Access Valve Replacement: A Novel Approach for Off-Pump Valve Implantation Using Valved Stents”, Journal of the American College of Cardiology, vol. 46, No. 2, Jul. 19, 2005, pp. 366-370.
Huber H.C., et al., “Do Valved Stents Compromise Coronary Flow?”, European Journal of Cardio-thoracic Surgery, Jan. 23, 2004, vol. 25; pp. 754-759.
Ing F., “Stents: What's Available to the Pediatric Interventional Cardiologist?” Catheterization and Cardiovascular Interventions, 57:374-386 (Jun. 2002).
International Search Report dated Dec. 29, 2003 in Intl PCT Patent Appl. U.S. Appl. No. PCT/DE2003/002669.
International Search Report and Written Opinion for PCT Application No. PCT/EP2009/052230 dated Jun. 29, 2009, 12 pages.
International Search Report and Written Opinion for PCT Application No. PCT/EP2010/052429 dated Jun. 14, 2010, 12 pages.
International Search Report and Written Opinion for PCT Application No. PCT/EP2011/002524 dated Apr. 23, 2012, 15 pages.
International Search Report and Written Opinion for PCT Application No. PCT/EP2011/052674 dated Jul. 5, 2011, 12 pages.
International Search Report for PCT Application No. PCT/US1999/020736dated Jan. 28, 2000, 3 pages.
International Search Report and Written Opinion for PCT Application No. PCT/EP2009/050762 dated Jun. 23, 2009, 12 pages.
International Search Report & Written Opiniondated Jul. 18, 2016 for PCT Patent Appl No. PCT/EP2016/059839, 10 pages.
International Search Report and Written Opinion for Appl. No. PCT/EP2016/055783, dated May 30, 2016, 15 pages.
International Search Report and Written Opinion for Application No. PCT/EP2013/057431 dated Jul. 26, 2013, 9 pages.
International Search Report and Written Opinion for Application No. PCT/IB2018/050438 dated Apr. 12, 2018, 11 pages.
International Search Report and Written Opinion for International Application No. PCT/EP2010/063306, dated Nov. 17, 2010, 9 pages.
International Search Report and Written Opinion for PCT Application No. PCT/EP2006/010519 dated Mar. 1, 2007, 13 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US06/36286 dated Jul. 9, 2007, 4 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2004/041513 dated Jun. 10, 2005, 4 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2004/043607 dated Mar. 20, 2006, 4 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2005/020947 dated Oct. 6, 2005, 5 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2006/038352 dated May 19, 2008, 4 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2006/043484 dated Jun. 25, 2008, 4 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2007/003992 dated Jan. 10, 2008, 5 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2007/02970 dated Oct. 19, 2007, 7 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2009/060531 dated May 13, 2010, 6 pages.
International Search Report and Written Opinion for PCT/DE2006/000056 dated Jun. 7, 2006, 11 pages.
International Search Report and Written Opinion for PCT/EP2007/061117 dated May 20, 2008, 16 pages.
International Search Report and Written Opinion for PCT/EP2008/003803 dated Aug. 20, 2008, 10 pages.
International Search Report and Written Opinion for PCT/EP2009/055958 dated Oct. 21, 2009, 8 pages.
International Search Report and Written Opinion for PCT/EP2010/056558 dated Oct. 7, 2010, 14 pages.
International Search Report and Written Opinion for PCT/EP2012/067617 dated Dec. 19, 2012, 10 pages.
International Search Report and Written Opinion for PCT/IL2007/001149 dated May 1, 2008, 4 pages.
International Search Report and Written Opinion for PCT/US2011/027730 dated May 25, 2011, 9 pages.
International Search Report and Written Opinion of the International Search Authority for International Application No. PCT/EP2008/064558, date of completion of report is Mar. 18, 2009, 14 pages.
International Search Report for Application No. PCT/DE2001/000837, dated Aug. 7, 2001, 4 pages.
International Search Report for Application No. PCT/EP2006/012455, dated Sep. 27, 2007, 5 pages.
International Search Report for Application No. PCT/EP2010/057798, dated Sep. 12, 2010, 6 pages.
International Search Report for Application No. PCT/EP2011/066677, dated Feb. 17, 2012, 7 pages.
International Search Report for Application No. PCT/EP2012/067617 dated Dec. 19, 2012, 3 pages.
International Search Report for Application No. PCT/EP2012/067714 dated Dec. 18, 2012, 3 pages.
International Search Report for Application No. PCT/EP2013/073318, dated Apr. 17, 2014, 5 pages.
International Search Report for Application No. PCT/EP2014/065817, dated Jan. 7, 2015, 6 pages.
International Search Report for Application No. PCT/EP2016/055783, dated May 30, 2016, 5 pages.
International Search Report for Application No. PCT/EP2016/058532, dated Jul. 11, 2016, 4 pages.
International Search Report for Application No. PCT/IB2008/002180, dated Apr. 15, 2009, 7 pages.
International Search Report for Application No. PCT/IB2018/050438 dated Apr. 12, 2018, 3 pages.
International Search Report for PCT/DE2001/000836 dated Jun. 13, 2001, 6 pages.
International Search Report for PCT/EP2006/010023 dated Mar. 30, 2007, 6 pages.
International Search Report for PCT/EP2007/007413, dated Jan. 28, 2008, 4 pages.
International Search Report for PCT/IB2017/052718, dated Sep. 5, 2017, 4 pages.
Kato et al., “Traumatic Thoracic Aortic Aneurysm: Treatment with Endovascular Stent-Grafts.” Radiol., 205:657-662 (Dec. 1997).
Khambadkone, “Nonsurgical Pulmonary Valve Replacement: Why, When, and How?” Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Jul. 2004, pp. 401-408.
Knudsen et al., “Catheter-implanted prosthetic heart valves”, Intl J. of Art. Organs, 16(5):253-262, May 1993.
Kort et al., “Minimally Invasive Aortic Valve Replacement: Echocardiographic and Clinical Results.” Am. Heart J., Sep. 2001, vol. 142(3), pp. 476-481.
Kuzela L., et al., “Experimental evaluation of direct transventricular revascularization,” Journal of Thoracic and Cardiovascular Surgery, 57(6):770-773 (Jun. 1969).
Laborde et al., “Percutaneous Implantation of the Corevalve Aortic Valve Prosthesis for Patients Presenting High Risk for Surgical Valve Replacement,” EuroIntervention, 1(4):472-474 (Feb. 2006).
Lawrence et al., “Percutaneous Endovascular Graft: Experimental Evaluation”, Radiology, May 1987, vol. 163(2), pp. 357-360.
Levi et al., “Future of Interventional Cardiology in Pediactrics.” Current Opinion in Cardiol., 18:79-90 (Mar. 2003).
Levy, “Mycobacterium chelonei Infection of Porcine Heart Valves.” The New England Journal of Medicine, Washington DC, 297(12), Sep. 22, 1977, pp. 667-668.
Lichtenstein et al., “Transapical Transcatheter Aortic Valve Implantation in Humans: Initial Clinical Experience”, circulation, American Heart Association vol. 114, Jul. 31, 2006, pp. 591-596.
Lichtenstein, S.V., “Closed heart surgery: Back to the future” The Journal of Thoracic and Cardiovascular Surgery, vol. 131(5), May 2006, pp. 941-943.
Liu et al., “Effect of Fiber Orientation on the Stress Distribution within a Leaflet of a Polymer Composite Heart Valve in be Closed Position”, Journal of Biomechanics, 4:1099-1106 (Jan. 2007).
Lonescu et al., “Prevalence and Clinical Significance of Incidental Paraprosthetic Valvar Regurgitation: A prospective study using transesophageal echocardiography.” Heart, 89:1316-21 (Oct. 2003).
Love S.C. et al., The Autogenous Tissue Heart Valve: Current Status, Journal of Cardiac Surgery, , Mar. 1991, vol. 6(4), pp. 499-507.
Lutter et al., “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation.” J. of Thoracic and Cardio. Surg., Apr. 2002, vol. 123(4), pp. 768-776.
Lutter et al., “Percutaneous Valve Replacement: Current State and Future Prospects,” Annals of Thoracic Surgery, Netherlands Dec. 2004, pp. 2199-2206.
Ma L., et al., “Double-crowned valved stents for off-pump mitral valve replacement,” European Journal of Cardio-Thoracic Surgery, vol. 28, No. 2, 2005, pp. 194-199.
Mack, M.J., “Minimally invasive cardiac surgery”, Surg Endosc, 20:S488-S492 (Mar. 2006).
Magovern et al., “Twenty-five-Year Review of the Magovern-Cromie Sutureless Aortic Valve”, Ann. Thorac. Surg., 48:S33-S334 (Jan. 1989).
Maraj et al., Evaluation of Hemolysis in Patients with Prosthetic Heart Valves, Clin. Cardiol. 21:387-392 (Jun. 1998).
Marcus RH et al., “Assessment of small-diameter aortic mechanical prostheses: physiological relevance of the Doppler gradient, utility of flow augmentation, and limitations of orifice area estimation,” Circulation, 98(9):866-872 (Sep. 1998).
McKay G. R. et al., “The Mansfield Scientific Aortic Valvuloplasty Registry: Overview of Acute Hemodynamic Results and Procedural Complications.” J. Am. Coll. Cardiol., 17(2):485-491 (Feb. 1991).
Mills N.L., et al., “Valvulotomy of valves in the saphenous vein graft before coronary artery bypass,” The Journal of Thoracic and Cardiovascular Surgery, 71 (6):878-879 (Jun. 1976).
Mirich et al., “Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study”, Radiology, 170:1033-1037 (Mar. 1989).
Moazami N et al. “Transluminal Aortic Valve Placement: a Fesibility Study with a Newly Designed Collapsible Aortic Valve”, ASAIO Journal, vol. 42, No. 2, Mar.-Apr. 1996.
Moulopoulos et al., “Catheter-Mounted Aortic Valves,” Annals of Thoracic Surg., vol. 11, No. 5, May 1971, pp. 423-430.
MUNRO 1., et al., “The possibility of myocardial revascularization by creation of a left ventriculocoronary artery fistula,” The Journal of Thoracic and Cardiovascular Surgery, 58(1):25-32 (Jul. 1969).
Nath J., et al., Impact of Tricuspid Regurgitation on Long-term Survival, Journal of the American College of Cardiology, 43(3):405-406 (Feb. 2004).
Nietlispach F., et al., “Current Balloon-Expandable Transcatheter Heart Valve and Delivery Systems”, Catheterization and Cardiovascular Interventions, 75:295-300 (Sep. 2009).
Palacios., “Percutaneous Valve Replacement and Repair, Fiction or Reality?,” Journal of American College of Cardiology, 44(8):1662-1663 (Oct. 2004).
Palmaz J.C., et al., “Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog,” American Journal of Roentgenology, 145 (4):821-825 (Oct. 1985).
Palmaz J.C., et al., “Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertension,” American Journal of Roentgenology, 147(6):1251-1254 (Dec. 1986).
Paniagua et al., “Percutaneous Heart Valve in the Chronic in Vitro Testing Model.” Circulation, Sep. 17, 2002, vol. 106: e51-e52.
Parodi J.C., et al., “Transfemoral Intraluminal Graft Implantation for Abdominal Aortic Aneurysms”, Ann. Vasc. Surg., 5(6):491-499 (Nov. 1991).
Partial European Search Report dated Feb. 28, 2012 in EP Patent Appl. Serial No. 11178135.7 (1257).
Partial European Search Report for Application No. 10168525.3-1269 dated Sep. 20, 2010, 5 pages.
Partial European Search Report for Application No. 07116242.4-2310 dated Jan. 14, 2008, 5 pages.
Partial European Search Report for Application No. 11153142.2-1257 dated Apr. 4, 2011, 5 pages.
Partial European Search Report for EP Patent Appl. Serial No. 07110318.8, dated Mar. 10, 2008, 6 pages.
Partial European Search Report for EP Patent Appl. Serial No. 10163478.0, dated Nov. 2, 2010, 6 pages.
Partial International Search Report for International Application No. PCT/EP2014/055044, filed Mar. 13, 2014, 7 pages.
Pavcnik D., et al., “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement.” Radiology, 183:151-154 (Apr. 1992).
Pavcnik et al., “Aortic and venous valve for percutaneous insertion,” Min. Invas. Ther. & Allied Technol, 9(3/4):287-292 (Jan. 2000).
Pavcnik et al., “Percutaneous Bioprosthetic Venous Valve: A Long-term Study in Sheep,” Jounal of Vascular Surg., vol. 35, No. 3, Mar. 2002, pp. 598-603.
Pawelec-Wojtalk M., “Closure of left ventricle perforation with the use of muscular VSD occluder,” European Journal of Cardia-Thoracic Surgery, 27(4):714-716 (Apr. 2005).
Pelton A.R., et al., “Medical Uses of Nitinol”, Materials Science Forum, 327-328:63-70 (Jan. 2000).
Phillips et al., “A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic Insufficiency”, Annals of Thoracic Surg., Feb. 1976, 21(2), pp. 134-136.
Phillips S.J., et al., “Improvement in Forward Coronary Blood Flow by Using a Reversed Saphenous Vein with a Competent Valve,” The Annals of Thoracic Surgery, vol. 21 (1), Jan. 1976, pp. 12-15.
Raillat et al., “Treatment of Iliac Artery Stenosis with the Wallstent Endoprosthesis.” AJR, Mar. 1990, vol. 154(3), pp. 613-616.
Remadi et al., “Preliminary results of 130 aortic valve replacements with a new mechanical bileaflet prosthesis: The Edwards MIRA valve,” Interactive Cardiovasc. and Thorac. Surg., 2:80-83 (Mar. 2003).
Rogers J.H., et al., “The Tricuspid Valve: Current Perspective and Evolving Management of Tricuspid Regurgitation,” Circulation, 119(20):2718-2725 (May 2009).
Ruiz C.E.,“Transcatheter Aortic Valve Implantation and Mitral Valve Repair: State of the Art,” Pediatric Cardiology, 26(3):289-294 (Jun. 2005).
Schurink et al., “Stent Attachment Site-related Endoleakage after Stent Graft Treatment: An in vitro study of the effects of graft size, stent type, and atherosclerotic wall changes”, J. Vasc. Surg., vol. 30(4), Oct. 1999, pp. 658-667.
Search Report dated Oct. 15, 2003 from the European Patent Office for European Patent Application No. EP 02291953.4, 2 pages.
Sochman et al., “Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study.” Cardiovasc. Intervent. Radiol., Sep. 2000, 23: 384-388.
Stanley et al., “Evaluation of Patient Selection Guidelines for Endoluminal AAA Repair With the Zenith Stent Graft: The Australasian Experience.” J. Endovasc. Ther., 8:457-464 (Oct. 2001).
Stassano., “Mid-term Results of the Valve-on-Valve Technique for Bioprosthetic Failure”, European Journal of Cardiothoracic Surgery, Oct. 2000, vol. 18, pp. 453-457.
Stein D.P., et al., “Turbulent blood flow in the ascending aorta of humans with normal and diseased aortic valves”, Circulation Research by American Heart Association, 39:58-65 (Jul. 1976).
Steinhoff et al., “Tissue Engineering of Pulmonary Heart Valves on Allogenic Acellular Matrix Conduits.” Circulation102 [suppl. III], pp. III-50-III-55 (Nov. 2000).
Supplemental Search Report from EP Patent Office for EP Application No. 04813777.2, dated Aug. 19, 2011.
Supplemental Search Report from EP Patent Office for EP Application No. 04815634.3, dated Aug. 19, 2011.
Supplemental Search Report from EP Patent Office for EP Application No. 05758878.2, dated Oct. 24, 2011.
Supplementary European Search Report dated Jan. 2, 2012 in EP Patent Appl. Serial No. 09820051.2.
Thompson et al., “Endoluminal stent grafting of the thoracic aorta: Initial experience with the Gore Excluder,” Journal of Vascular Surgery, Jun. 2002, pp. 1163-1170.
Topol, Eric., Textbook of Interventional Cardiology, 4th Ed; Chapter 24: “Endovascular Options for Peripheral Arterial Occlusive and Aneurysmal Disease,” Saunders, pp. 499-503, 949-953 (Dec. 2003).
Triennial Review of the National Nanotechnology Initiative: “A Matter of Size”, The National Academies Press, Washington DC, V-13, Retrieved from the Internet: URL: http://www.nap.edu/catalog/11752/a-matter-of-size-triennial-review-of-the-national-nanotechnology, 200 pages (Mar. 2006) (Parts 1-5).
Vahanian et al., “Percutaneous Approaches to Valvular Disease”, Circulation, Apr. 6, 2004, 109: 1572-1579.
Van Herwerden et al., “Percutaneous Valve Implantation: Back to the Future?”, Euro. Heart J., Sep. 2002, 23(18):1415-1416.
Walther et al., “Transapical approach for sutureless stent-fixed aortic valve implantation: experimental results”, European Journal of Cardio-thoracic Surgery 29, 703-708 (May 2006).
Webb et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery”, Circulation, American Hea Association, vol. 113, Feb. 6, 2006, pp. 842-850.
Weerasinghe A., et al., “First Redo Heart Valve Replacement: A 10-Year Analysis,” Circulation, 99(5):655-658 (Feb. 1999).
Weyman AB et al., “Aortic Stenosis: Physics and Physiology—What Do the Numbers Really Mean?”, Rev Cardiovasc Med., 6(1):23-32 (Jan. 2005).
White et al., “Endoleak as a Complication of Endoluminal Grafting of Abdominal Aortic Aneurysms: Classification, Incidence, Diagnosis, and Management,” J. Endovasc. Surg., 4:152-168 (May 1997).
Written Opinion for Application No. PCT/EP2006/012455, dated Sep. 27, 2007, 11 pages.
Written Opinion for Application No. PCT/EP2007/007413, dated Jan. 28, 2008, 5 pages.
Written Opinion for Application No. PCT/EP2011/058506, dated Nov. 3, 2011, 5 pages.
Written Opinion for Application No. PCT/EP2014/065817, dated Jan. 7, 2015, 7 pages.
Written Opinion for PCT/EP2006/010023 dated Mar. 30, 2007, 10 Pages.
Written Opinion for PCT/EP2012/067714 dated Dec. 18, 2012, 5 Pages.
Yonga G.O., et al., “Percutaneous Transvenous Mitral Commissurotomy in Juvenile Mitral Stenosis”, East African Medical Journal, 80(4):172-174 (Apr. 2003).
Yoshioka et al., “Self-Expanding Endovascular Graft: An Experimental Study in Dogs.” AJR 151, Oct. 1988, pp. 673-676.
Zhou et al., “Self-expandable Valved Stent of Large Size: Off-Bypass Implantation in Pulmonary Position”, Eur. J. Cardiothorac, Aug. 2003, 24: 212-216.
Aortenklappenbioprothese erfolgreich in der Entwicklung, May 16, 2003 (1 page).
English translation of Aortenklappenbioprotheseerfolgreich in der Entwicklung (2 pages), (May 2003).
Screen shots from http://www.fraunhofer.de/presse/filme/2006/index.jsp, 2006 (2 pages).
Liang, Ma, et al., “Double-crowned valved stents for off-pump mitral valve replacement,” Eur. J. Cardio-Thoracic Surgery, vol. 28, pp. 194-198 (2005) (5 pages); Aug. 2005.
Huber, Christoph H., et al. “Direct Access Valve Replacement (DAVR)—are we entering a new era in cardiac surgery?” Eur. J. Cardio-Thoracic Surgery, vol. 29, pp. 380-385 (2006) (6 pages); received Mar. 2006.
English translation of DE 19 546 692 A1 (4 pages), (Jun. 1997).
English translation of EP 1 469 797 B1 (16 pages), (Nov. 2005).
Klein, Allan L. et al., “Age-related Prevalence of Valvular Regurgitation in Normal Subjects: A Comprehensive Color Flow Examination of 118 Volunteers,” J. Am. Soc. Echocardiography, vol. 3, No. 1, pp. 54-63 (1990) (10 pages), Jan.-Feb. 1990.
Gummert, J.F et al., “Cardiac Surgery in Germany During 2007: A Report on Behalf of the German Society for Thoracic and Cardiovascular Surgery,” Thorac. Cardiov. Surg., vol. 56, pp. 328-336 (2008) (9 pages), Sep. 2008.
Gummert, J.F et al., “Cardiac Surgery in Germany During 2006: A Report on Behalf of the German Society for Thoracic and Cardiovascular Surgery,” Thorac. Cardiov. Surg., vol. 55, pp. 343-350 (2007) (8 pages), Sep. 2007.
International Search Report for PCT/EP2011/058506, dated Nov. 3, 2011 (3 pages).
Related Publications (1)
Number Date Country
20200323629 A1 Oct 2020 US
Provisional Applications (1)
Number Date Country
61348036 May 2010 US
Continuations (2)
Number Date Country
Parent 15658955 Jul 2017 US
Child 16794423 US
Parent 13114582 May 2011 US
Child 15658955 US